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When corporations set out to do good for the environment and society, they usually do so under the 
banner of corporate social responsibility. This approach has become commonplace among the public, 
in business schools, and in issues of academic journals. However, corporate social responsibility has a 
few flaws. First, some corporations may never be socially responsible because of their core business.  
Second, there are corporations who pursue corporate social responsibility campaigns that are highly 
removed from their core business and these campaigns seem inappropriate. Finally, there are 
corporations for whom corporate social responsibility is unattainable because it requires too many 
resources. 
 This thesis offers another tool for social responsibility: harm reduction for corporations. My 
harm reduction framework fills the gaps left by corporate social responsibility and encourages every 
corporation to set and meet goals that reduce the harms that they do to the environment and society. 
My harm reduction framework offers a low threshold for engagement, where corporations can reduce 
harms for any reason they choose and to any extent that they choose. This low threshold approach 
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 1 
Introduction 
In this dissertation, I achieve two goals. First, I establish corporations as an arena where harm 
reduction frameworks can apply. Second, I develop a framework for applying harm reduction to the oil 
and gas and pharmaceutical industries. I chose these industries because they have been met with 
significant public criticism for being harmful to the environment and/or society. They also teach us 
important lessons about the usefulness of my harm reduction framework. I suspect that these industries, 
especially the oil and gas industry, will become the typical examples of harm reduction being applied 
to corporations. They will serve as a starting point for future harm reduction researchers who want to 
apply harm reduction frameworks to other industries. 
 Before we proceed to a discussion about harm reduction for corporations, it seems important 
to explain why harm reduction frameworks are useful in the current business context. Currently, 
corporations who wish to do social good, or wish to appear to do social good, usually do so under the 
banner of corporate social responsibility. This is an approach where corporations do environmental or 
social good to be socially responsible entities that exist in society. Corporate social responsibility is 
based on two fundamental principles. First, corporations exist as businesses. Nobody thinks that 
corporations should use corporate social responsibility to become non-profit organizations. Second, 
corporations must do some kind of social good, broadly construed. Corporations typically donate to 
charitable organizations, volunteer their employees for environmental or social initiatives, and reduce 
their impact on the environment. 
 Despite its broad reach, the exact definition of corporate social responsibility is up for debate. 
It is often confused with other related concepts, such as corporate citizenship and sustainability 
(Schwartz and Carroll 2008). Further, the definition of corporate social responsibility has itself been 
contested. Many definitions of corporate social responsibility have been suggested (e.g. Carroll 1979; 
Elkington 1998; Garriga and Melé 2004; Sarkar and Searcy 2016; Schwartz and Carroll 2008) and the 
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literature has settled on none of them. In fact, Okoye (2009) argues that the definition of corporate 
social responsibility is impossible to nail down because the concept is the kind of thing that cannot be 
universally defined. Regardless of the difficulty with defining corporate social responsibility, the 
approach has been proven to offer corporations many benefits. It increases a corporation’s ability to 
compete in the market (Burke and Logsdon 1996), protects a corporation’s reputation (Minor and 
Morgan 2011), and attracts job applicants (Duarte et al. 2014). 
 Many consumers criticize corporations for pursuing corporate social responsibility for the 
above-mentioned pragmatic reasons. Instead, consumers argue, corporations should be socially 
responsible because that is the right thing to do. Indeed, the reader might have the intuition that 
businesses that perform corporate social responsibility initiatives for the sake of increasing profits are 
somehow less good than the corporations who pursue these initiatives out of the goodness of 
executives’ hearts. I will say more about this intuition below. The point I want to make here is that it 
seems undeniable that corporations play a part in protecting our environment and taking care of society 
regardless of their motivations. The demand for corporate social responsibility initiatives is high, to the 
point where it is difficult to name a large corporation that does not have a formal corporate social 
responsibility platform. It seems that corporate social responsibility is here to stay.  
 Now, let us pause here for a moment to think about these varying reasons for pursuing corporate 
social responsibility. It seems as if we have discussed two of them. First, corporate social responsibility 
can boost the bottom line. In addition to the pragmatic reasons for pursuing corporate social 
responsibility listed above, by pursuing environmental or social initiatives, corporations attract more 
customers and customers are willing to pay more for the product. This is beneficial for the business 
overall. The second reason to pursue corporate social responsibility initiatives is because the 
corporation’s leaders care about being socially responsible. Perhaps they have a particular cause that 
they want to support or just think that businesses should contribute to making the world a better place 
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in ways aside from profit-making. To many, it may seem like it is better for corporations to pursue 
corporate social responsibility for the second reason, but many corporations will do so for the first 
reason alone. 
 I will not argue that one of these approaches to corporate social responsibility is superior to the 
other. Instead, I want to focus on the fact that regardless of the reason for pursuing corporate social 
responsibility initiatives, some good is being done by corporations. When we consider how many 
corporations have corporate social responsibility campaigns, it seems undeniable that at least some of 
them have done some good for the world. However, there are a few major issues with corporate social 
responsibility.  
First, there are certain types of corporations that may never truly be socially responsible 
because their core mission is socially irresponsible. Consider oil and gas companies, whose primary 
business is to sell an environmentally damaging product that is obtained through environmentally 
damaging means. Also consider the meat packing industry, which keeps animals in inhumane 
conditions and slaughters billions of them every year so that consumers have access to cheap meat.  
Second, there are corporations that pursue corporate social responsibility campaigns that are 
highly removed from their core business and thus seem misaligned with corporate operations. This 
phenomenon has been noted in Dowling and Moran’s 2012 paper, “Corporate Reputations: Built in or 
Bolted on?”. Corporations with “built in” corporate social responsibility campaigns have initiatives that 
align with their core business operations. For example, Starbucks sources coffee in a way that respects 
its farmers. Since they must source coffee anyway, they are being socially responsible as a part of their 
core business. In contrast, “bolted on” corporate social responsibility campaigns have initiatives that 
seem further removed from their core business operations. For example, Ronald McDonald Charities 
help parents stay close to their sick children while the children are in the hospital.  This charity 
conveniently distracts from the fact that McDonald’s has been exposed for failing to pay their workers 
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a living wage. Dowling and Moran argue that “bolted on” campaigns are highly replicable and do not 
provide a distinct source of competitive advantage. They advocate instead for “built in” corporate social 
responsibility campaigns and argue that these are better for bolstering a corporation’s reputation. This 
conclusion aligns neatly with the intuition that some corporations pursue the seemingly wrong kind of 
corporate social responsibility initiatives. Instead of being socially responsible as a business, they 
perform unrelated activities that they call corporate social responsibility but are often a distraction from 
the major harms that they do in the course of their operations. 
Finally, there are corporations for whom corporate social responsibility is impossible because 
they do not have the resources to support such a program. Many mid-sized businesses, and certainly 
small businesses, fall into this category. This is not to say that mid-sized and small businesses do not 
pursue socially responsible missions, since many of them do, but it is more difficult for them because 
of their limited resources. An approach to social responsibility that requires fewer resources would be 
beneficial for those that do not currently have corporate social responsibility campaigns.  
Harm reduction has the power to address all three of these gaps in corporate social 
responsibility. For corporations that can never truly be socially responsible, harm reduction offers a 
lower threshold for engagement. That is, the demands on the corporation to do good for the environment 
and society are lowered from having to do social good to simply reducing harms. For corporations who 
pursue corporate social responsibility activities that are unrelated to their business, harm reduction 
forces them to look at the harms done throughout the course of their normal operations and address 
those particular harms. This is to say that harm reduction frameworks push corporations toward “built 
in” behaviours by nature. Since a corporation under a harm reduction framework would be reducing 
harm that they do to the environment and/or society, they are forced to confront the harms that their 
operations lead to. Importantly, this is not to say that corporations who reduce harm in “bolted on” 
ways are not harm-reducing. Indeed, the pluralistic nature of a harm reduction framework would still 
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encourage “bolted on” harm reduction initiatives. However, harm reduction naturally leads 
corporations toward more “built in” initiatives that are better aligned with their operations. Finally, 
again, since harm reduction has a lower threshold for engagement, corporations who cannot or will not 
put the resources into corporate social responsibility initiatives can turn to harm reduction instead.  
Further, taking a harm reduction view of corporations allows us to ask corporations to do less 
harm to the environment and society while continuing to pursue profits as aggressively as they like. 
This tension between doing good and maintaining profits is at the heart of many difficulties that 
executives are faced with when they implement corporate social responsibility campaigns. A 
framework that allows both reducing harm and seeking profits is surely welcome. 
The above discussion is, I hope, enough to get the project off the ground. It motivates my 
project by identifying issues with the existing corporate social responsibility framework and aims to 
solve it with an alternative framework. Here, I want to add one more note before we begin. Some may 
question the viability of using the term “harm reduction” in the context of a corporation marketing its 
good deeds to consumers. It may seem imprudent or detrimental to include the word “harm” in the 
term. This may be true. However, I use the term “harm reduction” in this dissertation to identify a 
concept and framework off which I build my ideas. The actual term that is used by corporations to 
denote what I call “harm reduction” is a matter for further research. It is possible that another term 
would be more appropriate, or perhaps what I call “harm reduction” could be subsumed under the term 
“corporate social responsibility” for the purposes of marketing. Nonetheless, “harm reduction” denotes 
a specific concept and framework that I use in this dissertation and I will continue to use the term here 
for clarity. Further research and marketing prowess could determine the ultimate term that is used to 
describe what I call “harm reduction” in practice. 
Now, my dissertation will proceed in five chapters. In the first chapter, I review existing harm 
reduction frameworks and develop a cluster concept to define harm reduction. In Chapter 2, I analyze 
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the cluster concept in the context of corporations and conclude that harm reduction frameworks can 
apply fruitfully to corporations. In the third and fourth chapter, I apply my harm reduction framework 
to the oil and gas and pharmaceutical industries. Here, I identify the specific harms that the industry 
does to the environment and society and offer suggestions on how to reduce that harm. In the fifth and 
final chapter, I explain how a harm reduction framework could be implemented in a corporation. 
A final note is in order before I begin. While this dissertation is a project in ethics insofar as it 
discusses the way that corporations ought to behave, it is not a traditional project in normative ethics. I 
do not draw on any one moral theory or suite of moral theories and I do not develop any of them in any 
depth. Instead, this is a project in harm reduction where I develop a framework that is meant to be used 
as a tool for businesspeople while overseeing business operations. My focus is on the practical 
application of a harm reduction framework to corporations. At best, this dissertation develops a tool 
that businesspeople now have in their toolbox for overseeing business operations in a way that is more 





Existing Harm Reduction Frameworks 
Harm reduction is a concept from the health policy and social services domains. Broadly speaking, it 
refers to a process by which the harms that are associated with a behaviour are reduced without 
requiring cessation of the behaviour itself. It has been applied in a variety of contexts, including 
injection drug use, tobacco use, and sex work, which I will discuss in this chapter. Other notable 
applications of harm reduction include alcohol use, cannabis use, and many forms of high-risk sexual 
behaviour. 
The first step to applying harm reduction frameworks to corporations is to understand what 
harm reduction frameworks are. As I am hoping to import this framework into corporate operations, it 
is important that I stay true to the fundamental nature of harm reduction and respect the principles by 
which it operates. Thus, a review of this fundamental nature of harm reduction and its principles is in 
order. From this review, I extrapolate a definition of harm reduction that is more widely applicable than 
existing definitions of harm reduction, though it continues to respect the core of harm reduction 
frameworks. 
I begin this chapter with an overview of the basics of harm reduction frameworks. I then 
provide a brief history of harm reduction. Next, I present eight key principles for harm reduction and 
show how they apply to the cases of injection drug use, tobacco use, and sex work. I then move on to 
define harm reduction. I start with an explanation of why a definition of harm reduction is important. 
This is followed by a definition of harm reduction as a cluster concept. I conclude the chapter with 
some thoughts on applying the cluster concept to corporations. 
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1.1 What is Harm Reduction? 
Though many trace the origins of harm reduction back to the 1980s AIDS epidemic in America, harm 
reduction activities have actually been taking place since the early 1920s. At this time, a collaboration 
between Dr. John Rolleston and the British government made it legal for doctors to prescribe opiates 
and cocaine to drug users for maintenance therapy. Rolleston understood drug addiction as a medical 
disease that needed to be treated as opposed to a moral failure that needed to be shunned. This 
collaboration was important because it was the first step in understanding drug use as an activity that 
could be appropriately and effectively managed without requiring abstinence (Collins et al. 2012). 
However, the concept of harm reduction had little traction for five decades after this collaboration. 
 Next, in the 1970s in the Netherlands, many groups recognized cannabis use as importantly 
different from other illicit drug use. They differentiated between these classes of substances based on 
their harms, where cannabis was understood as being significantly less harmful than other illicit drugs. 
Pressure from these groups led to the 1976 Dutch Opium Act, which implicitly decriminalized cannabis. 
When the Netherlands saw an increase in cocaine and opiate use in the 1980s, the government 
recognized harm reduction as the official policy response to the issue. Additionally, an advocacy group 
named the Rotterdamse Junkiebond (Rotterdam Junkie Union) provided health education to the public, 
stood in favour of basic rights and health care for substance users, and provided clean syringes for 
injection drug users. This advocacy led to the world’s first government-backed needle and syringe 
exchange program in 1984, which eventually expanded to 60 Dutch cities by the late 1980s (Collins et 
al. 2012). 
The first real push for harm reduction in North America began in grassroots campaigns during 
the American AIDS epidemic in the 1980s. Injection drug use quickly became a target for reducing the 
spread of HIV and other diseases, mainly through grassroots movements that provided educational 
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resources to gay men. Needle and syringe exchanges were also made available by grassroots advocates 
who modelled their harm reduction after the Dutch needle and syringe exchanges (Collins et al. 2012).  
In 2002, Vancouver, British Columbia, Canada was battling a public health emergency arising 
from a drastic increase in heroin overdoses in Vancouver’s Downtown Eastside. Larry Campbell was 
elected mayor of Vancouver and support for a supervised injection site was key to his platform. Once 
he was elected, a coalition of health agencies and all levels of government worked together to tackle 
the emergency. In 2003, Vancouver became the first city with a safe injection site in Canada (Dooling 
and Rachlis 2010). The safe injection site is now known as Insite (Insite for Community Safety). It is a 
key pillar in the battle for Canadian harm reduction programs.  
In January 2006, a new Conservative government was elected in Canada. The government, 
along with the Royal Canadian Mounted Police, challenged the evidence that leaned in favour of a safe 
injection site. However, even these reports stated that Insite led to increased detoxification treatment 
and increased the number of injection drug users seeking treatment. In 2008, the British Columbia 
Supreme Court ruled that Insite qualified as an operation that provided health care, which falls under 
provincial jurisdiction. Further, according to this ruling, the federal government’s actions were 
inconsistent with Section 7 of the Canadian Charter for Rights and Freedoms that grants all Canadians 
the right to life, liberty, and the security of the person. Because of this ruling, Insite was permitted to 
continue its operations. In 2010, this ruling was appealed by the federal government. The appeal was 
defeated by the British Columbia Court of Appeal (Dooling and Rachlis 2010). The federal government 
appealed the decision yet again to the Supreme Court of Canada. In 2011, this court upheld the previous 
rulings in a unanimous vote (2011 SCC 44). 
As we can see, harm reduction was largely started because of the harms from injection drug 
use. Further, harm reduction initiatives that target injection drug users are effective. The National 
Institute for Health and Care Excellence (NICE) is a body in the United Kingdom that provides 
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evidence-based recommendations to health, public health, and social care experts. Their guidance is 
used by the National Health Service for effective, cost-efficient health care options. According to NICE 
(2014a) research, needle and syringe exchange programs are effective on a variety of measures. For 
example, these programs have been shown to reduce HIV infection rates, decrease emergency room 
admissions, and almost a dozen analyses demonstrate that these programs are cost-effective in terms of 
reducing the risk of HIV. As of September 2019, NICE’s (2014b) official position is that needle and 
syringe exchange programs reduce the risk of HIV and other viruses transferred by sharing needles. 
“Needle and syringe programs (NSPs) need to be considered as part of a comprehensive substance-
misuse strategy that covers prevention, treatment, and harm reduction” (NICE, 2014b). 
Today, harm reduction is described as “a set of compassionate and pragmatic approaches for  
reducing harm associated with high risk behaviors and improving quality of life” (Collins et al. 2012, 
p. 5). Harm reduction is compassionate because it respects, addresses, and includes individuals who 
perform high-risk behaviours. It allows individuals to give their input on their plans for harm-reducing 
activities. Further, harm reduction frameworks are pragmatic in that they use scientific evidence to 
determine the best ways to reduce harm. Even though some of these behaviours may fall into legal grey 
areas, such as the opening of Insite in Vancouver, harm reduction advocates continue to push for 
solutions that are empirically supported. As we have already seen, sometimes this scientific evidence 
is contrary to public opinion, but favour for harm reduction frameworks is gained by appeals to human 
rights and cultural competence. For example, the right to health care is often cited as a reason in favour 
of harm reduction initiatives (Harm Reduction Coalition, n.d.). If we understand harm reduction as a 
way of securing health care for many individuals, it is much more easily accepted. Finally, quality of 
life is addressed by customizing harm reduction initiatives according to each individual’s needs. This 
customization is important to harm reduction initiatives and pursuing this customization is a core part 
of harm reduction frameworks. 
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Instead of taking a stance on whether high risk behaviours are right or wrong, harm reduction 
frameworks focus on the harms associated with a behaviour and seek to reduce that harm without 
requiring cessation of the behaviour itself. Unsurprisingly, harm reduction today focuses on high-risk 
behaviours. Collins et al. define “high-risk behaviours” as “fluid and dynamic social constructs” (2012, 
p. 18) as a way of allowing harm reduction practitioners and users the flexibility to define their harm 
reduction needs and reduce judgment surrounding the behaviours in question. With this in mind, Collins 
et al. identify eight key principles to harm reduction (p. 18-22): 
1. High-risk behaviours are formed from cultural values, norms, and beliefs.  
2. High-risk behaviours are tenacious. At least in the context of injection drug use, plentiful 
evidence has shown that abstinence-only campaigns have been unsuccessful. 
3. There are benefits and drawbacks to performing high-risk behaviours. 
4. Substance use should not be immediately labelled as addiction. In the context of injection drug 
use, there is a difference between use and addiction. 
5. Harm and harm reduction operate on a scale from least to most harmful. There are ways to 
engage in risky behaviours that are less risky than others. 
6. An individual’s behaviour only makes sense in the context of their social, economic, and 
political environment. 
7.  Harm reduction is driven by pragmatic solutions instead of generalized theory. Those who 
provide harm reduction services should look at each individual case separately and identify an 
appropriate solution for each particular case. 
8. Harm reduction is ethical. Harm reduction frameworks emphasize community engagement, 
social justice, and human rights. 
These eight principles make the most sense in the context of injection drug use, which is not 
surprising given that this is where harm reduction started. Understanding injection drug use in terms of 
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these eight principles of harm reduction dramatically shifts that way that some may think about the 
issue. Consider that injection drug use is the result of cultural values, norms, and beliefs, instead of a 
moral failing on the part of the individual. Injection drug use is certainly tenacious and has benefits, 
such as immediate relief of negative feelings, and drawbacks, such as long-term addiction. Injection 
drug use shifts away from being a disease and is instead understood on a scale from use to addiction, 
which results in fewer or more harms to the individual. To understand injection drug use fully, we must 
understand the social, economic, and political environment that injection drug users face. Harm 
reduction for injection drug users, as we have seen in the case of Insite, are based on pragmatic solutions 
that are customized to each individual. Finally, harm reduction for injection drug users is argued to be 
ethical by engaging communities, upholding social justice, and protecting human rights. 
In many ways, these eight principles represent a dramatic shift in the way that we think about 
harmful behaviours. Often, the response to a harmful behaviour is to try and get rid of it entirely. This 
response is evident in policies and laws surrounding paradigmatic applications of harm reduction like 
injection drug use and sex work that are described below. However, once evidence shows that we 
cannot, or will find it very difficult to, eliminate these harmful behaviours, some think that we ought to 
take a different, harm reductive approach. The typical reasoning is as follows: if the harmful behaviour 
is going to persist, we should make it as safe as possible to participate in that behaviour. Thus, harm 
reduction was designed to be pragmatic, address existing harms in ways that respect the autonomy of 
the people who choose to perform harmful behaviours, and address the context in which the harmful 
behaviour exists. Proponents of harm reduction often say that they “meet people where they are” (e.g. 
School of Population and Public Health, 2016; Canadian Mental Health Association, 2020) and help 
people in effective, compassionate, and respectful ways. The above eight principles, along with 
compassion, pragmatic behaviour, and increasing quality of life, are at the core of harm reduction 
frameworks and are incredibly important to keep in mind as we do harm reductive activities. With these 
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basic principles in place, we can look at three existing applications of harm reduction frameworks: 
injection drug use, tobacco use, and sex work. 
1.1.1 Injection Drug Use 
Today, injection drug use is the classic example of the fruitfulness of harm reduction efforts. Needle 
and syringe exchanges (Sander and Murphy 2017), opioid substitution therapy (Aceijas 2012), and 
support services such as housing support and counselling (Boucher et al. 2017) are just some examples 
of harm reduction services available to injection drug users. All these interventions are meant to reduce 
the harms associated with injection drug use without requiring cessation of the drug use itself. For 
example, needle and syringe exchanges ensure that users inject with clean needles, which helps to 
prevent the spread of HIV and other diseases.  
Needle and syringe exchanges and, to a lesser extent, opioid substitution therapy have become 
so important that these programs have been implemented in prisons, most notably in Europe and Central 
Asia (Lines et al. 2009), to reduce the harm associated with drug use in prison (Resiak, Mpofu, and 
Athanasou 2016; Stoever 2002). Harm reduction programs have been found to be effective at reducing 
the risk of transmitting HIV in prisons (Moller et al. 2008; Sander and Murphy 2017). However, 
opposition to harm reduction programs remain, as many countries retain zero tolerance policies in 
prisons, perhaps for political reasons (Watson 2014). There remain risks associated with drug use in 
prison (Chakrapani et al. 2013; Qaramah and Parausanu 2005; Sawitri et al. 2016).  
The core principles of harm reduction are most clearly operationalized in the case of injection 
drug use. In these cases, harm reduction providers tailor their services toward each individual user to 
give them personalized harm reduction plans that align with the user’s motivations, goals, and values. 
These harm reduction services “[start] where the patient is” and “meet the client as an individual” 
(Tatarsky and Kellogg, 2012, p. 39). This means that the harm reduction provider recognizes the user’s 
unique world. The goal of the harm reduction provider is to find the user’s strengths and use those to 
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help the user make small steps toward their goals. Abstinence is not required of the user at any point 
and reducing the stigma around substance use is a priority (p. 40). 
1.1.2 Tobacco Use 
Over 90% of the harms that come from smoking cigarettes come from smoke inhalation (Phillips and 
Rodu 2013; Stimson 2016). Given this fact, many scholars, including those cited in this section, have 
argued that harm reduction frameworks should apply to smoking. Finding a way for tobacco users to 
use without inhaling smoke represents a huge benefit in their health outcomes. E-cigarettes are one 
popular alternative to cigarettes. E-cigarettes are tobacco-free devices that deliver nicotine to the user 
through vapour. Using an e-cigarette mimics the action of smoking and thus may be more satisfying 
than other nicotine replacement therapies like gum or the patch (Snowdon 2013). E-cigarettes have 
been shown to be much safer than cigarettes (Nitzkin 2014; Phillips and Rodu 2013) and are at least 
part of the solution to reducing cigarette use around the world (Moore, Mckee, and Daube 2016). Many 
advocate for e-cigarettes as a safer alternative to cigarette smoking (e.g. Cahn and Siegel 2011).  
 Despite the promise of e-cigarettes for tobacco users, other evidence might make us pause 
before supporting the introduction of e-cigarettes in society. The most recent Canadian data suggests 
that “vaping”, the colloquial term for the use of e-cigarettes, has become incredibly popular among 
teenagers. Starting in May 2018, e-cigarettes were permitted to be sold in Canada. In the six months 
since then, Dr. David Hammond found that vaping rates have increased drastically and teenage cigarette 
smoking rates have also increased (Crowe 2018). Further, Juul, a major e-cigarette distributor, launched 
its Canadian operations and has seen dramatic growth with little competition (Herzog and Kanada 
2018). All this data suggests that vaping is popular among teenagers, a relatively vulnerable population, 
and e-cigarettes are not purchased exclusively as a harm reductive approach to cigarette smoking. In 
fact, this data suggests that many teenagers are using e-cigarettes without having previously used 
traditional cigarettes, which exposes them to the risks of nicotine addiction. This data nicely illustrates 
 
 15 
that mixed evidence and a range of potential harms can make it difficult to determine which options 
reduce the most harm. In the spirit of harm reduction, the use of e-cigarettes should be monitored and 
empirical data should be leveraged to help policy makers determine the best way to capture the benefits 
of e-cigarettes for tobacco users while minimizing its negative effects on teenagers.  
 Another smokeless tobacco alternative is snus or snuff. Snus is a tobacco product that is 
consumed by sucking on a teabag-like pouch under the upper lip. It is currently banned in the European 
Union with the exception of Sweden, which enjoys the lowest rate of tobacco-related mortality in all 
of Europe despite consuming the same amount of tobacco as other European countries (Snowdon 2013). 
There is no evidence that snus increases the risk of any cancers (Hall 2005; Ornberg 2013), which 
makes it safer than cigarettes. Like e-cigarettes, many advocate for the use of snus as a less harmful 
alternative to cigarettes (e.g. Gartner and Hall 2010; Gilmore et al. 2008; Lund 2013).   
 Tobacco use is not currently an arena where harm reduction is widely practiced. Tobacco harm 
reduction initiatives are currently underway in only Scandinavia and some areas of the United States. 
Despite the lack of momentum for harm reduction initiatives, the fruitfulness of harm reduction efforts 
for tobacco users is quite clear. There are existing nicotine alternatives that are much safer than 
cigarettes.  
Unfortunately, there is misinformation about tobacco use, e-cigarettes, and snus among 
activists, the public, clinicians, policy makers, and health researchers. Anti-smoking campaigns have 
been highly successful at getting all stakeholders to believe biased and incorrect information about 
smokeless tobacco products (Phillips et al. 2012, p. 132). Instead of embracing tobacco harm reduction, 
many will only support abstinence for tobacco users. Health experts, international organizations, and 
university departments have launched a “prohibitionist crusade” (Phillips and Rodu 2013, pg. 76) 
against tobacco and nicotine as a whole, while other individuals and organizations are attached to a 
“utopian vision of a world where no one uses nicotine” (pg. 77). All this amounts to anti-tobacco harm 
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reduction sentiments in society despite the scientific evidence for the efficacy of tobacco harm 
reduction initiatives. According to Phillips and Rodu (2013), “We are aware of no organization or 
individual activist who acknowledges the basic scientific evidence about the benefits of [tobacco harm 
reduction] and then proceeds to present an argument against [tobacco harm reduction]” (pg. 77). They 
go on to explain that anti-tobacco harm reduction campaigns are fraught with deceptive information 
campaigns and ad hominem arguments. For tobacco harm reduction to be successful, harm reduction 
providers will have to combat this misinformation through pro-health campaigns and grassroots 
activism (Phillips et al. 2012, p. 136). 
1.1.3 Sex Work 
There are several harms that come with sex work, especially survival sex work. Sex workers are a group 
that has some of the highest HIV infection rates worldwide and are often forgotten when it comes to 
HIV prevention strategies (Andrasik and Lostutter, 2012). Sex workers are also vulnerable to violence 
from their clients. This violence includes beatings, rape, and threats with weapons (Surratt et al. 2004). 
Other harms to sex workers depend on the type of sex work they are engaging in. Indoor sex workers, 
such as those who work in strip clubs and massage parlours, are concerned about the safety of their 
working environment. Out-call workers, who go to a place of their clients’ choosing, are worried about 
how many people they will encounter, whether there will be any weapons at the client’s location, and 
whether they will encounter any violence. In-call workers, where clients go to a site of the sex worker’s 
choosing, are worried about clients uttering threats and being violent. Finally, street-based workers are 
concerned with public interference and police sweeps (Shaver, Lewis, and Maticka-Tyndale 2011).  
 Harm reduction efforts with respect to sex work have been focused on increasing condom use 
(Barreto 2017; Chiao et al. 2009) and fostering a safe working environment (Shannon et al. 2008; 
Shaver, Lewis, and Maticka-Tyndale 2011; Weitzer 1999). Some have argued that larger structural and 
political changes must occur to help sex workers stay safe. For example, Weitzer (1999) argues against 
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blanket decriminalization and legalization. Blanket decriminalization has almost no public support 
while blanket legalization ignores the needs of many sex workers who fall outside of the scope of 
existing regulations. Instead, Weitzer puts forth a two-track model where resources are put toward 
helping street-based sex workers stay safe, since they face far greater risks than indoor sex workers.  
 While STI and HIV prevention through condom use and fostering a safer work environment to 
the best of the sex worker’s ability are important, they do not address many of the other harms of indoor, 
out-call, in-call, and street-based sex workers listed above. More effective harm reduction strategies for 
sex workers involve addressing social factors such as poverty, gender inequality, discrimination, and 
social marginalization. We must also reduce the stigma associated with sex work, including the stigma 
against STI and HIV testing (Andrasik and Lostutter 2012). 
 Many think that addressing social factors such as poverty, gender inequality, discrimination, 
and social marginalization would eliminate sex work altogether. While these factors do contribute to 
individuals entering sex work, it is not true that all sex workers are forced or coerced into the industry. 
Many sex workers find the sex that they have with clients to be pleasurable (Kontula 2008). In fact, one 
sex worker says that she “decided to start using [men] just for sexual satisfaction” (p. 610). Others take 
pleasure in orgasms, reactions from their clients, and performing sexual acts (Kontula 2008). Further, 
research has shown that pornography actors can lead relatively “normal” lives with supportive family 
members and a college education. They can also live without valuing their lives as less fulfilling or 
important because of their career choice (Ryder and Monroe 2010). Thus, it is not the case that all sex 
workers are unwilling participants in the industry. However, it is still important to address the harms 
that the industry causes to both willing and unwilling participants.  
1.1.4 Expanding Harm Reduction 
When we review the existing applications of harm reduction frameworks, it is clear that the eight core 
principles of harm reduction apply very well. However, when we think about examples of harm 
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reduction outside of these three contexts, it becomes useful to think about harm reduction a little 
differently. While the core principles of harm reduction remain the same, the actual definition of harm 
reduction may shift slightly. 
1.2 Harm Reduction as a Cluster Concept 
There are many definitions of harm reduction that exist today. Collins et al. provide one description of 
harm reduction, which I reviewed at the beginning of this chapter. Another notable definition comes 
from the Centre for Addiction and Mental Health (n.d.), where harm reduction strategies “aim to 
provide a variety of options that reduce the harms the activity may have, both for the people involved 
and for the community around them”. The Centre for Addiction and Mental Health views harm 
reduction largely from the lens of substance use. Yet another notable definition comes from Harm 
Reduction International (2020), where harm reduction “refers to policies, programmes and practices 
that aim to reduce the harms associated with the use of psychoactive drugs in people unable or unwilling 
to stop”. 
 We can see that today’s definitions of harm reduction largely centre around injection drug use. 
However, harm reduction must apply more broadly if legitimate applications of harm reduction 
frameworks include tobacco use and high-risk sexual behaviours as discussed above. Thus, the 
challenge is to provide a definition of harm reduction that is broad enough to capture the essence of 
harm reduction as a policy while excluding behaviours that merely reduce harm without a harm 
reduction framework. 
 It is useful here to think about what kinds of behaviours we wish to capture and which kinds of 
behaviours we wish to exclude. Obvious cases of behaviours that we want to include are injection drug 
use, tobacco use, sex work and other high-risk sexual behaviours, alcohol use, and cannabis use. These 
are areas where harm reduction frameworks have already been applied in the scholarly literature. 
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Further, these behaviours seem to share many traits that can be captured in a definition of harm 
reduction.  
 There are some behaviours to which we think that harm reduction should not apply. Consider 
murder, which many of us deem to be intolerable. Harm reduction for murder might involve ensuring 
that the victim suffers less during the murder itself or reducing the amount of times that a serial killer 
acts on their urges to kill. This application of harm reduction seems incorrect. When there is an 
intolerable behaviour, we ought to get rid of the behaviour altogether instead of only reducing the harms 
associated with that behaviour. 
Given that the definition of harm reduction is complex, I argue that harm reduction is best 
described as a cluster concept. A cluster concept is a concept that is defined by a list of qualities that 
may or may not apply to each example of that concept. The more qualities on the list that apply to some 
example, the more likely it is that the example belongs to that concept. Typically, very few of the 
qualities on the list are necessary or sufficient. This flexibility allows us to apply harm reduction as a 
cluster concept to a variety of domains. 
 Cluster concepts were made popular by Wittgenstein in Philosophical Investigations (1968). 
Wittgenstein begins by discussing language-games, which he understands as the activity of using a 
language to convey meaning (p. 23). The difficulty with language-games is that there are innumerable 
ways of using the language’s symbols, words, and sentences (p. 22). Further, the way that these 
symbols, words, and sentences are used is continually changing (p. 22). For example, the utterance 
“two!” could mean “bring me two blocks” or “there are two red objects” or a variety of other sentences 
depending on the context. Suppose that, in this instance, we utter “two!” and mean “bring me two 
blocks”. To define this utterance, we would have to define “bring” and “block”, then we would have to 
define the words that we used to define “bring” and “block” and so on. This chain will continue 
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endlessly (p. 29). This observation leads Wittgenstein to point out that it is very hard to come to a 
definition of a word that captures all its possible meanings. 
 Another complication in defining symbols, words, and sentences is that there are all sorts of 
language-games. There are questions, assertions, demands, and so on. Wittgenstein’s claim is that there 
is no essential feature or form of language-games that encompass them all. So, when we say that we 
are “using a language”, we really mean that we are taking part in an activity that resembles “using a 
language” to a certain extent (p. 65). To illustrate this point further, Wittgenstein gives the example of 
games. There are all sorts of games, including board games, card games, the Olympic games, and so 
on. According to Wittgenstein, these games share no one thing in common. Consider some candidates 
for a common quality among all games. Perhaps this common quality is that they are all fun. However, 
not all games are fun for all people, and yet we still call them games. Perhaps this common quality is 
that they all have rules. However, there exist rules for several things that are not games, including rules 
for traffic and rules for conducting a safe laboratory test. Perhaps this common quality is that they are 
all competitive. However, there are many cooperative games that exist.  
Thus, Wittgenstein argues, instead of a singular common quality of all games, you will find 
“similarities, relationships, and a whole series of them at that” (p. 66). Wittgenstein calls these “family 
resemblances” (p. 67). This is to say that all games share similarities, but there is no one thing in 
common for all of them. So, instead of creating a strict definition for something like “games”, we should 
list their family resemblances and understand a game as something that shares in some of these 
resemblances. Today, we understand these family resemblances as qualities that are a part of a cluster 
concept. 
 Wittgenstein explains that we could create a strict definition for a concept like “games”, but 
that would involve drawing boundaries for the sake of creating a definition where no boundary used to 
exist. In other words, we would be artificially drawing a line between what does and does not count as 
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a game. Wittgenstein argues that we do not need to draw these boundaries for a concept to be functional 
(p. 69). This assertion means that we do not need a strict definition of a concept before we can use that 
concept fruitfully. 
 So, to say that harm reduction can be described as a cluster concept is to say that there is no 
one strict definition of “harm reduction” in terms of a list of necessary and sufficient conditions. Instead, 
instances of harm reduction all share similar qualities and are related to each other in meaningful ways. 
Below are six qualities that I argue are related to the cluster concept of “harm reduction”. I will go 
through each of these qualities in turn. Remember that understanding harm reduction as a cluster 
concept means that not all six qualities will apply to every case of harm reduction. However, approaches 
that display more of these qualities are more likely to be appropriate cases of harm reduction. 
1. There is at least one identifiable harm associated with the behaviour. 
2.  The behaviour is tenacious at the population level. 
3.  The behaviour is, to some extent, tolerable. 
4.  The primary harms are to the self. 
5.  The harm is worth reducing even if it is not cost-efficient to do so. 
6.  Significant harms are due to stigma or criminalization of the behaviour.  
1.2.1 There is at least one identifiable harm associated with the behaviour.  
This is the only necessary condition for harm reduction. It seems quite straightforward that for there to 
be harm reduction, there first needs to be some harm that can be reduced. Of course, harms can vary in 
nature and I understand “harm” broadly. For example, harms vary in intensity, duration, and certainty, 
among other considerations. There can be harms to ourselves and harms to others. I will discuss these 
varieties of harm in a later chapter, but my conclusion will be that, in the context of corporations, any 
kind of harm and any amount of harm can be reduced for any reason and this will count as harm 
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reduction. However, for now, it is simply important to note that the nature of harms can vary across 
multiple dimensions. 
1.2.2 The behaviour is tenacious at the population level. 
Harm reduction tends to apply to cases where the behaviour is tenacious, at least at the population level. 
This is to say that certain individuals may stop the behaviour in question, but there will usually be 
instances of that behaviour when we step back and observe the population as a whole. Tenacity is 
important because it seems important to eliminate harmful behaviours entirely if it is easy to do so. For 
example, if a single and simple policy change would change the attitudes of all businesses and private 
individuals such that we would eliminate all future environmental pollution, it seems reasonable to 
suggest that the government should enact the policy. A good example is the ban on chlorofluorocarbons. 
These were used widely in the 1980s as coolants in refrigerators and air conditioners. They were banned 
in 1996 in Canada due to the fact that they deplete the ozone layer. Since the ban, the hole in the ozone 
layer has shrunk. Unfortunately, this example is not our reality with carbon emissions and it is very 
difficult to eliminate or even reduce pollution across corporations and private individuals. Thus, given 
that polluting behaviours are tenacious at the population level, harm reduction seems like an appropriate 
route to take. 
 What I mean by “tenacity” can be several different things. It might mean that a behaviour is 
repeated and will inevitably reoccur. It might mean that we cannot stop others from enacting the 
behaviour through rational persuasion. It might also be that, by nature, the behaviour is ineliminable. 
Still, we might mean inevitable repetition. To clarify, what I mean here by “tenacious” is that a 
behaviour will reoccur at the population level for any reason. Whether the reoccurrence is due to a lack 
of ability to rationally persuade people to stop the behaviour, whether the reoccurrence is inevitable, or 
whether the behaviour is, by nature, ineliminable, is not important. So long as the behaviour will persist 
at the population level, the behaviour exists, and is a potential site for harm reduction.   
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 I choose this definition of “tenacious” for very practical reasons. Harm reduction, at its core, is 
about practical application and less about theory. Thus, I look at the practical outcomes of tenacious 
behaviours instead of providing a theoretical discussion of tenacity. In practice, any behaviour that will 
reoccur at the population level is tenacious in the sense that there will be instances of that behaviour in 
society. That is what is important to harm reduction. So long as the behaviour exists, there may be harm 
reduction to be done. 
 The reader will notice that I discuss two things that might be tenacious throughout this 
dissertation: the industry (and its corporations) and harms. These are distinct since tenacious 
corporations within a certain industry may not enact tenacious harms. Further, there are many harms 
that are enacted against society and the environment that corporations are in a unique position to enact. 
To show that the harmful behaviour will exist at the population level requires me to demonstrate that 
there are harms that will occur and that there will be corporations existing to enact those harms. For 
example, as we will see in Chapters 3 and 4, the oil and gas and pharmaceutical industries enact great 
harms that they are in a unique position to enact due to their business model. Thus, to demonstrate 
tenacity, I am required to show that both the harm is tenacious and the corporations that do the harms 
are tenacious as well. 
 Notably, demonstrating that both the industry and harms are tenacious is different from harm 
reduction as we understand it today. In needle and syringe exchanges, tobacco use, and sex work, the 
harms are distinct from the agent, or the person doing the harm. It makes sense to talk about the agent 
and the harm separately. Further, it makes sense to talk about the harm as tenacious but saying that the 
agent is tenacious is odd. However, with corporations, it is sometimes difficult to maintain this 
separation, since the harms that the corporation enacts is so closely tied to the business model of the 
corporation itself, such that the corporation being tenacious necessitates the harms being tenacious. For 
example, in the case of the injection drug user, the harm is not a necessary part of the agent. However, 
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as we will see in the oil and gas and pharmaceutical industry, the harm is often a necessary part of doing 
business. For example, it is impossible to extract oil and gas from the earth without causing severe 
environmental damage. This disanalogy is not enough, I think, to abandon the project of using harm 
reduction frameworks to discuss corporations. However, I am careful to identify the difference between 
tenacious corporations and tenacious harms where I can. This will hopefully clarify the theoretical 
nature of my discussion. 
1.2.3 The behaviour is, to some extent, tolerable. 
Here, it is important that I explain what I mean by “tolerable”. While I cannot provide a strict definition 
of what counts as “tolerable”, I will do my best to at least help us think through whether a behaviour is 
tolerable or not. It seems to me that behaviours can be classified into three categories: behaviours that 
everybody agrees is tolerable, behaviour that everybody agrees is intolerable, and behaviours where 
people disagree over whether it is tolerable. I will address each of these categories in turn.  
First, consider a behaviour that everybody agrees is tolerable. Releasing small amounts of 
greenhouse gases into the environment to manufacture life-saving goods is one example. This is the 
kind of behaviour where we would have no trouble applying harm reduction, such as educating the 
company on how to reduce their greenhouse gas emissions even more. Now, consider a behaviour that 
most people agree is intolerable. With a few exceptions, hiring child labour would be an example of 
such a behaviour. In these cases, children are often purchased or taken from their families and put into 
factories to work extremely long hours for the sake of producing cheap goods for little or no pay. This 
practice deprives children of an education and play that is crucial for a children’s development. It is 
also a form of abuse. Further, this practice perpetuates the cycle of poverty in developing nations. Many 
would be discontent if companies advertised that they used less child labour than they have in the past. 
Instead, many would want companies to stop using child labour altogether. Thus, harm reduction for 
child labour might be seen by many as an inappropriate application of the concept.  
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These two examples are not tricky cases, but non-tricky cases are rare. It is unlikely that 
everybody will either agree or disagree on whether a certain behaviour is tolerable or not. I suspect that 
this is because we have different beliefs about which behaviours are right and wrong. MacCoun (2012) 
has shown that disgust plays a significant role in whether somebody thinks that a behaviour ought to 
be eliminated or merely harm reduced. Other factors included whether a person thought the behaviour 
was immoral, dangerous, or irresponsible. MacCoun groups all these factors together and terms it 
“moral outrage”. Further, MacCoun found that people on different ends of the political spectrum had 
different views on whether they preferred elimination of a behaviour or harm reduction, depending on 
the behaviour in question. For example, MacCoun found that liberal individuals preferred harm 
reduction for heroin, but elimination of ritual female circumcision. Needless to say, people are always 
going to disagree about what morally outrages them and we will likely always have considerable 
variation in political views. Thus, it seems to be a fruitless project to try and have everybody agree on 
which behaviours we should eliminate and which behaviours should be harm reduced. 
So, if we hold these different beliefs about which behaviours should be eliminated and which 
should be harm reduced, I argue that we will disagree about which behaviours are tolerable and which 
are not. It is beyond the scope of this project to resolve this dilemma, but I can offer some factors that 
affect whether we think a behaviour is tolerable or not. 
First, consider the physical context in which a behaviour occurs. For example, compare 
sampling snacks from your kitchen pantry and sampling snacks at a local bulk food store. In the former 
context, it is perfectly tolerable for you to take one bite of every snack that you have in the pantry and 
put the rest of the bitten snacks back, assuming that you do not share those snacks with others. In the 
latter situation, it is unacceptable to do the same. Thus, different contexts dictate whether some 
behaviours are tolerable or not. In the context of harm reduction, it might mean that injection drug use 
is tolerable in a safe injection site, but intolerable in public parks near children.  
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We can also consider the social context where a behaviour occurs. Previously, many thought it 
was intolerable for same sex couples to hold hands in public. Today, Canada has laws against 
discrimination based on sexual orientation, in part because of the recognition that there are almost no 
harms associated with non-heterosexual sexual orientation. Thus, the social context can change whether 
a behaviour is viewed as generally tolerable or not. The social context of a particular behaviour may be 
difficult to determine, but we can look to key Supreme Court rulings and legal sanctions as a guide for 
what a particular society accepts or rejects. We can also look at the way that the majority of a society’s 
population responds to said behaviour. I want to emphasize here that these are simply guides to help us 
determine whether a behaviour is tolerable or not in a given population. The legal system and the 
majority of the population’s opinion does not definitively determine whether a behaviour is overall 
tolerable, nor do they determine whether a behaviour is morally right or wrong.  
Further, we can consider the epistemic position of those who have opinions on whether a 
behaviour is tolerable or not. For example, a person who has no knowledge of the history of Indigenous 
peoples in Canada should rightfully have very little say over whether certain treaties that the state has 
with Indigenous peoples should be broken. This is to say that those who are uninformed about an issue 
should have relatively little say over how the issue is resolved. Likewise, those who are uninformed 
about a behaviour and its resultant harms should have relatively little say over how that behaviour is 
managed in society. Note that considering one’s epistemic position means that a behaviour might be 
overall tolerable even though a significant majority of a population believes that it is intolerable, 
provided that this majority is uninformed, misinformed, or significantly biased in some way.  
So far, I have discussed whether a behaviour is tolerable, but since harm reduction focuses on 
the harms themselves, it is important to ask whether the actual harms are tolerable. In her work on evil, 
Card (2002) puts forth an influential definition of “intolerable harm”. She defines “evil” as “harm that 
is (1) reasonably foreseeable (or appreciable) and (2) culpably inflicted (or tolerated, aggravated, or 
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maintained), and that (3) deprives, or seriously risks depriving, others of the basics that are necessary 
to make a life possible and tolerable or decent (or to make a death decent)” (p. 17). In this case, Card 
posits that “tolerable” means a life that is “at least minimally worth living for its own sake and from 
the standpoint of the being whose life it is, not just as a means to the ends of others” (p. 18). From these 
quotes, we can gather than an intolerable harm is one that makes a life not worth living for its own sake 
from the point of view of the sufferer. If we are to extrapolate from Card, then, a harm becomes 
intolerable when a person feels that the harm makes their life not worth living for its own sake.  
Building on Card’s work, Calder (2009) separates evils suffered from evils perpetrated. 
According to Calder, an evil can be suffered even if there is no corresponding perpetrator of that evil. 
He offers the example of Danielle, who buys discount shoes for the purpose of saving some money. 
However, in buying those shoes, Danielle knowingly promotes sweatshops. Kali is the sweatshop 
worker that made Danielle’s shoes and she suffers intolerable harm in working at this sweatshop.  
In this case, there is a clear intolerable harm suffered by Kali. However, it would be 
inappropriate to say that Danielle perpetrated evil in buying her discount shoes. Calder reasons that 
Danielle’s will was to buy cheap shoes, not to harm Kali or any number of other sweatshop workers. 
In contrast, a person who pays a hitman extends their will through the hitman for the victim to die. 
Since Danielle’s will does not extend in this way, she has not done evil. Instead, she has just done 
wrong. 
Calder goes on to separate evils suffered from evils perpetrated in the case of institutions. While 
it is perfectly obvious that intolerable harms are suffered under several institutions, the institutions 
themselves are not evil unless the intolerable harm is an “essential component” of the institution’s 
operations. For example, spousal abuse leads to intolerable harm, but the institution of marriage does 
not necessitate spousal abuse. “Spousal abuse is not an essential component of marriage” (p. 28). As a 
result, marriage as an institution is not evil, although it may facilitate bad – though not evil – behaviour. 
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“An institution, or practice, is evil only if intolerable harm is an essential component of the institution 
and there is no sufficient moral justification for the harm” (p. 30).  
Calder’s treatment of institutions is very interesting when it comes to asking whether 
corporations are evil. Uncontestably, businesses are always doing intolerable harms to people all over 
the world. However, there exist many businesses who do not do intolerable harms to anybody, which 
is enough to show that corporations are not, in fact, evil, since intolerable harm is not an essential 
component of doing business. Regardless, these intolerable harms should be addressed since they are 
still wrong. One way to do so is to reduce the harm such that it is no longer intolerable.  Harm reduction 
allows us to pursue this course of action. 
I have so far provided some ways for us to think through whether a behaviour or action is 
tolerable enough for harm reduction initiatives to apply, but I still cannot strictly delineate between 
tolerable and intolerable behaviours or actions. Even seemingly non-tricky cases like child labour may 
have some harm reduction proponents. I wish to remain completely open to definitions and 
classifications of tolerable harms and behaviours. Many may object to this, as my definition of what is 
tolerable is left extremely wide and catches seemingly almost any harmful behaviour. However, where 
many see this as an objection, I see this as a benefit to my view. The very places where harms are 
thought to be intolerable and should be gotten rid of may be the very tricky places that harm reduction 
may apply. After all, harm reduction can reduce intolerable harms to tolerable ones. One need only 
remember how harm reduction for injection drug use started to remember that a behaviour that is 
viewed as extremely intolerable may turn out to be a fruitful site for harm reduction. Thus, to prevent 
any potentially fruitful harm reduction initiatives from being excluded, I leave my definition of 
“tolerability” extremely wide. 
What I can say for certain, then, is that if some individuals think that some harmful behaviour 
is tolerable, then that behaviour is at least a candidate for harm reduction initiatives. Perhaps it is only 
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that one group that tolerates the harm reduction initiatives, but they can apply harm reduction initiatives 
nonetheless. 
Note here that whether a harm or behaviour does, in fact, turn out to be objectively tolerable or 
intolerable, if that is even a possible distinction to make, does not necessarily change whether harm 
reduction is appropriately applied. The benefit of a cluster concept is that it allows for disagreements 
over some of the qualities of the concept and not every instance of the concept needs to have all the 
qualities on the list. So, just because a behaviour is intolerable to some does not mean that harm 
reduction cannot apply. This point is very clear in the examples of paradigm harm reduction initiatives, 
such as injection drug use and sex work. In these cases, many individuals think that the behaviours are 
intolerable, but harm reduction still applies among the groups of individuals who think that those 
behaviours are, in fact, tolerable. 
1.2.4 The primary harms are to the self. 
In the cases of injection drug use, tobacco use, and sex work, the harms that are reduced are primarily 
harms to the very individuals who practice the risky behaviour. There is some consideration of  harms 
to others, such as harms to the injection drug user’s children and safety concerns around improperly 
discarded needles, but the harms are primarily to the user themselves. This quality seems to be 
important for harm reduction frameworks because part of harm reduction is respecting each individual’s 
autonomy, which often means respecting an individual’s choice to continue performing a harmful 
behaviour. At least in the context of harm reduction frameworks, respecting autonomy means allowing 
individuals the choice to perform a behaviour that is harmful to themselves. We may think that this is 
different from respecting somebody’s autonomy when it comes to hurting other people. In other words, 
we might be more inclined to reduce the prevalence of the behaviour instead of merely reducing harms 
if the harms are done to other people. 
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Notice here that situations where the primary harms are to other people give us greater incentive 
to intervene. This is to say that many may have the intuition that we should do more to prevent harms 
done to other people than harms done to the self. Thus, I argue that there is no good reason for limiting 
harm reduction to situations where harm is done primarily to the individual practicing the behaviour. 
After all, harm to others is still harm and I see no good reason not to reduce the harm done to those 
individuals as well. Harm to others is still harm that is worth reducing. To go even further, harm to 
others may be even more important to reduce than harms to selves. 
1.2.5 The harm is worth reducing even if it is not cost-efficient to do so. 
Public health workers often use a cost-benefit analysis to convince policy makers that harm reduction 
efforts are worthwhile. For example, public health workers could save the government thousands of 
dollars by distributing clean needles instead of users sharing needles and increasing the need to treat 
Hepatitis C and HIV/AIDS in a public health care system. However, it seems that at least in the cases 
of injection drug use and sex work, we ought to show these individuals compassion and help them 
reduce the harms of their behaviour regardless of whether the cost-benefit analysis works out positively. 
Thus, it is important that there is a compassionate dimension of harm reduction above and beyond a 
simple cost-benefit analysis. This aligns with the core harm reduction principles and the many 
definitions of “harm reduction” explored earlier. 
In practice, whether in a public or private health care system, there are limited resources for 
health care. Thus, while we ought to show compassion to individuals who experience harm, we may 
not have enough resources to fund harm reduction programs while continuing to fund all other facets 
of health care. Whether harm reduction programs are prioritized highly enough to get funded when the 
cost-benefit analysis does not work out in its favour is up to policy makers. The only point that I am 
making here is that we ought to show compassion for these individuals. Whether we do that through 
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funding harm reduction programs or in some other way is something that is decided by a myriad of 
considerations that policy makers take on when they address health care in their respective nations.  
1.2.6 Significant harms are due to stigma or criminalization of the behaviour. 
In all three cases of existing applications of harm reduction, stigma or criminalization of the behaviour 
is part of the harms associated with the behaviour itself. This is to say that the stigma toward or 
criminalization of a behaviour is part of what makes the behaviour harmful. For example, injection drug 
users and sex workers deal with police officers who charge them in the legal system instead of acting 
as a bridge toward social workers and therapists who are more effective at helping injection drug users 
and sex workers. Thus, part of the harm reductive efforts involve reducing the stigma against the 
behaviour and/or decriminalizing the behaviour altogether. 
1.3 Conclusion 
In this chapter, I presented a brief history of harm reduction practices and offered eight core principles 
of harm reduction frameworks from the existing literature. I reviewed three major behaviours where 
harm reduction has been applied: injection drug use, tobacco use, and sex work. I then presented the 
notion of a cluster concept, where a list of qualities that seem to be related to a concept is presented and 
an instance of the concept is adjudicated based on how well it fits those qualities. Finally, I generated 
a cluster concept definition of “harm reduction”, which involved six qualities, only one of  which was 
necessary. 
 With this foundation of knowledge in harm reduction and an understanding of harm reduction 
as a cluster concept, we can begin to see how harm reduction can be applied to arenas outside of public 
health and social policy. Indeed, Chapter 2 will apply this cluster concept to harm reduction for 





The Corporate Angle 
Now that we have a good grasp of what harm reduction is and how it is defined, we can move on to 
applying the concept of harm reduction to alternative contexts. The focus of this chapter is to apply the 
concept of harm reduction to the context of corporations. Before we do that, however, it is important to 
explain why a harm reduction framework is important for corporations. After all, corporations have had 
corporate social responsibility campaigns for years and have been making strides toward leaving the 
environment and society in a better place. Only once we establish why harm reduction is useful for 
corporations does it make sense to apply the framework to corporations.  
This chapter starts with an overview of corporate social responsibility, followed by three 
reasons for using harm reduction frameworks instead of corporate social responsibility frameworks. 
Next, I apply the cluster concept of harm reduction to corporations and show that harm reduction 
frameworks do apply appropriately to corporations. After that, I explain two features of my harm 
reduction framework for corporations. First, the corporation’s motivation for pursuing harm reduction 
initiatives is irrelevant. Second, any amount of harm reduction, however small, should be encouraged. 
These two features of my harm reduction framework are controversial, but I explain my reasoning for 
these two features in this chapter.  
2.1 Corporate Social Responsibility1 
One influential account of corporate social responsibility comes from Archie B. Carroll. He introduced 
his four-part definition of corporate social responsibility in 1979. Carroll listed four responsibilities of 
business: economic, legal, ethical, and discretionary. Economic responsibilities recognize that a 
 
1 This section is an adaptation of my previous work on Chapter 4 of With a Clear Conscience (2018). 
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business’s first responsibility is to generate profit, otherwise all other areas of corporate social 
responsibility become moot. Legal responsibilities require businesses to generate profits within the 
bounds of the law. Ethical responsibilities are actions that are expected of a business but are not legally 
required. These responsibilities go beyond legal responsibilities. For example, eliminating unnecessary 
pollution could be argued to be expected but not legally required. Finally, discretionary responsibilities 
are social actions that a business can choose to perform, but these actions are not expected of a business 
nor legally required. Carroll admits that discretionary responsibilities are vague, but includes them in 
his framework nonetheless. 
Though the four parts of corporate social responsibility are described separately in this 
characterization, they are dynamic and sometimes addressed simultaneously. For example, a 
pharmaceutical company that recalls a drug due to adverse side effects may be simultaneously fulfilling 
its economic, legal, and ethical responsibilities. It is interesting to note that economic and legal 
responsibilities are often fulfilled simultaneously. Further, ethical responsibilities push the boundaries 
of legal responsibilities, such that actions that we think are ethically required often become codified in 
regulations, as we will see with the example of stanchion barns below. Clearly, the four parts of 
corporate social responsibility are heavily intertwined. 
Carroll (1991) later characterized the four parts of corporate social responsibility as a pyramid 
of corporate social responsibility. The pyramid depicts economic responsibilities as the foundation of 
the pyramid to show that these responsibilities are most important for the firm to fulfill. Next come 
legal responsibilities, then ethical responsibilities, and finally philanthropic responsibilities, as opposed 
to his previously-named discretionary responsibilities. In this later paper, Carroll argues that 
philanthropic actions are those that make a firm a good corporate citizen. Again, the four parts of 
corporate social responsibility are presented separately but are intertwined in reality. 
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Carroll’s pyramid of corporate social responsibility has several shortcomings, which are listed 
in Schwartz and Carroll (2003). First, the use of a pyramid might lead one to think that philanthropic 
responsibilities are most important because they are at the top of the pyramid. In fact, this is the opposite 
of what Carroll intended, as he says that economic responsibilities are the most fundamental. Further, 
a pyramid does not depict the overlapping nature of these corporate social responsibility domains. 
Second, philanthropic responsibilities are ill-defined and often subsumed under ethical responsibilities. 
This is because it is difficult to differentiate between ethical and philanthropic activities and 
philanthropic actions could be purely based on economic interests. In other words, we often do not have 
access to a corporation’s motivations for performing an ethical or philanthropic activity, so it is difficult 
to differentiate between the two. Finally, Schwartz and Carroll criticize the pyramid of corporate social 
responsibility for inadequately developing the economic, legal, and ethical responsibilities of business. 
Building off Carroll’s pyramid of corporate social responsibility, Schwartz and Carroll (2003) 
propose the Three-Domain Model of Corporate Social Responsibility. The model uses a Venn diagram 
to depict the economic, legal, and ethical responsibilities of business. The economic domain is defined 
as any direct or indirect activity meant to maximize profit or share value. Most of a business’s actions 
are expected to fall under the economic domain.  
The legal domain is split into three categories: compliance, avoidance of civil litigation, and 
anticipation of the law. Compliance is further subdivided into three categories: passive compliance, 
restrictive compliance, and opportunistic compliance. Passive compliance occurs when a business is 
doing what it wants to do and happens to be complying with the law. Restrictive compliance occurs 
when a business is performs an action that it would not perform if it were not for the legal requirement. 
Finally, opportunistic compliance occurs when a business finds a loophole in the law or operates in a 
certain area because of the particular legal requirements in that area. 
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Avoidance of civil litigation occurs when a business performs an action to avoid future 
litigation for negligence. Voluntary recalls or ceasing environmentally unfriendly activities fall under 
this category. Finally, anticipation of the law occurs when a business changes it practices due to 
upcoming or expected legislative changes. 
Schwartz and Carroll divide the ethical domain into three groups: conventional, 
consequentialist, and deontological ethical standards. Conventional standards refer to the norms in a 
given organization, industry, profession, or society for ethical behaviour. Consequentialist standards 
encompass activities that promote the general good of society by creating the greatest net benefit or 
lowest net cost to society. Finally, deontological standards refer to duty-based ethical standards, 
including, but not limited to, those of moral rights and justice. Schwartz and Carroll explain that the 
three domains overlap and provide a myriad of possible combinations of the three domains to describe 
one particular behaviour.  
Another influential theory of corporate social responsibility is Elkington’s “Triple Bottom 
Line” (1998). The three components of the triple bottom line are economic prosperity, environmental 
quality, and social justice. These components are sometimes summarized as “people, planet, profit”. 
The triple bottom line requires companies to balance their environmental and human impacts with profit 
generation by opting for net-triple-bottom-line profit instead of profit on its own. According to 
Elkington, the triple bottom line prepares corporations for a “global cultural revolution” (p. 3) and helps 
them make a “sustainability transition” (p. 4). This revolutionized way of doing business includes 
increased competition due to a higher demand for sustainability, a shift in values toward environmental 
and social issues, increased transparency, and increased attention to corporations’ long-term impacts. 
One of the benefits of the Triple Bottom Line is that it considers sustainability and social justice to be 
just as important as profits. This perspective contrasts with the above-mentioned theories that see profits 
as being foundational with ethical demands coming only after profits are satisfactory. 
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The broad reach of corporate social responsibility is impressive. Every major business-related 
academic journal regularly publishes information on corporate social responsibility. Corporate social 
responsibility campaigns are often discussed in the media and consumers look to these initiatives to 
make purchasing decisions (Becker-Olsen et al. 2006). Corporate social responsibility is taught across 
many business schools and undergraduate business students are graduating with the expectation of 
getting a job within a responsible company. 
 Despite its broad reach, and the multiple explanations that Carroll, Schwartz and Carroll, 
Elkington, and others put forth for corporate social responsibility, its exact definition is up for debate. 
It is often confused with other related concepts, such as corporate citizenship and sustainability 
(Schwartz and Carroll 2008). Further, the definition of corporate social responsibility has itself been 
contested. Many definitions of corporate social responsibility have been suggested (e.g. Carroll 1979; 
Elkington 1998; Garriga and Melé 2004; Sarkar and Searcy 2016; Schwartz and Carroll 2008) and the 
literature has settled on none of them. In fact, Okoye (2009) argues that the definition of corporate 
social responsibility is impossible to nail down because the concept is the kind of thing that cannot be 
universally defined. He applies Gallie’s (1956) concept of an “essentially contested concept” to the 
concept of corporate social responsibility and finds that corporate social responsibility indeed fits under 
Gallie’s conception of such. However, all theories agree that corporations should continue to generate 
profits and should do some kind of good, broadly defined. Regardless of the difficulty with defining 
corporate social responsibility, the approach has been proven to offer corporations many benefits. It 
increases a corporation’s ability to compete in the market (Burke and Logsdon 1996), protects a 
corporation’s reputation (Minor and Morgan 2011), and attracts job applicants (Duarte et al. 2014). 
In practice, corporations that wish to do social good, or wish to appear to do social good, usually 
do so under the banner of corporate social responsibility. Corporations have a wide variety of options 
when it comes to implementing corporate social responsibility initiatives in their organizations. Some, 
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like L’Oreal (2015), choose to focus on just one aspect of corporate social responsibility, like 
sustainability. Others, like Starbucks (2019), choose to deliver impactful change on a variety of causes, 
such as ethical sourcing, environmental health, and diversity. The efficacy of these initiatives varies 
and are often documented in annual corporate social responsibility reports put forth by the corporation 
itself. Some organizations, like Sustainalytics (2018), integrate and compare data on corporate social 
responsibility initiatives for investors who wish to support responsible corporations.  
This section has characterized corporate social responsibility as a concept that many 
businesses, academics, and business students look to for guidance on how to act ethically while doing 
business. We have seen that there are several dimensions of corporate social responsibility and that its 
uptake is impressive. Despite conceptual issues of the exact definition of “corporate social 
responsibility”, the term is still pragmatically useful. Given the wide reach of corporate social 
responsibility, it might seem as if there is no need for any other concept that attempts to help businesses 
act more ethically. The next section shows that this assertion is mistaken. 
2.2 The Need for Harm Reduction 
There are at least three major gaps in corporate social responsibility. First, there are certain types of 
corporations that may never seem socially responsible because their core mission is socially 
irresponsible. Consider oil and gas companies, whose primary business is to sell an environmentally 
damaging product that is obtained through environmentally damaging means, despite the industry’s 
attempts at painting themselves as ethical. Also consider the meat packing industry, which keeps 
animals in inhumane conditions and slaughters thousands of them every year so that consumers have 
access to cheap meat. 
Second, there are corporations that pursue corporate social responsibility campaigns that are 
highly removed from their core business and thus seem misaligned with corporate operations. This 
 
 38 
particular gap in corporate social responsibility is a pragmatic worry for corporations. Consider 
Dowling and Moran’s 2012 paper, “Corporate Reputations: Built in or Bolted on?”. Corporations with 
“built in” corporate social responsibility campaigns have initiatives that align with their core business 
operations. For example, Starbucks sources coffee in a way that respects its farmers. Since they have 
to source coffee anyway, they are being socially responsible as a part of their core business. In contrast, 
“bolted on” corporate social responsibility campaigns have initiatives that seem further removed from 
their core business operations. For example, Ronald McDonald House Charities (2019) help parents 
stay close to their sick children while the children are in the hospital. This charity is beneficial to many 
families, but has very little to do with McDonald’s core operations of serving fast food at low prices. 
Dowling and Moran argue that “bolted on” campaigns are highly replicable and do not provide a distinct 
source of competitive advantage. They advocate instead for “built in” corporate social responsibility 
campaigns and argue that these are better for bolstering a corporation’s reputation. This conclusion 
aligns neatly with the intuition that some corporations pursue the seemingly wrong kind of corporate 
social responsibility initiatives. Instead of being socially responsible as a business, they perform 
unrelated activities that they call corporate social responsibility, but are often a distraction from the 
major harms that they do in the course of their operations. 
Third, there are corporations for whom corporate social responsibility is impossible because 
they do not have the resources to support such a program. Many mid-sized businesses, and certainly 
small businesses, fall into this category. These types of businesses often need to invest as much capital 
as possible into the maintenance and growth of the business and thus cannot afford to spend money on 
corporate social responsibility campaigns. This is not to say that mid-sized and small businesses do not 
pursue socially responsible missions, since many of them do, but it is more difficult for them because 
of their limited resources. An approach to corporate responsibility that requires fewer resources would 
be beneficial for those that do not currently have corporate social responsibility campaigns. As we will 
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see, using my harm reduction framework will allow all companies, including those with strained 
resources to participate fully in harm reduction. 
Harm reduction has the power to address all three of these gaps in corporate social 
responsibility. For corporations that can never truly be socially responsible, harm reduction offers a 
lower threshold for engagement. That is, the demands on the corporation to do good for the environment 
and society are lowered from going “above and beyond” to simply reducing harms. For corporations 
who pursue corporate social responsibility activities that are unrelated to their business, harm reduction 
forces them to look at the harms done throughout the course of their normal operations and address 
those particular harms. This is to say that harm reduction frameworks push corporations toward “built 
in” behaviours by nature. Since a corporation under a harm reduction framework would be reducing 
harm that they do to the environment and/or society, they are forced to confront the harms that their 
operations lead to. Importantly, this is not to say that corporations who reduce harm in “bolted on” 
ways are not harm reducing. Indeed, the pluralistic nature of a harm reduction framework would still 
encourage “bolted on” harm reduction initiatives. However, harm reduction naturally leads 
corporations toward more “built in” initiatives that are better aligned with their operations. Finally, 
again, since harm reduction has a lower threshold for engagement, corporations who cannot or will not 
put the resources into corporate social responsibility initiatives can turn to harm reduction instead.  
My framework for harm reduction is even more distinct from corporate social responsibility. I 
argue that harm reduction for corporations has two explicit features that corporate social responsibility 
is silent on. First, my framework does not judge corporations for their motivations for pursuing harm 
reduction. Second, my framework celebrates any amount of harm reduction, however tiny. More will 
be said about these two features later on in this chapter, but it is important to note here that corporate 
social responsibility is silent on these two explicit features that I draw out in my framework.  
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At this point, I want to be clear that harm reduction fills these gaps in corporate social 
responsibility. However, harm reduction does not replace the need for corporate social responsibility. 
In fact, it is very much in the spirit of harm reduction to coexist with several other theories for doing 
environmental and social good. So, in some situations, theories of corporate social responsibility are 
sufficient, while in other cases, like the cases listed above, my harm reduction theory is more 
appropriate. A corporation could even conceivably use both concepts to ensure that they are doing good 
for the environment and society. Think of corporate social responsibility and harm reduction as two 
tools that corporations can use to do environmental and social good. 
2.3 Applying Harm Reduction to Corporations 
Let us return to the discussion of harm reduction as a cluster concept. This section will demonstrate 
that corporations are, indeed, an appropriate site for harm reduction applications. If we were to apply 
harm reduction to corporations, we would take the following stance: instead of judging corporate 
operations as right or wrong, we focus on reducing the harms related to corporate operations without 
ceasing corporate operations altogether. Let us address each of the qualities in the cluster concept in 
turn. 
2.3.1 There is at least one identifiable harm associated with the behaviour.  
Recall that this is the only necessary condition for harm reduction. It is abundantly clear that many 
corporations do massive harms to the environment and society. For example, corporations are massive 
polluters (Lober 1998). According to the United States Environmental Protection Agency, air pollution 
released by corporations continues to decrease year over year. However, over 5 billion tons of emissions 
continued to be released in 2017, which represents a significant amount of environmental harm.  
Some corporations also hire child labour (Boje and Khan 2009) or fail to safeguard against 
contractors who use child labour. Child labour is harmful because it prevents children from going to 
 
 41 
school and is positively correlated with poverty (Ray 2000). However, corporations continue to make 
use of child labour directly or quietly ignore the use of child labour among its contractors because it 
can be economically efficient (Baland and Robinson 2000). Corporations allow children in developing 
nations to perform work because the firm can pay low wages and thus minimize costs. It is important 
to note here that hiring child labour or failing to safeguard against it is a natural extension of other 
harmful business practices, such as offshoring and sub-contracting for the corporation’s benefit of 
paying low wages. Lack of workplace protection and failure to uphold health and safety hazards, such 
as ensuring adequate fire evacuation protocols, are also part of the problem. So, while child labour is 
certainly horrible, other workplace practices that make child labour commonplace are also problematic. 
Further, corporations in certain industries enact specific harms against consumers. For 
example, the pharmaceutical industry often raises prices on life-saving medication. In 2015, the price 
of Daraprim went from $13.50 per pill to $750 per pill overnight (Pollack 2015). Less dramatically, but 
notably, Pfizer raised the price of 148 drugs by an average of 8.8% at the beginning of 2018 (Crow 
2018). Other companies followed suit. These behaviours have sparked criticism from consumers and 
policymakers alike. Price increases have driven governments to consider enacting legislation on 
pharmaceutical pricing (Abbott 1995; Puig-Junoy 2010; Vernon, Golec, and Hughen 2006).  
These are just some of the harms that corporations do to society and the environment. The list 
can no doubt be expanded, but what I have included here is enough to make my point. Corporations do 
vast harms to society and the environment in the course of their operations. These are harms that should 
be reduced. However, corporations are simultaneously important for the proper functioning of society. 
Corporations bring us many goods and services that support survival and improve our quality of life. 
They also employ billions of people around the world and work with governments to bring essential 
goods and services, like vaccines, to the public. It would be a mistake to outlaw corporations and give 
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up these benefits. Given that corporations should be here to stay, harm reduction is even more 
appropriate because it allows us to preserve the benefits of corporations while reducing its harms.  
Further, it is true that not every corporation enacts harms against the environment or society. I 
am perfectly happy to accept that harm reduction may be irrelevant for certain corporations who do not 
do any harm. To those who think that a particular corporation does not do any harm to the environment 
or society, I invite you to inspect its operations carefully before coming to this conclusion. It is my 
personal view that there are very few corporations that do no harm to the environment or society. 
Regardless, corporations that truly do no harms to the environment or society can be directed toward 
corporate social responsibility to encourage the corporation to go “above and beyond”. Indeed, 
corporate social responsibility initiatives are compatible with harm reduction initiatives. 
2.3.2 The behaviour is tenacious at the population level. 
Corporate operations are clearly tenacious. We interact with corporations all the time, often without 
consciously realizing it. Consider, for example, all of the money that you spend in a month. Paying rent 
or a mortgage, buying groceries, filling your car up with gas, and heating your home are all transactions 
that involve interactions with corporations. It seems hard to imagine a world without corporations.  
Another way that we can think about the tenacity of corporations is to imagine what would 
have to happen for corporations to be eliminated. Presumably, such a drastic change would have to 
happen through legislation, where governments and law enforcement prevent people from organizing 
into corporations and prevent corporations from buying, selling, trading, hiring labour, and so on. 
However, governments are unlikely to eliminate corporations in this way. First, corporations are 
significant financial contributors to political campaigns, which disincentivizes politicians to eliminate 
corporations. Further, corporations pay taxes that fill government coffers and allow the government to 
provide social services to the public. Second, as mentioned earlier, corporations do provide a lot of 
benefit to society through producing jobs and providing employees the means to live their conception 
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of a good life. Thus, politicians are friendly to corporations that benefit their country’s economy. For 
example, Canadian Prime Minister Justin Trudeau was present at the opening of the Google Canada 
engineering headquarters in 2016 (Dingman 2016). Examples like these show us that corporations and 
governments can often work hand in hand. As a result, the elimination of corporations through 
legislation is unlikely. 
A revolution may also lead us to away from capitalism and thus corporations. However, this is 
also unlikely given the tenacity of capitalism. Mark Fisher, author of Capitalist Realism: Is there no 
alternative? (2009) argues that “capitalism can only be resisted, never overcome” (p. 28). Even though 
we may believe deeply that capitalism is bad, we still behave as if money has intrinsic value. In fact, 
Fisher argues, we are only able to value money so much because we believe that it is so bad (p. 13). 
Further, we are so attached to capitalism that we fail to question it and would rather look for ways to 
mitigate its consequences rather than bring it to an end, given that we lack any kind of viable alternative 
(p. 14). Capitalism, and thus corporations, will persist. 
Fisher’s commentary is interesting because of the connection between capitalism and 
corporations. At its core, and at its best, capitalism is an economic and political system that empowers 
individuals to trade privately for their own benefit and minimizes state intervention. This system often 
gives rise to corporations, where individuals can buy and sell in an organized manner. Thus, in a 
capitalist society, corporations become incredibly important for the basic functioning of society. If 
capitalism is going to persist, then there will be demand for corporations and the goods and services 
that they provide. 
This is not to say that capitalism is a good or an ideal way to organize society all the time. Vast 
harms to the environment and society are compatible with a capitalist society, and indeed many other 
types of societies, that involve corporations. Thus, it becomes important for us to think deeply about 
the harms that capitalism, and corporations, bring about, then try to reduce those harms accordingly.  
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Now that I have argued that corporations are tenacious, it becomes important to ask whether 
corporate harms are tenacious, as discussed in Chapter 1. After all, harm reduction for corporations 
would be useless if corporations were tenacious but enacted no harms against the environment or 
society. The way that I see corporate harms is as follows. Markets can operate either efficiently, which 
involves encouraging competition, or inefficiently, which involves de facto or actual monopolies in 
some industries. No matter which of these is the case, corporate harms will occur. 
In a competitive market, corporations are constantly trying to outdo the other. This involves 
appeasing shareholders by increasing net profits while simultaneously appeasing the customer by 
charging lower prices. This is not to say that every corporation in every industry is going to charge a 
low price, but there will likely be a low-priced alternative for most goods, given that competition drives 
prices downward. Increasing net profits while charging low prices necessarily involves cutting costs. 
This behaviour involves cutting corners where the company can, perhaps by reducing the quality of 
their products, reducing labour costs, reducing sourcing costs, and so on. The business news constantly 
reminds us that cutting corners is where a lot of damage to the environment and society comes from. 
For example, the BP Deepwater Horizon explosion reminds us that cost-cutting can come at the expense 
of safety and environmental protection (Broder 2011). Thus, in a competitive market, corporations will 
at least be tempted to cause harm to the environment and society. 
In a non-competitive market, monopolies or de facto monopolies tend to form. This 
arrangement usually drives prices upward, which harms consumers. In other words, monopolies make 
it difficult for free trade to occur between the firm and the consumer. This behaviour is clearly 
detrimental to our ideal of a free market where people are able to trade what they have for what they 
want at market value. 
Therefore, in a capitalist system with a market, either competitive or non-competitive, harm is 
often done to the environment and society. Again, this is not to say that every corporation will be 
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harmful to the environment and society, but it is enough to make my point to say that some corporations 
will harm the environment and society. So long as these harms occur, and it is very likely that they will, 
there is a place for harm reduction for corporations. 
2.3.3 The behaviour is, to some extent, tolerable. 
It seems needless to say that we tolerate at least most corporations in our day to day lives. Many people 
willingly provide their personal information to technology giants like Google and Apple that track their 
every move. Our lives are constantly made easier by the myriad of products and services that we buy 
to solve our problems. Without a doubt, corporations are ubiquitous in our lives and they continue to 
flourish due to consumer participation. 
Corporations may be even more tolerable than we think, as they are also flourishing in areas 
where we might expect them to fail. The Forbes Global 2000 lists the top 2000 publicly traded 
companies in the world. The 2018 list includes notable corporations in communist China like ICBC 
(#1), China Construction Bank (#2), and Alibaba (#82). Overall, Chinese corporations occupy over 
10% of the Forbes Global 2000 2018 list with 18 companies in the top 100. This is clear evidence that 
corporations have managed to perform well in regions that have historically made active effor ts to 
reduce capitalist values. Indeed, China’s willingness to take on some capitalist values is more evidence 
of corporate tenacity. 
Many also argue that businesses are overall good for our society. In theory, this is indeed the 
case. Corporations make jobs that trade labour for money that employees can then use to lead a fulfilling 
life. As a result, countries have flourishing economies and have satisfied citizens. Further, corporations 
provide important goods and services that help improve the quality of life for its customers. Thus, 
corporations can lead to fulfilling, high-quality livelihoods. 
Note here that while a business may do all the good deeds listed in the above paragraph, they 
may still harm the environment or society in the process. For example, a corporation may continue to 
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pollute the environment or treat its contractors in faraway nations poorly while stimulating the economy 
in multiple countries and providing high-value products. To say that businesses are good overall is not 
to say that businesses are always good. All this assertion means is that businesses do more good than 
harm. This position is perfectly compatible with a harm reduction framework for corporations, where 
we reduce the harms that exist while corporations continue to do good. Simply put, the net good that 
corporations do to the environment and society may make them tolerable but this does not mean that 
they do not do any harms whatsoever. 
There is a further question of whether corporate harms are tolerable. I have already touched on 
some of the harms that corporations enact that might be tolerable. However, I want to draw attention to 
the fact that there is a myriad of corporate harms that are being done, ranging from small, almost benign 
harms, to straightforward disasters. Clearly, at least some of these harms are tolerable, especially the 
small harms, and so this is enough to demonstrate that harm reduction is applicable to at least some 
harms that corporations enact on the environment and society. 
2.3.4 The primary harm is to the self. 
As explained in Chapter 1, all of the key examples of harm reduction involve harms that are primarily 
done to the very person who is practicing the high-risk behaviour. However, in the case of corporations, 
most of the harms that we discuss are harms done to other populations outside of the corporation. This 
difference between classic harm reduction and harm reduction for corporations is important.  
 As alluded to in Chapter 1, we might think that the harm being done to the self is important 
because of personal autonomy. Most people are thought to have autonomy over their own bodies, so 
they reserve the right to do almost whatever they want with their bodies. Thus, if a person understood 
the consequences of the harmful behaviour but wanted to risk the harm anyway, they should be allowed 
to do so, often with the caveat that the behaviour does not stop anybody else from also doing whatever 
they want with their own body. Respect for autonomy underlies much of the classic harm reduction 
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theory where we “meet people where they are” and do not force any harm reduction measures onto 
unwilling participants.  
The caveat identified above is key. People are usually thought to be able to do whatever they 
want with their own bodies so long as the behaviour does not prevent anybody else from doing whatever 
they want with their own body. In the cases of injection drug use, tobacco use, and sex work, it is largely 
the case that the harms are done to the person performing the harmful behaviours and do not extend to 
other people. However, the case of corporations is very different. In these cases, few harms are done to 
the individual corporation, but several grievous harms are done to others either directly or indirectly 
through damaging the environment. These harms to others suggest, according to the above principle, 
that corporations should cease their harmful behaviours because they are reducing the ability of others 
to remain unharmed. Ceasing these harms is thought to be even more important than ceasing harms that 
individuals do to themselves. In other words, the mandate to reduce harms to others is stronger than the 
mandate to reduce harms to selves because of personal autonomy. Thus, the fact that corporations do 
harm to others and the environment gives us even greater reason to want to reduce those harms. 
The harms that corporations do to others seem countless. The sheer scale of the harm to others 
should motivate us to apply harm reduction to corporations. Again, recall the harms that corporations 
do to people and the environment. Pollution, child labour, and specific harms to consumers are massive 
problems that have no easy solutions. Corporations impact people and the environment on a global 
scale, especially when we focus on multinational corporations. Corporate harms to the environment 
and society affect us all. This results in an incredible amount of harm that we ought to be motivated to 
reduce. Again, while some individual corporations may not harm the environment or society, many 
corporations do, and we should be motivated to reduce these harms. 
Finally, recall that defining harm reduction as a cluster concept means that not every quality 
needs to be satisfied for an example to qualify as part of a concept. Though corporations do not exhibit 
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harms that are done primarily to themselves, they can still qualify as an appropriate site of harm 
reduction. 
2.3.5 The harm is worth reducing even if it is not cost-efficient to do so. 
This quality seems to apply to corporations in a relatively straightforward way. The vast harms done to 
the environment and society are worth reducing for the sake of our environment and society, even if it 
did not turn out to be profitable to reduce these harms. Massive pollution, child labour, and specific 
harms to consumers are not appropriate even if the cost-benefit calculation works out in favour of 
corporations operating under the status quo. Indeed, there ought to be a deep intuition that the 
environment is worth saving, children deserve an education and play, and consumers deserve fair 
treatment. 
More recently, Nicholas King (2019) has argued that harm reduction is worthwhile even if the 
cost-benefit analysis does not work out in favour of harm reduction programs. King argues that harm 
reduction programs are fundamentally compassionate and not simply about increasing social utility. He 
points out that the need to help children with leukemia or helping trapped adventurers is not justified 
by the behaviours increasing social utility. Instead, these actions are justified because we should be 
compassionate toward others. Likewise, there is no need to justify helping injection drug users or sex 
workers on the grounds of social utility. Instead, we should justify helping these people because of 
compassion. 
My assertion, then, is that it is worth reducing the harms that corporations do to the environment 
and society because corporations hold vast amounts of power over the environment and society.  
Following King’s arguments, corporations need no pragmatic reason, like a cost-benefit analysis, to 
care for the environment and society. It is simply required of them to do so.  
Importantly, a company ought to reduce harm for reasons other than cost-efficiency, but one 
might rely on cost-efficiency arguments to convince them to reduce the harm. We see this very clearly 
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in needle and syringe exchange programs when public health experts meet with governments to 
convince them to institute needle and syringe exchanges. They will often present the cost-benefit 
analysis to demonstrate that, for example, needle and syringe exchanges reduce the burden on hospitals 
to treat patients with HIV (T. Mercer, personal communication, Feb 1, 2019). This cost-benefit analysis 
may be very convincing to policy makers and is absolutely a tool in the harm reduction toolbox to 
convince others to adopt the project. However, this does not reduce the need for compassion when it 
comes to taking care of those who are harmed in ways that are applicable and respectful to the 
individual. 
2.3.6 Significant harms are due to stigma or criminalization of the behaviour. 
This last condition does not seem to apply to corporations. There is usually very little stigma against 
corporate operations or profit-seeking and while some corporations or industries are banned from 
operation in certain locations, corporations as a whole are far from being criminalized. In fact, as 
discussed earlier, many believe that corporations are beneficial to society overall by increasing 
economic prosperity and individual wealth. Thus, this last trait does not apply to corporations.  
It seems that this feature of today’s harm reduction programs arises because many of them 
relate to the healthcare field. Stigmatization and criminalization of many behaviours that are illegal or 
illicit do, indeed, affect many existing harm reduction programs and the people that they aim to help. 
However, when taking harm reduction out of the healthcare field, this stigma and criminalization 
largely falls away.  
This is not to say that there is no stigma or criminalization related to corporate behaviours. 
Certain industries are stigmatized or dismissed as being harmful to consumers. For example, payday 
loan companies are heavily regulated to the point where there are few distinctions between competing 
firms. This regulation has come about due to severe harms that the industry was doing to consumers. 
Further, certain behaviours related to corporations, such as insider trading, are illegal. These regulations 
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have been enacted to help markets work efficiently. So, some behaviours within the corporate domain 
are frowned upon or illegal. 
It is important to notice that the stigma and criminalization of some corporate behaviours is 
different from the stigma and criminalization of injection drug use, tobacco use, and sex work. In the 
classic cases of harm reduction, the stigma and criminalization occur at the level of the individual. For 
example, a sex worker would endure name-calling or demeaning behaviour themselves and would be 
taken to jail if found to be violating a law. In this case, the sex worker themselves suffers the 
consequences of performing sex work. In the case of corporations, the stigma and criminalization 
happen at the level of the firm. Certainly, some employees of these firms are targeted, but by and large, 
it is entire corporations that are called out in the media and not individual people. This distinction is 
important because faceless corporations enduring stigma and criminalization of certain behaviours does 
not affect any one person directly in the sense that it does not dramatically reduce or make difficult the 
firm’s potential to work in the way that the stigma and criminalization does for the sex worker. In this 
way, the corporation offers protection to the employees and executives who make decisions within it. 
So, while stigma and criminalization attach to certain corporations or industries, it is not nearly as 
damaging as the stigma and criminalization that attaches to individuals in the cases of injection drug 
use, tobacco use, and sex work. 
Despite these differences, a harm reduction framework can still apply to corporations. Recall 
that not every feature of this cluster concept needs to apply to a case for that case to count as harm 
reduction. This is simply one feature that does not apply to corporations. 
2.3.7 Summary 
The above analysis has shown that four out of the six major traits of appropriate applications of harm 
reduction apply to corporations. This, I argue, is sufficient for concluding that it is appropriate to apply 
harm reduction to corporations. Further, as alluded to above, the sheer scale of the harms that 
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corporations do to the environment and society should convince us that harm reduction is an important 
step to take in making our world a better place to live in.  
2.4 Two Features of Harm Reduction for Corporations 
There are two features of my conception of harm reduction for corporations that are important but will 
likely be objectionable. These features are explicitly stated in my framework, which makes my harm 
reduction framework importantly different from corporate social responsibility. As we will see in this 
section, both features of my harm reduction framework for corporations come from deeply respecting 
the core principles of harm reduction. Specifically, harm reduction is a pragmatic practice that seeks to 
reduce the harm associated with a behaviour instead of asking for abstinence or even a reduction in the 
behaviour itself. The focus is on reducing as much harm as possible given the individual’s own 
motivations, beliefs, and desires.  
In this section, I first argue that corporations can pursue harm reduction for any reason. Second, 
I argue that corporations can perform any amount of harm reduction, however, small, and that should 
count as a good thing. 
2.5 Motivations for Pursuing Harm Reduction 
Some of us have the intuition that doing harm reduction or corporate social responsibility for the 
purpose of making profits is the wrong motivation to have. We might recall the time that we rolled our 
eyes at Walmart for advertising their environmentally friendly initiative of turning off the lights in their 
stores at night. Since this was a way for the company to save money, it might have seemed like the 
worth of the initiative was diminished in some way. Instead, one might think, we should only support 
those companies who perform harm reduction or corporate social responsibility activities because they 




 Although I share this intuition, my reasoning leads me to a different conclusion. I argue that 
the motivation for pursuing harm reduction or corporate social responsibility does not matter. We 
should not care about a corporation’s motivations for action and should focus only on the outcomes of 
their actions. My reasoning goes something like the following. Consider Corporation A, which has 
executives that really care about protecting the environment, and so take on Environmental Mission B. 
Unfortunately, Corporation A is horrible at the execution of this mission, and so fails to make any 
difference to the environment. Now consider Corporation C, which has done rigorous calculations and 
has come to the conclusion that Environmental Mission B could increase its profits. They have the 
resources and talent to execute Environmental Mission B properly, and they do so. They benefit the 
environment and so advertise their successes widely to attract consumers.  
 Now, would you rather have Corporation A or Corporation C in your city? Perhaps we would 
prefer to be friends with the executives in Corporation A, but in the end, they make no difference to the 
environment. It seems then, if we actually care about the environment, that we should prefer  
Corporation C. This example shows that if we care about changes being made to the environment and 
society, we should prefer corporations that are effective, regardless of their motivations. Further, it 
seems fairly obvious that most of us do care about actual changes being made to the environment and 
society, so most of us would prefer Corporation C. Besides, a corporation must care about its profits, 
otherwise it will not be a corporation for very long. Thus, requiring corporations to only pursue harm 
reduction or corporate social responsibility out of the goodness of its heart is untenable. Further, 
preferring effectiveness over motivation respects the harm reduction principle of acting in pragmatic 
ways. Since I am focused on effectiveness instead of motivation, I am prioritizing pragmatic 
interventions over internal motivations that may or may not result in an actual reduction in harms.  
 This is not to say that motivations are completely irrelevant. We might think that corporations 
that are both motivated by a need to improve the environment and society and are effective at making 
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those improvements are the most morally worthy. It is also possible that a corporation that is motivated 
by a need to improve the environment and society is more likely to do more to reduce harm. I do not 
contest these claims, but I also do not argue in favour of or against them. What I am saying is that 
corporations that are motivated by profits alone and are effective at making improvements to the 
environment and society should also be thought of as doing something good for the world. 
 This conclusion is key to opening harm reduction to the possibility of a corporate application. 
In the public health domain, the emphasis is placed on efficiency. Their goal is to spend as little as 
possible to heal the highest amount of injury or illness. Thus, in the public health domain, regulators 
and health care workers alike are motivated by efficiency. In contrast, many corporations seek only to 
increase profits and are strongly encouraged to do so. Thus, a harm reduction framework is only 
compatible with corporations if it allows, or even encourages, them to continue seeking profits as 
aggressively as they like. In the case of corporations, then, the motivation is often to increase profits. 
Despite this being a different motivation from the public health domain, it is just as legitimate. My 
harm reduction framework captures these two motivations nicely by allowing the harm reducer to be 
motivated by anything they choose. Notice too that this allows corporations to be motivated by 
protecting the environment and society as well, but this is not necessary for an effective harm reduction 
initiative to occur. 
2.6 Amount of Harm to be Reduced 
There is another intuition that corporations need to exceed some threshold of harm reduction before we 
want to count that harm reduction as a good thing. After all, corporations that reduce only a tiny amount 
of harm may seem like they are not really making a difference. However, this presents the question: 
what amount of harm reduction is enough for it to count? My answer to this question may be striking 
to many. I argue that any amount of harm reduction, however small, counts as good. Actions count as 
harm reduction as long as the resulting situation is less harmful than the original situation. Put another 
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way, we should focus less on how impactful the harm reduction initiative is, as long as there is some 
impact in the right direction.  
 This answer can be highly off-putting. After all, there seems to be some standard amount of 
harm that has to be reduced before we want to accept the action as harm reducing in a meaningful way. 
I share this thought, but my reasoning has again led me to a different conclusion. First, consider the 
fact that we, as individual consumers, have little control over how corporations act. Sure, they might 
respond to collective calls for boycotts and correct some of their most serious ethical failings if they 
are exposed, but this usually takes the form of a press release or formal statement that is quickly 
forgotten in our collective consciousness. Further, it seems that even if one corporation is called out for 
bad behaviour, another corporation will be called out the next day for doing something similar. 
Anybody who follows the business news knows to expect an ethical failing by a corporation on a regular 
basis. In this business environment, it seems like harm by corporations is incredibly tenacious. Thus, 
as I reason, it is better to live in a less horrible business environment than a more horrible one. Any 
change to make the business environment less horrible should be encouraged. They might not meet 
some intuitive standard for doing enough good, but at least they are doing less bad. We should 
encourage any movement toward being less bad because at least this less-bad situation is better than 
the situation before it. Holding a standard for how much harm reduction is enough does not seem to 
align with the above reasoning. 
 This kind of reasoning maps on nicely to the debate between what Valentini (2012) calls “end-
state reasoning” and “transitional theory”. Though Valentini discusses these theories in the context of 
justice, it makes sense to import the ideas here. Valentini’s goal is to map out the differences between 
ideal and non-ideal theory. She argues that there are several ways to understand the difference between 
them. We might think that ideal theory involves full-compliance theory, idealistic theory, or end-state 
theory while non-ideal theory involves partial compliance theory, realistic theory, or transitional theory. 
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The political philosophy literature is rich with examples of each of these kinds of theory, and Valentini 
reviews them in her paper. For the purposes of this dissertation, the contrast between end-state theory 
and transitional theory is most important. 
End-state reasoning occurs when you identify the kind of ideal that you would like to see 
realized and focus on what that ideal looks like. This, I argue, is what a lot of business ethicists these 
days are in the business of doing. They attempt to identify what a perfectly moral business environment 
would look like. For example, Sarkar and Searcy (2016) offer a definition of corporate social 
responsibility that incorporates six other socially responsible concepts and suggest that a corporation 
should only be considered socially responsible if they meet this high standard. In contrast, transitional 
theory, a form of non-ideal theory, focuses on the steps that need to be taken to get to, or closer to, 
some end-state. Harm reduction neatly falls into this category. Instead of imagining a world where 
businesses are perfectly ethical, we instead ask about what happens in our current world and identify 
steps that can be taken toward a more ideal, but not necessarily a perfectly ideal, world. My theorizing 
about harm reduction operates in the realm of non-ideal theory. It provides a way to move forward in 
identifying a step that can be taken toward a more ideal business environment.  
Non-ideal theory is a powerful tool. Scholars have criticized ideal theory for allowing both 
individuals and institutions to ignore oppression (Mills 2005). By doing ideal theory, Mills argues, we 
are abstracting away from the very injustices that make human interactions and institutions so deeply 
wrong. Thus, by doing ideal theory, we will never address this oppression and injustice. According to 
Mills, “ideal theory, I would contend, is really an ideology, a distortional complex of ideas, values, 
norms, and beliefs that reflects the nonrepresentative interests and experiences of a small minority of 
the national population” (p. 172, original emphasis). In the context of harm reduction, doing ideal 
theory requires abstracting away from the very harms that are in question. Indeed, many of the harms 
listed in this dissertation disproportionately affect women, people of colour, and people in living in 
 
 56 
poverty. None of these groups are part of the upper-to-middle-class white male scholars that have 
dominated ideal theory. Thus, to even get my project off the ground, we must work in the realm of non-
ideal theory and pay attention to harms that affect those who are less advantaged in society.  
Ideal theory has also been criticized by Farrelly (2007). He argues that the extreme end of ideal 
theory adopts “fact-insensitivity” (p. 846) where scholars abstract away from non-compliance and 
unflattering historical, social, and economic conditions, much like the ones identified by Mills above. 
On the other hand, the extreme end of non-ideal theory assumes that all existing historical, social, and 
economic conditions are necessary, which leaves no room for movement in the direction of justice. The 
better way to theorize about justice, according to Farrelly, is to take a stance in between the two. We 
must acknowledge that justice has costs and we must therefore make trade-offs when it comes to 
developing a theory of a more just society. We must try to strike “a reasonable balance between 
conflicting fundamental values” (p. 860). 
 An example of non-ideal theorizing may serve to demonstrate its connection to harm reduction. 
Consider the meat industry. In Europe, the EEC Regulation 1804/1999 bans stanchion barns for organic 
livestock. Stanchion barns are barns where livestock are kept separated and cannot walk around freely. 
The banning of stanchion barns represents a significant gain in animal welfare. However, the minimum 
standards that were put in place to replace stanchion barns are, indeed, minimal. According to Sundrum 
(2001), the EEC Regulation does not address many aspects of the livestock’s well-being, including its 
relationship with its handler and various hygienic concerns (p. 212). Sundrum is careful to point out 
that this gain in animal welfare does not mean that animals are housed appropriately.  
 Now, the question becomes this: would you rather that livestock be kept out of stanchion barns 
or not? Banning stanchion barns does not mean that the livestock will have a high level of well-being 
and we may well think that the livestock’s conditions remain morally abhorrent. However, according 
to Sundrum, the minimal standards were put in place as a compromise between various parties and the 
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regulation was very much political (p. 212). So, it seems reasonable to suggest that the EEC Regulation 
1804/1999 represented the best conditions that animal welfare activists could get given the political 
situation. Our only options, then, are to accept the EEC regulation as a good thing or reject it as not 
good enough, though in either case, we may continue to push for more improvement in animal welfare. 
 It seems to me that the appropriate response to this case is to accept the ban on stanchion barns 
as a good thing. Though the animals may not experience much more subjective well-being, their well-
being is improved at least a little bit. Given that the negotiators for the regulation came to this particular 
regulation as a compromise, it seems as if this is the best we can do for the animals for now. Further, it 
seems appropriate to admit that the banning of stanchion barns is at least a step in the right direction 
for animal welfare, albeit a small step. Finally, accepting the ban on stanchion barns in no way prevents 
us from continuing to push for better standards for animal welfare. So, looking at the entire situation, 
it seems best for us to accept the ban on stanchion barns as a good thing. 
 Examples where there are minimal benefits from harm reduction are important to consider 
because one prominent strategy for corporations to take in a competitive market is to keep prices low 
for the consumer. It is difficult to name a product that does not have a low-cost alternative. Indeed, I 
argue that there will always be demand for cheap alternatives for almost all products. In order to achieve 
low prices for consumers while making a profit, corners are cut and expensive investments, such as 
those into corporate social responsibility initiatives, are ignored. Further, these corporations market 
toward price-conscious consumers who care less about the ethicality of their products and more about 
the low price. Given that these types of corporations and their consumers will seemingly always exist, 
it makes sense to lower the threshold for them and acknowledge what little harm they do reduce. After 
all, they could have easily chosen to not reduce harm at all, except in the case of regulatory compliance. 
 Here, I want to remind the reader that just because the threshold for harm reduction is very low, 
it does not mean that any amount of harm reduction, in any context, is permissible. Recall that one of 
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the qualities of harm reduction frameworks is that the behaviour and harms are, to some extent, 
tolerable. So, consider a corporation that employs children to mine conflict diamonds. This behaviour 
is seemingly intolerable to many of us for a variety of reasons. Thus, according to the cluster concept 
of harm reduction, it seems like we have strong reason to reject children mining conflict diamonds as 
an appropriate site for harm reduction frameworks. For example, it would not be appropriate to simply 
provide these children with better food or more comfortable beds to sleep in at night. Thus, this low 
threshold for harm does not apply. Instead, we should seek to eliminate the behaviour altogether.  
 There remains a worry that allowing such low thresholds for harm reduction may make 
consumers and corporations feel as if they are doing good, or at least feel less guilty for their behaviours, 
which discourages them from doing more to reduce harm. For example, a consumer might purchase 
chicken from a factory farm after the EEC regulation and feel less guilty for eating chickens that were 
raised in inhumane conditions. Thus, they may be discouraged from paying more for free-range chicken 
or they might decide not to become vegetarian. My response to this challenge is that consumers choose 
what they buy based on a variety of factors, including quality, cost, and convenience. For many, their 
purchasing decisions are based primarily on alignment with their values, which might bring them to 
purchase meat from the free-range farm. Others make their purchasing decisions based primarily on 
cost, which brings them to purchase the less expensive factory farmed meat. Still others make their 
purchasing decisions based on a variety of factors, and might compromise between the product cost 
and the product aligning with their values. Regardless of what consumer group you fall into for any 
given product, there will always be a range of consumer preferences. So long as this range exists, there 
will be companies to fulfill those preferences. This means that there will likely always be demand for 
cheap meat, and thus, factory farms. Many companies will tailor their meat toward this type of 
consumer and follow only the bare minimum regulations. It makes sense then, for us to celebrate any 
kind of harm reduction in these companies as a good thing. 
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 For those who are still wary, it may bring some comfort to know that tiny amounts of harm 
reduction will probably not be pursued very often. Instead, larger contributions to harm reduction 
should be expected. Recall again that corporations may pursue corporate social responsibility, and as I 
argue, harm reduction, for at least one of two reasons. First, it makes profits. Second, the corporation’s 
leaders care. If it is the first case, corporations would want to reduce enough harm that its consumers 
see the harm reduction as appropriate and impactful. Thus, they will be inclined toward harm reduction 
initiatives that reduce more harms. If corporations are acting for the second reason, it seems likely that 
they would not be satisfied with a tiny amount of harm reduction. They would want to do more than 
the minimum for their cause. Thus, they will likely take on substantial harm reduction initiatives. In 
both of these cases, the market pressures work in the favour of those who want more harm reduction. 
2.7 Why Harm Reduction? 
According to my harm reduction framework, the motivation behind enacting harm reduction initiatives 
does not matter. However, it might be useful to think about some reasons why a corporation would 
want to take on a harm reduction framework. This is especially the case for corporations that have 
already implemented corporate social responsibility initiatives. What reason do they have for switching 
to my harm reduction framework? 
 First, a corporation need not switch from corporate social responsibility to harm reduction. The 
two are compatible with each other and can exist simultaneously within a corporation’s overall strategy. 
Implementing a harm reduction framework may involve additional initiatives that reduce harm to the 
environment and society. Corporate social responsibility can encompass all the “above and beyond” 
actions that a corporation may want to take, which we encountered earlier in this chapter as ethical and 
discretionary or philanthropic activities.  
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 Second, a harm reduction framework may allow a corporation to be proud of its 
accomplishments instead of chasing the higher bar of corporate social responsibility. Sometimes, harm 
reduction is all that a corporation can justify doing given its various commitments to stakeholders and 
their strong, and sometimes legal, mandate to maximize profits. In these cases, we applaud corporations 
for improving the state of the environment and society. This applause is well-deserved and legitimate, 
as the corporation has truly made strides to bettering our world. Praising corporations for harm 
reduction initiatives may also convince other corporations to implement harm reduction initiatives 
where before, they did not have the resources or motivation to reach the high bar of corporate social 
responsibility. 
 Third, my harm reduction framework allows for considerable flexibility in the way that 
executives choose to implement it. As we will see in Chapter 4, even extremely complex industries can 
make use of my harm reduction framework so long as the appropriate experts are available to implement 
it. The two features of my harm reduction framework allow a lot of flexibility that cannot matched by 
corporate social responsibility frameworks.  
 Finally, we come to the fourth and largest benefit of my harm reduction framework. 
Corporations who implement my harm reduction framework can do good for the environment and/or 
society without sacrificing their drive to maximize profits. My harm reduction framework is perfectly 
compatible with a corporation that aggressively pursues additional profit. Thus, I defend my low 
threshold approach to harm reduction, as it encourages all corporations to contribute even a tiny amount 
to the environment and society where they otherwise would contribute nothing due to the pressure to 
put all resources into increasing profits. As we will see in Chapter 3, miniscule changes that benefit the 
environment and society are worthwhile. Unlike a corporate social responsibility framework, using my 
harm reduction framework encourages more of these miniscule changes that add up to great progress 




The reader can now see that harm reduction frameworks can be implemented in corporate settings. 
Corporate social responsibility has several gaps that can be filled by a harm reduction framework and 
filling those gaps would help corporations do less harm to the environment and society. I have shown 
that harm reduction frameworks apply neatly to the case of corporations, as four out of the six qualities 
of the harm reduction cluster concept apply to corporations. However, to apply harm reduction 
frameworks to corporations appropriately, we must not judge a corporation’s motivations for pursuing 
harm reduction and only emphasize their effectiveness at reducing harm. Further, we must accept any 
amount of harm reduction as a step in the right direction.  
 Now that we have worked through the theoretical issues with applying harm reduction 
frameworks to corporations, I will move on to apply harm reduction to two different industries: oil and 
gas (Chapter 3) and pharmaceuticals (Chapter 4). These applications will show how harm reduction 





Harm Reduction for the Oil and Gas Industry 
The previous chapters in this dissertation claimed that harm reduction frameworks can be beneficially 
applied to various industries. This chapter will be the first of two that help to demonstrate that this claim 
is true. This chapter surveys the oil and gas industry while Chapter 4 surveys the pharmaceutical 
industry. Both chapters aim to describe how my harm reduction framework can help oil and gas and 
pharmaceutical companies reduce the harms that they do to the environment and society. 
Canada is the third largest producer of oil and gas in the world. This oil and gas production is 
concentrated in the Alberta oil sands, which contain 67% of all Canadian oil. While this industry 
activity is huge boon to the Canadian economy, several severe harms arise from oil and gas production.  
This chapter will identify these environmental and social harms and provide an in-depth 
examination of the environmental harms and how they can be reduced. I start this chapter by describing 
the processes of locating, extracting, and refining crude oil. I then evaluate the oil and gas industry 
against the cluster concept of “harm reduction” that I developed in Chapter 1 of this dissertation. This 
evaluation will show that my harm reduction framework applies very well to the oil and gas industry. 
Next, I review the environmental harms of exploratory drilling and analyze ways that these harms can 
be reduced. This analysis will give the reader an example of how harm reduction frameworks can be 
applied to specific companies and “meet people where they are”. This chapter will also demonstrate 
the benefits of my low threshold approach to harm reduction. 
3.1 Processes for Crude Oil 
There are several processes involved in extracting and refining crude oil into a product that can be 
used in automobiles and airplanes. This section will review these processes. This review is important 
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because we must first understand the processes of oil and gas production before we can identify its 
harms and offer solutions for mitigating said harms. 
3.1.1 Oil and Natural Gas Formation 
Millions of years ago, marine life died and fell to the ocean floor. Over these millions of years, layers 
upon layers of silt, sand, and rock covered them and created intense heat and pressure on the ocean 
floor. This heat and pressure formed what we know today as oil and natural gas. Given the way that 
oil and natural gas is created, we must drill deep into the Earth and filter out large amounts of residue 
in order to extract oil and gas for human use (U.S. Energy Information Administration 2018a). 
Further, since oil and natural gas take millions of years to form on the ocean floor, they are non-
renewable resources. Once our reserves of oil and gas are depleted, we will need to rely on alternative 
energy sources. 
3.1.2 Locating Bitumen (Leach 2017) 
In the Alberta oil sands, specialists in the oil and gas field services industry perform research on areas 
that might contain deposits of bitumen, which contain crude oil. Upon finding an area that seems 
likely to have bitumen deposits, they perform exploratory drilling. This exploratory drilling is used to 
test the area to confirm the existence of a bitumen deposit. If a substantial enough deposit of bitumen 
is confirmed, companies move on to perform development drilling. Compared to exploratory drilling, 
development drilling is far more expensive and uses much larger equipment. Development drilling 
involves drilling deep wells and then strengthening them with cement to make sure that the well 




3.1.3 Extracting Bitumen 
For shallow deposits of bitumen, mining is the standard form of extracting bitumen from the earth. 
Once the bitumen deposits are extracted from the ground, they are mixed with hot water to create a 
slurry. This slurry is then transported by pipelines into a processing plant, where a gravity process 
separates the debris, such as sand and rock, from the ore. This creates a bitumen froth. The froth is then 
treated with chemicals and solvents to allow operators to remove any remaining water and fine particles. 
After this process, the product is either greater than 99.8% bitumen, in which case it is sent to a refinery, 
or up to 98% bitumen, which needs to be upgraded before being sent to refineries (Oil Sands Magazine 
2017). 
The waste product of this mining process is called “tailings”. These are a mixture of water, 
debris, unrecovered bitumen, and remaining hydrocarbons. Tailings are stored in a tailings pond or a 
large facility until the solids settle to the bottom of the mixture. The remaining water is recycled for 
use in the processing plant while the solids are used to reclaim the land after the mining process is 
complete (Oil Sands Magazine 2017). 
 For deeper deposits, which include 80% of Alberta’s oil sands deposits, extraction is done 
through in-situ methods. In-situ extraction starts with water being converted into hot steam, which is 
then pumped into the bitumen well and mixed. The heat causes the bitumen to liquefy. This mixture of 
water and liquefied bitumen is pumped to the earth’s surface and then separated from each other. The 
bitumen is then upgraded and the water is treated so that it can be reused (Oil Sands Magazine 2020a).  
 In-situ extraction requires smaller wells compared to mining extraction. It uses and reuses water 
efficiently and does not create a tailings pond. In-situ mining is also less expensive than mining and 
easier to maintain. However, in-situ extraction has lower recovery rates of bitumen compared to mining, 
releases more greenhouse gases, and the process cannot be easily stopped and started in case of 
emergency (Oil Sands Magazine 2020a). 
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3.1.4 Refining Crude Oil 
Refineries purchase their crude oil from extractors. At this point, the product is at least 99.8% bitumen. 
Some refineries are able to process crude oil that is called “light” or “sweet”, which means that it has a 
low sulphur content. Other refineries can process crude oil that is relatively “heavy” or “sour”, which 
means that the oil has a higher sulphur content. Generally, light or sweet crude oil is more valuable 
than heavy or sour crude oil. Alberta’s oil sands mostly produce heavy, sour crude oil (Oil Sands 
Magazine 2020b). 
 The refining process involves three steps: separation, conversion, and treatment. During 
separation, crude oil is pumped through heated furnaces. This removes liquids and vapours from the 
crude oil and separates the crude oil into fractions based on a product’s boiling point. Light fractions 
have low boiling points and thus rise to the top. These create butane and gasoline. Medium fractions 
create naphtha, kerosene, jet fuel, diesel, and heating oil. The heavier fractions create heavy gas oil and 
residual gas oil (U.S. Energy Information Administration 2018b). 
 During conversion, heavy gas oil and residual gas oil is treated to become lighter and thus more 
valuable. This is usually done through “cracking”, where heat, pressure, and catalysts are used to reduce 
the weight of heavy hydrocarbons. Other methods of conversion include alkylation, which adds high 
octane hydrocarbons to motor or jet fuel to convert it into gasoline (U.S. Energy Information 
Administration 2013), and reforming, which uses heat, pressure, and catalysts to convert naphtha into 
high octane gasoline components (U.S. Energy Information Administration 2018b). 
 Finally, treatment involves testing and quality control to ensure that the refined crude oil meets 
all standards. Once treatment is finished, the final products are stored in tanks until the product can be 
transported through pipelines, trains, and trucks (U.S. Energy Information Administration 2018b). 
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3.2 Oil and Gas Industries 
Now that we are familiar with the processes of locating, extracting, and refining crude oil, we can 
look at the companies that support these processes. The oil and gas industry in Canada is serviced by 
at least three groups of service providers: oil drilling and gas extraction, oil and gas field services, and 
petroleum refining. Other related companies include ones related to gas pipeline construction, gas 
machinery manufacturing, and gas machinery wholesaling. 
3.2.1 Oil Drilling and Gas Extraction (Leach 2018a) 
The oil drilling and gas extraction industry in Canada develops oil and gas fields and extracts crude oil 
and natural gas. For 2018, the industry is expected to generate revenues of $102.4 billion and is 
projected to grow at an annualized rate of 4% for the years 2018-2023. It is a highly capital intensive 
and risky industry. Low profit margins, 3.5% in 2018, that depend on highly volatile global prices of 
crude oil and natural gas and incredibly expensive exploration of oil and gas fields are to blame. The 
industry experienced a downturn in 2014-2016 due to low global prices of crude oil and natural gas, 
but has since recovered, albeit not to its 2013 position. Despite this setback, the industry is expected to 
grow due to increasing production and global prices. 
 The largest oil and gas field in Canada is the Athabasca Oil Sands in Alberta. These oil sands 
produce approximately 67% of all domestic oil. Increased use of hydraulic fracturing and horizontal 
drilling has increased the output of the oil sands and has attracted additional global investment. These 
new technologies allow the extraction of more crude oil and natural gas compared to traditional 
methods. Despite this technological change, the oil drilling and gas extraction industry in Canada is 
mature and expected to grow slowly due to increasing crude oil and natural gas prices.  
 Approximately 60% of the oil drilling and gas extraction industry’s products are crude oil and 
the other 40% are natural gas. 96.2% of the crude oil extracted in Canada is exported to refineries in 
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the United States. Overall, this industry exports 84.7% of its products, with the remainder being sold 
to domestic oil refineries or natural gas distributors. 
 The companies with the largest market share in the oil drilling and gas extraction industry 
include Canadian Natural Resources Ltd. with 17.2% market share, Suncor Energy Inc. with 15.2% 
market share, and Imperial Oil Ltd. with 10% market share. All three companies operate in the Alberta 
oil sands and have been growing steadily.  
 These companies are subject to significant regulation at both the federal and provincial level. 
Federal regulations include the Canada Petroleum Resources Act and the Canada Oil and Gas 
Operations Act. Provincial regulations include the Canada-Newfoundland Atlantic Accord 
Implementation Act and the Canada-Nova Scotia Offshore Petroleum Resources Accord 
Implementation Act, which both regulate offshore petroleum. In Alberta, the Energy Resources 
Conservation Board regulates energy resources for the province. Success in this industry depends on 
the company’s ability to follow these regulatory requirements while cutting costs and maintaining 
production. 
3.2.2 Oil and Gas Field Services (Leach 2017) 
The oil and gas field services industry supports the oil drilling and gas extracting industry. It provides 
research, exploratory and development drilling, and other related services to the companies that extract 
crude oil and natural gas. These companies also support mining companies, such as those that mine 
coal and potash. It is interesting to note that over 67% of the industry work is in providing development 
drilling services while the remainder of the work is in predrilling research (15.6%), oil  and gas 
exploration drilling (9.2%), and appraisal (7.9%). Industry revenues in 2017 were projected at $28 
billion with 2.1% projected annual growth for 2017-2022. Like the oil drilling and gas extracting 
industry, this industry is subject to heavy federal and provincial regulation. 
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 This industry also suffered from the dramatically decreased prices of crude oil and natural gas 
from 2014-2016 but was recovering in 2017. These price pressures have forced the oil and gas field 
services industry to offer lower rates for their services, thus decreasing profits. However, with the 
recovery in 2017, profit margins were around 6% and are expected to remain stable through 2022.  
 One major industry issue is that there is not enough pipeline capacity to transport oil and gas. 
This lack of infrastructure puts a limit on how much oil and gas can be produced in Canada, which in 
turn puts a limit on the need for oil and gas field services. This phenomenon puts a cap on industry 
revenues. 
 Despite being a mature industry, the oil and gas field services industry is highly segmented. 
Companies bid on contracts for oil extractors, natural gas extractors, and mining companies. 
Contractors are chosen based primarily on price, but also on quality of service, safety, equipment, 
location, and reputation. Thus, experienced companies have an advantage over newer ones.  
 According to leaders in market research at IBISWorld, there is only one major player in the oil 
and gas field services industry in Canada: Schlumberger. However, its market share is only 7%, which 
reinforces the conclusion that the rest of the industry is incredibly fragmented. Schlumberger is a highly 
respected company that provides drilling and well support services to oil, natural gas, and mineral 
extractors. It operates in 85 countries around the world. 
3.2.3 Petroleum Refining (Leach 2018b) 
Once crude oil and natural gas are extracted, they are sent to refineries to refine the crude oil and natural 
gas into gasoline, diesel fuel, aviation fuel, fuel oils, and other petroleum products. This $63.6 billion 
industry is projected to grow at an annual rate of 2.9% from 2018-2023 due to new car sales and an 
improving economy. The industry is heavily affected by crude oil prices, since crude oil is the primary 
input for refining companies. When the price of crude oil is high, refining companies increase their 
prices to compensate. When the price of crude oil is low, heavy competition forces refining companies 
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to reduce their prices. Profit margins have fluctuated heavily. The industry had a 7.1% profit margin in 
2018 compared with a 14% profit margin in 2013. 
 Approximately 30% of refined petroleum is exported to the United States and other countries. 
Manufacturing and heavy industry companies consume approximately 27% of the refined petroleum, 
while consumers purchase 20% and commercial companies, such as transportation companies, 
purchase 18%. The remaining 4% is consumed by aviation companies.  
 It is important to note that Canada lacks pipelines that connect Western Canada with Eastern 
Canada. As a result, refineries in Western Canada have access to cheaper West Texas Intermediate 
crude oil while Eastern Canada pays a premium for crude oil imported from international regions. Since 
purchasing crude oil accounts for over 73% of the industry’s costs, Western Canada distributors have 
a competitive advantage over Eastern Canada distributors. 
 Growth has largely been focused on increasing the efficiency of existing equipment as opposed 
to building new refineries, since a new refinery can cost billions of dollars. Refining capacity has largely 
stabilized. This is in line with the petroleum refining industry being mature. Also in line with a mature 
industry, market share is largely concentrated between five companies: Imperial Oil Ltd. (35.1%), 
Suncor Energy Inc. (15.1%), Shell Canada Ltd. (11.2%), Federated Co-operatives Limited (8.6%), and 
Irving Oil (8.4%). Many of these refining companies distribute gasoline and diesel across Canada 
through brands such as Esso and Mobil (Imperial Oil Ltd.), Petro-Canada (Suncor Energy Inc.), Shell 
(Shell Canada Ltd.), and FCL (Federated Co-operatives Limited). 
 Like the previous two industries, the petroleum refining industry is risky and involves heavy 
capital investment. Combined with the concentrated market share, the industry is unlikely to see new 
entrants. The risk is due to volatile prices of crude oil which heavily affect costs, and thus profit 
margins, and the heavy capital investment is due to the equipment needed to refine petroleum. 
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 The petroleum refining industry is subject to a number of federal and provincial regulations. 
Air and water quality is regulated by Environment Canada and environmental and human health 
protections are governed by the Canadian Environmental Protection Act of 1999. The petroleum 
refining industry is also accountable to the National Energy Board, which regulates exports of crude 
oil and other petroleum products. Emission and public health concerns are addressed by the National 
Framework for Petroleum Refinery Emission Reductions. Finally, provincial regulations involve 
pricing regulations. 
3.3 Applying Harm Reduction to the Oil and Gas Industry 
Though I have already shown that the cluster concept of harm reduction applies to corporations, it is 
important to ask if the cluster concept applies to the oil and gas industry in particular. As alluded to in 
previous chapters, there might be certain industries that we find intolerable and might therefore render 
harm reduction frameworks inappropriate. This section will show that harm reduction frameworks do, 
in fact, apply to the oil and gas industry. Each heading below corresponds with one of the qualities of 
the cluster concept of harm reduction reviewed in Chapter 1. 
3.3.1 There is at least one identifiable harm associated with the behaviour. 
There are at least two identifiable harms that the oil and gas industry does to the environment and 
society. The first is harm to communities that are near oil and gas industry operations. The second, 
related to the first, is harm to the environment. 
Indigenous peoples are the traditional habitants of much of the land and water where oil and 
gas activities take place. In theory, oil and gas activity on traditional Indigenous land could be beneficial 
for both Indigenous peoples and the oil and gas companies. An oil and gas project brings jobs and 
spending money to Indigenous communities while the oil and gas companies extract resources for a 
profit. Because of these benefits, Indigenous communities can side with oil and gas companies and 
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campaign in favour of oil and gas activity (Tasker 2018a). However, in many cases, Indigenous peoples 
are left without these benefits. For example, non-Indigenous individuals usually occupy the highest 
paying jobs on oil and gas projects (Manley-Casimir 2011). Even when concerns of Indigenous peoples 
are heard, they can be ignored or otherwise not appropriately accounted for (Chalifour 2010). An 
example of this latter harm comes from the 2018 Federal Court of Appeal rejection of the Trans 
Mountain pipeline due to insufficient consultation with First Nations communities (Kane 2018). 
Further, harm is done to Indigenous peoples through decreased air quality, threats to marine 
populations, public health issues, and threats to spiritual and sacred lands (Dana et al. 2009). Indigenous 
peoples disproportionately bear these harms because they rely more on the land and waters for spiritual 
and relational purposes compared with non-Indigenous individuals. When oil and gas companies are 
finished extracting resources, they leave the Indigenous lands spoiled, since land reclamation efforts 
are often piecemeal and inadequate (Allred et al. 2015). The remaining communities are socially, 
environmentally, and culturally damaged (Manley-Casimir 2011). Lack of hospitals and health care 
practitioners exacerbate these harms (Dana et al. 2009). Indigenous communities continue to fight for 
royalties, taxing power, and environmental protection of their lands (Chipello 2006). Thus, some 
Indigenous groups lobby against oil and gas activity (Tasker 2018b). 
Non-Indigenous communities that live on or near oil and gas operations are also harmed. In a 
semi-structured interview conducted by Evans and Garvin (2009), rural Albertans expressed their 
appreciation of their remote, natural, clean, and independent communities. Oil and gas companies were 
seen as infringing on these community values, which threatened the interviewee’s identities. The 
interviewees were also concerned with a failure on the part of oil and gas companies to act in accordance 
with community standards to be good neighbours, follow rules, and keep public spaces clean. Finally, 
interviewees were concerned about being stigmatized as activists and blacklisted. 
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Let us now discuss the environmental harms from oil and gas industry operations. Shiell and 
Loney (2007) estimate the cost of environmental damage from greenhouse gas emissions in the oil 
sands by quantifying greenhouse gas emissions from the oil sands and then assigning a dollar amount 
to those emissions based on the economic literature. They concluded that the damage from greenhouse 
gas emissions range from $15 to $64 per tonne of carbon, or $2 to $8 per barrel of oil. Given that 
Alberta’s crude bitumen production was approximately 2.8 million barrels per day in 2017 
(Government of Alberta 2020), this totals $2 billion to $8.1 billion of damage per year. These figures 
do not account for environmental damage due to land use, water use, or other types of emissions, which 
means that the real cost of environmental damage is much higher than the amounts quoted here. Further, 
as alluded to above, land is permanently destroyed due to extraction efforts and oil and gas companies 
have yet to make good on their promise, and regulatory requirement, to reclaim 100% of the land used 
to extract oil and gas (Natural Resources Canada 2020).  
Oil and gas transportation safety has also been under fire. Pipeline spills occur frequently and 
spills in America are documented in great detail by the US Department of the Interior (2020b). Spills 
also happen when tanker trucks transporting oil and gas are overturned (U.S. Department of the Interior 
2020a). Finally, most will recall the BP Deepwater Horizon Oil Spill of 2010, which occurred after the 
offshore Deepwater Horizon oil rig exploded due to pressure from natural gas. It should be noted that 
this explosion occurred after a similar incident of an explosion of a BP offshore oil rig in 2008 (Pallardy 
2019). These spills reduce the safety of the land and water for the surrounding communities and 
wildlife.  
Finally, it is important to understand the contribution of the oil and gas industry to global 
climate change. Industry spokespeople, including the Canadian Association of Petroleum Producers 
and the International Energy Agency forecast an increase in demand for oil. Unfortunately, the 
production and use of oil and gas increases the release of greenhouse gases into the environment, which 
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is a form of pollution that leads to climate change, including higher risk for natural disasters and drought 
in many areas of the world. It is important to recognize that, according to the Canadian Association of 
Petroleum Producers, burning oil and gas is a significant contributor to climate change. Of course, this 
is a difficulty with the industry, since they produce the very substance that significantly contributes to 
global climate change. This climate change is a threat to the stability of human, animal, and plant life. 
It is no exaggeration to say that climate change threatens the life of every living thing on Earth. The 
issue is so important and threatening that the United Nations Framework Convention on Climate 
Change (UNFCCC) takes climate action seriously and has made repeated attempts to convince 
countries around the world to participate in slowing and adapting to climate change. These attempts 
have led to the Kyoto Protocol and The Paris Agreement, where countries pledged to reduce global 
greenhouse gas and other harmful emissions. The UNFCCC remains active and committed to working 
with countries to slow and reduce the impacts of climate change. 
Some have argued that the negative effects of the oil and gas industry on the environment is 
much lower than we might think. For example, Steven Poruban (2008), then Senior Editor of the Oil & 
Gas Journal, points out that the Alberta oil sands account for less than 0.1% of the world’s greenhouse 
gas emissions. Note here, however, that the Alberta Oil Sands represent only one group of oil producers 
and does not encompass the entire oil and gas industry in Canada. Poruban then heavily quotes Len 
Webber, then the parliamentary assistant for Alberta Energy. Webber emphasizes Alberta’s 
commitment to the environment by supporting carbon capture and storage projects as well as support 
for public transit in Alberta. Webber also points out that less than 1% of the total oil sands region has 
been affected by oil and gas activity. He emphasizes robust land reclamation regulations and limits on 
water use by oil and gas companies. Further, oil and gas companies have recognized the need for 
environmental protection and have taken action to realize that goal. In March 2012, 13 oil and gas 
companies, representing 90% of the crude oil activity in the Alberta oil sands, formed the Canada’s Oil 
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Sands Innovation Alliance (COSIA). The goal was to share technological innovations to reduce the 
environmental impact of oil and gas industry activity on land, water, tailings, and greenhouse gas 
emissions. In its first year, COSIA spoke to over 350 influential public leaders and shared $900 million 
worth of technological innovation with each other (Jajuee 2014). 
I suggest that it would be prudent for us to take the above claims and activities with a grain of 
salt. Du and Vieira Jr. (2012) study the corporate social responsibility communications of six oil and 
gas companies. They emphasize the framing practices that these corporations use in order to make their 
company activities seem legitimate. For example, they offer carefully phrased factual arguments, two-
sided arguments where they acknowledge the harms that they have done as well as their efforts at 
reducing those harms, and cite the legitimacy of the industry organizations that they belong to. These 
tactics have been shown to increase the firm’s credibility on their corporate social responsibility reports 
and help to convince the consumer that the firm is doing good for the environment and society. 
According to Du and Vieira Jr., these kinds of communication are pursued with the mindset that 
corporate social responsibility is a public relations tool. Du and Vieira Jr. argue that oil and gas 
companies should focus on actually reducing the harms that they do to the environment through 
substantial investment in long-term renewable energy strategies as opposed to focusing on 
communication strategies that allow them to appear as if they are reducing harms. 
3.3.2 The behaviour is tenacious at the population level. 
As discussed above, all three groups of service providers associated with the oil and gas industry are 
projected to grow in the next five years. In fact, global growth in oil demand outpaces the world’s 
existing and projected capability to supply it. While both advanced and developing economies are 
expected to increase their use of low-carbon energy sources, developing economies are expected to 
increase their oil, gas, and coal use. Further, oil and gas use is increasing due to the transportation 
industry needing an additional 10 million barrels of oil per day by 2025. Coal is expected to remain the 
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largest source of power with gas remaining the second-largest (International Energy Agency 2018). 
Canada is expected to play a large role in this reliance on oil and gas. The oil sands are projected to 
provide an additional 2.5 million barrels of oil per day by 2044 (Natural Resources Canada 2020). This 
data implies that, regardless of the climate consequences, people will continue to use oil and gas to 
power their lives.  
This analysis suggests that the harms that come along with the oil and gas industry will likely 
persist. Environmental damage is necessary for oil and gas extraction to occur. Further, the use of oil 
and gas necessarily produces pollution in the form of harmful carbon dioxide. As a result, so long as 
the oil and gas industry exists, so too will many of its environmental harms.  In the case of the oil and 
gas industry, it seems as though the industry will persist, and so will its harms.  
3.3.3 The behaviour is, to some extent, tolerable. 
The oil and gas industry seems to be intolerable to some individuals, at least in certain ways. For 
example, massive protests have occurred across Canada over the Trans Mountain Pipeline Expansion 
construction. These protesters believe that they have a moral duty to protest against the pipeline 
(Pawson 2018). Notice here that the intolerability is not to the point of Card’s definition of “intolerable 
harm” where people are reduced to a life that they do not subjectively feel is worth living. Despite this, 
as we will see below, the effects of pipelines might be intolerable to many. As a result, we can interpret 
these protesters as fighting for prevention of future intolerable harms. 
Many others believe that pipeline construction and other oil and gas industry activities are 
necessary for Canada’s economic growth. For example, the Trans Mountain Pipeline Expansion will 
bring $7.4 billion into the Canadian economy at all levels of government and employ 15,000 individuals 
during pipeline construction with further employment of 37,000 for pipeline operations (Trans 
Mountain, n.d.). In May 2016, Canada’s National Energy Board concluded that the Trans Mountain 
Pipeline Expansion project was in the public interest and recommended approval, albeit with 157 
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conditions to, among other things, protect the interests of Indigenous peoples and the environment. This 
approval suggests that oil and gas operations are, at least to some extent, tolerable given their economic 
benefits. 
Further, vast numbers of people in Canada and around the world are expected to continue 
relying on oil and gas to power their lives. From this data, we can reasonably conclude that the use of 
oil and gas is tolerable to a significant portion of the global population, especially since there are 
increasing amounts of energy alternatives to coal and oil and gas. The fact that significant portions of 
the global population are choosing to use oil and gas to power their lives indicates that they tolerate the 
industry. 
However, a salient point arises when we think about the effects of climate change on the world. 
According to NASA, the effects of climate change include an increase in droughts, heat waves, and 
hurricanes, sea levels will rise and flood today’s lands, and temperatures will continue to rise to 
dangerous levels. Climate change has already affected our daily lives through intense heat waves and 
melting sea ice. According to the Intergovernmental Panel on Climate Change, “Taken as a whole, the 
range of published evidence indicates that the net damage costs of climate change are likely to be 
significant and increase over time”. Given that climate change threatens our very existence on Earth, it 
is no exaggeration to say that climate change will become intolerable in the sense that it will claim the 
lives of millions of people around the world. Thus, in one sense, the oil and gas industry is obviously 
tolerable but in another sense, the industry is obviously not. This difficulty arises due to the nature of 
the term “tolerable” that I discussed in Chapter 1. As concluded in that chapter, the fact that at least 
some people think that the oil and gas industry is tolerable makes harm reduction for the oil and gas 
industry applicable for that group. 
Here, one might be convinced that the oil and gas industry produces intolerable harms overall. 
Since unwanted death is clearly a harm that is intolerable to everybody, the harms from climate change 
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are intolerable as per Card (see section 1.2.3). Indeed, for many parts of the world, the harms from 
climate change are already intolerable. According to my framework as I have developed it to this point, 
the fact that climate change is intolerable for many suggests that we should seek harm elimination for 
these people. Unfortunately, in this case, harm elimination is not possible, as climate change will 
continue threatening the entire planet, even if everybody on Earth ceased to pollute immediately. It 
seems that harm reduction is the only option left for responding to climate change. Indeed, human 
activity has permanently destroyed the environment to the point of no return. Thus, in this particular 
case, while harm reduction may not be the ideal response, it is one of the only responses that we have 
left.  
3.3.4 The primary harms are to the self. 
Interestingly, the oil and gas industry harms itself in a roundabout way. Since oil and gas is a non-
renewable resource, the more oil and gas the industry sells, the less oil and gas it will have to sell in the 
future. Eventually, we will deplete all the world’s oil and gas reserves and the oil and gas industry will 
go out of business. Alternatively, we will all have been tormented by the effects of climate change to 
the point where many of us, including those who work for oil and gas companies, are dead or struggling. 
Yet another outcome could be that the effects of climate change start becoming salient to more people 
and actions are taken against oil and gas companies to reduce or slow the effects of climate change, 
quite probably in the form of regulation that requires dramatically reducing oil and gas operations. No 
matter how we analyze the situation, it seems that the oil and gas industry will eventually fall away.  
However, the ways that the oil and gas industry harm themselves are not in the same ways that 
injection drug users, tobacco users, and sex workers harm themselves. This difference is because oil 
and gas companies do not have personal autonomy in the same way that individuals have personal 
autonomy. However, it is interesting to note that, unlike corporations as a whole as discussed in Chapter 
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2, the oil and gas industry is more susceptible to harming itself in other ways compared to the average 
corporation.  
Further, the oil and gas industry does massive harms to the environment and society that we 
ought to want to reduce for the reasons argued in Chapter 2. As explored above, the industry clearly 
harms Indigenous peoples, who have been disproportionately affected by oil and gas industry activities 
and have suffered serious harms to their ways of being. The oil and gas industry also harms 
communities that live in or close to their extraction activities. Further, though these harms do not 
directly affect individuals, the oil and gas industry damages marine and land ecosystems in the areas 
surrounding their activities. This, in turn, harms individuals through issues like poor water quality. It is 
important to note that these harms occur on a wide scale, with entire communities of individuals and 
ecosystems of animals being affected each time the oil and gas industry fails to maintain safe operations. 
Further, the oil and gas industry’s contribution to global climate change gives us a strong 
mandate to reduce the harms that the industry does to the environment and society. Global climate 
change has already started to affect populations around the world and it is no exaggeration to say that 
it is a threat to humanity’s survival on this planet. The oil and gas industry may not be harming itself 
directly in the same way that an injection drug user harms themselves when they use, but the sheer scale 
of harm that the oil and gas industry does to the world should be incentive enough for us to want to 
dramatically reduce its harms. Again, harm to others gives us a strong mandate to intervene.  
3.3.5 The harm is worth reducing even if it is not cost-efficient. 
Harms to Indigenous peoples, individuals living in nearby communities, and marine and land 
ecosystems are worth reducing even if it is not cost-efficient to do so. The industry must consider each 
group’s concerns and take seriously the difference in concerns within each group. For example, some 
Indigenous peoples may want oil and gas operations on their land so that they can profit from the 
activities while others may be opposed to such operations because it would harm the environment that 
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they rely on for survival. Reducing the harms of oil and gas operations to both groups by addressing 
their individual concerns is important. 
Further, it seems obvious that the harms of climate change are worth reducing even if it is not 
cost-efficient to do so. Again, climate change threatens humanity’s existence on this planet and 
avoiding such catastrophic events is valuable because of the lives that are saved. Importantly, reducing 
the harms due to climate change may involve cessation of the oil and gas industry’s activities altogether, 
either through government regulation or consumer pressure. For example, governments may limit the 
amount of oil and gas that can be extracted while transportation companies and everyday consumers 
may demand and eventually switch to transportation methods that do not require oil and gas. As 
mentioned above, the oil and gas industry may be tolerable for now but it may not be tolerable in the 
future. 
3.3.6 Significant harms are due to stigma or criminalization of the behaviour. 
Like corporations as a whole, there are few harms to individuals due to stigma or criminalization of oil 
and gas industry operations. Granted, there are social stigmas among some circles against those who 
are less environmentally-friendly. Further, oil and gas companies are frequently targeted in the media 
for behaving in ways that are detrimental to the environment (e.g. Sharp 2019). However, this attention 
might be understood not as harmful to the industry but as the reality of doing business. After all, many 
corporations have to respond to their detractors and make careful use of their public relations 
departments. Thus, dealing with industry critics might just be part of the cost of doing business. Further, 
as discussed in Chapter 2, this stigma and regulatory environment occurs at the level of the firm, which 
protects the individuals who work for the company in ways that sex workers are not protected. 
Regardless, if these stigmas are not deemed to be substantial enough to harm oil and gas 
corporations, this does not preclude harm reduction frameworks from applying to the oil and gas 
industry, as not all qualities in a cluster concept need to apply in order for the concept to apply overall. 
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I argue that, like corporations as a whole, harm reduction frameworks apply to the oil and gas industry 
despite there being no significant harms due to stigma or criminalization of its operations. 
3.4 A Deeper Dive: Exploratory Drilling 
Several harms arise from each of the processes of locating, extracting, and refining crude oil. As a 
result, harm reduction can happen at a variety of levels throughout. A closer look at exploratory 
drilling in particular can help to illustrate the kinds of harms that oil and gas companies do to the 
environment and can provide insight into the creative ways that these harms can be reduced.  
3.4.1 Environmental Harms of Exploratory Drilling 
Rates of success for exploratory drilling grew rapidly in the 1970s and early 1980s and have stabilized 
since then, despite technologies that were meant to improve exploratory drilling rates in the latter half 
of the 1980s. Interestingly, many wells that are labelled “dry”, which means that there is no significant 
bitumen deposit, are not actually dry. In fact, a well is deemed to be dry so long as it is unprofitable to 
retrieve the bitumen from that well. This profitability is determined by the price of oil and gas, the 
amount of oil available compared to natural gas and at what depth this oil is available at, and the size 
of the bitumen deposit (Forbes and Zanpelli 2000). This finding means that the environment is disturbed 
for the sake of exploratory drilling, but many of these wells are abandoned because they are considered 
unprofitable. Unfortunately, these wells leave a lasting impact on the environment.  
 Exploratory drilling, especially offshore exploratory drilling, has been found to harm the 
environment in significant ways. Currie and Isaacs (2004) found that exploratory drilling in the Minerva 
gas field in Victoria, Australia, resulted in significant changes to the seafloor community up to 200 
metres away from the well-head. These changes lasted for up to 11 months. The seafloor community 
remained significantly changed at the location of the well-head after 11 months, albeit with some 
recovery. These results suggest a threat to biodiversity in the marine ecosystem near drilling sites. Other 
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research has found that seafloor communities can remain disturbed over a year after drilling, up to 500 
metres from the drilling site (Santos et al. 2009). 
 Further, Dore et al. (2017) found significantly increased rates of barium, copper, and petroleum 
hydrocarbons in the Campos Basin, southeast of Brazil. These increased rates were detected up to 500 
metres away from the drilling site. These increases are significant, as barium is toxic to marine life 
(Lira et al. 2011). Barium can also impair the growth of and cause developmental defects in marine life 
(Choudhury and Cary 2001). Copper is damaging to marine macroalgae, which greatly affects the 
marine ecosystem (Babu et al. 2014). Finally, petroleum hydrocarbons impair ecological growth, 
reduce biodiversity, and are considered a “significant pollutant” in bodies of water (Pettigrove and 
Hoffmann 2005). 
3.4.2 Reducing the Harms of Exploratory Drilling 
Market research suggests that firms will be punished in the stock market when they get caught doing 
harms, especially when those harms result in stiff penalties from regulators and thus reduce profits. For 
example, after the BP Deepwater Horizon oil spill, firms that were directly related to the spill were 
punished in the stock markets the most. Further, firms in the oil and gas industry that were impacted by 
threats of increased regulation and higher costs were also punished in the stock market (Humphrey et 
al. 2015). This data suggests that stockholders distinguish between firms in the oil and gas industry and 
selectively punish those that do harms to the environment. Further, investors have been successful at 
influencing oil and gas companies to reduce their environmental damage (Gatehouse 2018). As a result, 
oil and gas companies have a financial incentive to make sure that their firm is not related to any 
environmental damage or disaster. 
 Further, exploratory drilling requires vast amounts of resources, including a lot of time and 
money. Thus, oil and gas companies have a prudential incentive to increase the success rates of their 
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exploratory drilling efforts. This incentive can lead firms to find creative ways to increase their 
exploratory drilling success rates, thus leading to less damage to the environment.  
 There are several creative ways that oil and gas companies can reduce their harms to the 
environment during exploratory drilling. One solution is to use water-based fluids instead of synthetic 
fluids during the drilling process. Marine communities within a 500-metre radius of the drilling site 
affected by water-based fluids recover fully after 22 months, while those communities affected by 
synthetic fluids do not (Netto et al. 2010).  
 Another option is to ensure that all drilling equipment is up to date. Better equipment drills 
more precisely, which means that less earth needs to be disturbed to mine bitumen. As a result, this 
drilling method does less harm to the environment. Better equipment also lasts longer, allows operators 
to more effectively maintain the equipment, and is more efficient, which gives companies additional 
prudential reasons to invest in updated drilling equipment (Anonymous, 2008). 
 The drilling method is also important to consider when choosing less environmentally-harmful 
bitumen extraction. Water-powered drilling has been shown to bring cuttings to the top of the drill hole 
without reducing the structural integrity of the drill hole itself. This process reduces leaks in the drill 
hole, which maintains the structure of the earth and requires less rehabilitation at the end of the project. 
Further, clean water can be used so that oil and other contaminants are not introduced to the drilling 
process or the environment (Anonymous, 2014).  
 These are some basic ways that an exploratory drilling company could reduce its environmental 
damage. Other methods of reducing environmental damage could come from creative experts in the oil 
and gas industry who are able to think “outside the box” for additional solutions. Other ways to reduce 
harm in the process of exploratory drilling involve reducing harms to Indigenous peoples (e.g. Young 
2012) and reducing harms to those who live on land that is to be mined. However, this harm reduction 
may seem paltry to many who are concerned about the rising costs and eventual catastrophe of global 
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climate change. My harm reduction framework does not deny that humanity is headed toward 
environmental disaster, but it does recognize that there are small reductions in harm to society and the 
environment that companies can perform to lessen their contribution to global catastrophe.  
3.5 Reducing Harm in the Oil and Gas Industry 
As shown by the example of exploratory drilling, there is much that can be done to reduce the harms 
in the oil and gas industry. Each step in the process of locating, extracting, refining, and transporting 
bitumen or crude oil is an opportunity to reduce environmental and social harms. A detailed analysis 
of each of these processes is outside the scope of this dissertation, but the example of exploratory 
drilling should be enough to illustrate the process that a harm reduction expert would take to identify 
harms and implement procedures to reduce them.  
 One important item to note is that this chapter reviews exploratory drilling as a whole. With 
the key harm reduction principle of “meeting people where they are at”, a deeper analysis into each 
exploratory drilling company would be the best way to perform a harm reduction analysis. As captured 
in the two features of my harm reduction framework, each individual company has their own priorities 
for which harms they want to or are willing to reduce and harm reduction takes these differences 
between companies seriously. Thus, each individual company should be encouraged to perform an 
analysis of the harms that they do to the environment and society in the process of their operations and 
decide which of those harms they want to reduce. Remember that, under my harm reduction framework, 
companies can choose to reduce these harms for any reason and to any extent. We still celebrate their 
harm reduction as a good thing. 
 One additional item to note is that the oil and gas industry is one that attracts heavy government 
regulation. Regulations can, for example, incentivize corporations to release less carbon dioxide into 
the atmosphere by making it more expensive to pollute. Thus, taking advantage of regulations becomes 
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a form of harm reduction. Notably, taking advantage of these regulations may attract less praise for 
corporations, since they are obviously incentivized by the government to act in certain ways. 
Regardless, the regulations incentivize corporations to reduce harms and that is the primary goal.  
3.6 The Oil and Gas Industry and Corporate Social Responsibility 
By now, the reader might be wondering why the harm reduction described above is any different from 
corporate social responsibility. After all, it seems as if corporations would be able to perform any of 
the above behaviours and classify them as corporate social responsibility both in theory and in their 
marketing efforts. Recall, however, that there are significant differentiators between corporate social 
responsibility and my harm reduction framework. 
 First, due to their significant contribution to global climate change, oil and gas companies may 
never be truly considered socially responsible by some individuals. Since these companies produce a 
product that so fundamentally damages the livelihood of humans, non-human animals, and plants 
around the world, one might argue that no amount of oil and gas activity is environmentally or socially 
responsible. If this is true, then oil and gas companies cannot be socially responsible unless they cease 
operations. However, this raises a contradiction, since a fundamental principle of corporate social 
responsibility is to fulfill economic responsibilities, which means that the company must generate 
profit, but corporate social responsibility also demands that corporations operate sustainably, which is 
impossible in this case. So, proponents of corporate social responsibility may find it difficult to say that 
oil and gas companies can be socially responsible while continuing their operations. In contrast, the 
lens of harm reduction allows oil and gas companies to avoid admitting defeat because it gives them a 
way to better the world without necessarily doing good. Using my harm reduction framework, 




 Second, recall that my harm reduction encourages corporations to reduce harms for any reason 
and to any extent. As a result, oil and gas corporations can choose to reduce whichever environmental 
and social harms they deem important to any extent that they deem important. This low threshold 
approach lowers the bar for corporations who currently operate under the banner of corporate social 
responsibility because corporations are no longer pressured to exclusively reduce harms that are 
impactful enough to highlight on a corporate social responsibility report. Instead, corporations are 
encouraged to make alterations that reduce even a tiny amount of harm. This encouragement may 
convince corporations to take several small steps to reduce harm, even if the outcome does not involve 
heavily marketed statements on how much money was contributed or how much impact was made. In 
this way, it is possible for more harms to be reduced overall.  
 Finally, remember that harm reduction “meets people where they are”. Each individual 
corporation is encouraged to look at their unique operations and reduce environmental and social harms 
that they themselves deem appropriate. There is no one initiative, such as joining an industry 
organization or contributing to research on alternative energy sources, that every corporation is 
expected to partake in. Instead, each corporation analyzes their existing situation and chooses the harm 
reduction strategies that are right for them. In this way, corporations are able to reduce harms that they 
are most willing, and potentially most able, to tackle. This arrangement allows corporations more 
freedom while participating in harm reduction, which may encourage them to take some action over 
none, or more action over less.  
3.7 Key Takeaways from the Oil and Gas Industry 
This analysis of the oil and gas industry shows us at least two things. First, not all corporations match 
up alongside my harm reduction framework in the same way. Second, it highlights the feature of my 
harm reduction framework that says that any amount of harm reduced should be counted as good.  
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 Above, we saw that, in some ways, the oil and gas industry and its workers harm themselves 
in the same ways that they harm the rest of society. People who work in the oil and gas industry are just 
as susceptible to the effects of climate change as anybody else. Thus, they are indeed harming 
themselves, albeit in a different way compared to injection drug users, tobacco users, and sex workers. 
Thus, not all corporations align with my harm reduction framework in exactly the same way that I laid 
out in Chapter 2. Due to the nature of a cluster concept, however, this misalignment does not create so 
much difference that my harm reduction framework cannot apply. This flexibility is a benefit of using 
a cluster concept to define harm reduction for corporations. 
 Additionally, the reader may have noticed that my suggestions for how the oil and gas industry 
could reduce harm to the environment and society seem rather feeble compared to the massive disaster 
that is global climate change. This observation would be correct. Indeed, even if every oil and gas 
company took on the harm reduction initiatives suggested in this chapter, Indigenous peoples will still 
have their lands improperly used, residents will still be uprooted, and climate change will most 
definitely still occur on a horrific scale. In a way, it may be argued that the harm reduction initiatives 
in this chapter do so little harm reducing that they may as well not be mentioned. This line of thinking, 
however, is misguided. While the harm reduction initiatives suggested here may be miniscule, they still 
make a difference. The difference is perhaps tiny, but there is a difference nonetheless. Now, it is overall 
better to have a situation be a tiny bit less harmful compared to the status quo. Further, tiny steps 
forward add up to great steps forward. For example, many of us think that it is important to turn off the 
tap while we brush our teeth or turn off the lights when we leave a room because small actions can 
make a big difference. Thus, I defend the feature of my harm reduction framework that says that any 
amount of harm reduction, however small, should be counted as a good thing. The oil and gas industry 




In this chapter, I reviewed the processes involved with the oil and gas industry and identified three 
types of companies that service the industry. I then demonstrated that the oil and gas industry is an 
appropriate site to apply harm reduction frameworks while simultaneously highlighting the harms that 
the industry does to the environment and society. I provided an example of exploratory drilling and 
showed how the exploratory drilling companies might choose to reduce their harms to the environment. 
This process can be repeated for locating, extracting, and refining crude oil products to identify other 
harms that can be reduced in the oil and gas industry. Finally, I explained how my harm reduction 
framework was importantly different from corporate social responsibility. 
 The next chapter in this dissertation will demonstrate how my framework of harm reduction 
for corporations applies to the pharmaceutical industry. This industry will be yet another example of an 





Harm Reduction for the Pharmaceutical Industry 
The pharmaceutical industry continues to be heavily criticized in today’s media for a variety of reasons. 
Just recently, John Kapoor, founder of Insys Therapeutics that manufactured fentanyl, was convicted 
of bribing doctors with money and exotic dancers to prescribe more of the drug (The Associated Press 
2019). Fentanyl is an opioid that is at the centre of the opioid crisis across Canada that has sparked a 
national response due to the high number of overdoses and deaths in 2018 and 2019 (Government of 
Canada 2019).  
Mirroring Chapter 3, this chapter analyzes harm reduction for the pharmaceutical industry. The 
pharmaceutical industry is especially interesting because of the complex network of relationships 
involved in the processes of researching, developing, manufacturing, marketing, and selling 
pharmaceutical products. In this chapter, I show that this network of relationships leads to several harms 
that are worth reducing. 
 This chapter opens with an overview of the brand-name, generic, and drug store industries in 
Canada. I then analyze the pharmaceutical industry with respect to the harm reduction cluster concept 
developed in Chapter 2. My analysis shows that the harm reduction framework set out in this 
dissertation applies well to the pharmaceutical industry. After that, I launch into a case study of Merck 
& Co. Inc. to demonstrate how a company in the Canadian brand-name pharmaceutical industry can 
reduce its harms even further. 
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4.1 Pharmaceutical Industries 
There are at least three industries that make up the pharmaceutical industry network in Canada: brand-
name pharmaceutical manufacturing, generic pharmaceutical manufacturing, and drug stores in 
Canada. This section will review each of these industries in turn. 
4.1.1 Brand-Name Pharmaceutical Manufacturing in Canada (Ozelkan 2018a) 
Brand-name pharmaceutical manufacturing includes all companies that research, develop, 
manufacture, and sell brand-name pharmaceuticals for use in humans and animals. The major 
companies in this industry are Pfizer Inc. (29.3% market share), Gilead Services (25.5% market share), 
Sanofi (17.8% market share), and Merck & Co. Inc. (10.4% market share). The pharmaceuticals 
manufactured by these companies are protected by patents, which give the manufacturer an effective 
monopoly on selling a drug for 20 years from the time that the drug is discovered. Once these 20 years 
have elapsed, information about the drug is released and generic drug manufacturers can make generic 
versions of the drug. The justification for these patents is that they stimulate research and development 
by offering some assurance that the manufacturer will recoup their expensive research and development 
costs in future sales. Nutritional supplements and cosmetics are excluded from this industry.  
By all accounts, brand-name pharmaceutical manufacturing in Canada is a large and profitable 
industry with room to grow. With revenues of $7.1 billion and a 24.5% profit margin in 2018, brand-
name pharmaceutical manufacturing is big business. Increasing health expenditures and an aging 
population are two key drivers that lead to the success of the brand-name pharmaceutical manufacturing 
industry. Further, a weakened Canadian dollar and the newly inked Comprehensive Economic and 
Trade Agreement with the European Union means greater opportunity for exports. In fact, exports were 
expected to represent $5 billion of the industry’s revenue in 2018. Exports to the United States continue 
to be especially important. Finally, brand-name pharmaceutical manufacturers benefit from 
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partnerships between universities and third-party contractors who shoulder some of the high research 
and development costs. Importantly, though it seems as if universities and contractors are paying the 
high research and development costs, it is ultimately the taxpayer that shoulders these burdens through 
funding public university salaries and government grants. 
The brand-name pharmaceutical manufacturing industry is under price pressure. The industry 
has three main groups of purchasers: federal, provincial, and territorial governments represent 42.6% 
of industry sales, private insurers represent 35.2% of industry sales, and private households shoulder 
the remaining 22.2% of sales out of pocket. Recently, all levels of government have shifted their focus 
toward lower cost generic drugs, which saves them billions of dollars every year. For example, Alberta 
sets a price ceiling of 18% of the brand-name drug price for all generic drugs and British Columbia has 
a ceiling of 20% of brand-name drug prices. The highest of these ceilings is 35% in Nova Scotia, Prince 
Edward Island, and Saskatchewan. With such low generic drug prices, it becomes difficult for 
governments to justify funding for brand-name drugs. Private insurers have also shifted in favour of 
generic drugs, again due to lower prices, although they remain more likely than governments to insure 
brand-name pharmaceuticals. In line with this trend, private households also often favour generic drugs 
due to their low costs. However, brand name prices are still paid for the various drugs that are under 
their 20-year patent protection. 
Research and development is important to brand-name pharmaceutical companies. This 
research generates drugs that can be patented and sold exclusively by the manufacturer for 20 years. 
Thus, it is beneficial for brand-name pharmaceutical manufacturing companies to constantly have drugs 
working their way through the research and development process. Companies do this by sponsoring 
academic research into drugs, contracting out research to other organizations, acquiring smaller 
companies that manufacturer drugs under patent, and doing in-house research. Unfortunately, research 
and development has not been keeping pace with patent expiries. The brand-name pharmaceutical 
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manufacturing industry has recently suffered from a “patent cliff”, where many important patents have 
expired between 2013 and 2018. As a result, generic substitutes are available for many of these drugs, 
which reduces revenue for brand-name manufacturers. Brand-name pharmaceutical manufacturers 
have responded by investing resources into research and development, specifically in biologics, which 
are pharmaceuticals that are made from biological substances such as cells and tissue. These drugs are 
more expensive to develop and manufacture, but also enjoy greater protection in the form of patents, 
as many biologics can use different mechanisms to achieve the same result in the patient. These 
differences in mechanisms allow brand-name pharmaceutical manufacturers to file multiple patents for 
similarly effective drugs, which provides greater protection for the brand-name manufacturer. 
4.1.2 Generic Pharmaceutical Manufacturing in Canada (Ozelkan 2018b) 
The generic pharmaceutical manufacturing industry develops, manufactures, and sells generic drugs. 
These drugs are not protected by patents and research and development for new drugs is left mostly to 
brand-name pharmaceutical manufacturers. The generic manufacturing industry is smaller than the 
brand-name manufacturing industry, but sells a significantly higher volume of product. Revenues are 
strong at $5.4 billion with a 17.9% profit margin in 2018. Major players include Apotex Inc. (10% 
market share), Pharmascience Inc. (10% market share), Teva Pharmaceutical Industries Ltd. (8.2% 
market share), and Novartis AG (6.5% market share). The industry continues to grow while mergers 
and acquisitions strengthen profit margins.  
 In many ways, the generic pharmaceutical manufacturing industry benefits where the brand-
name pharmaceutical manufacturing industry struggles. Governments, private insurers, and private 
households seek out generic drugs due to their huge cost savings compared with brand-name drugs. 
Though the pressure to keep these costs low is significant, generic pharmaceutical manufacturers make 
their money through volume of sales. In fact, they sold 70.6% of total prescription volumes in 2017. 
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Further, exports, especially to the United States, remain important to the industry. Total exports made 
up 77.8% of total revenue in 2018.  
4.1.3 Pharmacies and Drug Stores in Canada (Ozelkan 2018c) 
Pharmacies and drug stores are retail locations that sell prescriptions and over-the-counter drugs 
alongside a variety of consumer-packaged goods. They are the main distributor of brand-name and 
generic drugs and serve as the link between the manufacturer and end consumer. Revenues in 2018 
reached $44 billion with a profit margin of about 7%. Key players in this industry include Shoppers 
Drug Mart (28.8% market share), Metro Inc. (9.9% market share), McKesson Canada (7.2% market 
share), and Pharmasave Drugs National Ltd. (5.5% market share).  
 The high volume of generic drugs being sold to consumers acts as a boon to this industry. In 
fact, the industry thrives on a low price, high volume business model. Industry revenues and profits are 
expected to continue growing, especially since manufacturers compete to have their products carried at 
pharmacies and drug stores.  
 Many of the drivers that affect brand-name and generic drug manufacturers also apply to 
pharmacies and drug stores in Canada, including an increase in total health care expenditures and an 
aging population. Increasing competition from grocery stores and online pharmacies have driven the 
major players to offer higher convenience and better services, such as increasing hours of operation and 
offering diabetes monitoring and flu shots. Consolidation is also increasing and allows the industry to 
cut costs, which counteracts the fact that rebates for generic drugs have trended downward. Despite 
competition, the industry is expected to grow over the next five years through offerings of preventative 
health services. The patent cliff experienced by drug manufacturers also leads to growth, as cheaper 
generic drugs increase consumers’ rate of adherence to their medications, resulting in a higher volume 
of drugs being purchased from pharmacies and drug stores. 
 
 93 
 Pharmacies are heavily regulated by federal, provincial, and municipal governments. For 
example, price restrictions on generic drugs strongly impact profit margins and pharmacists must be 
licensed. Despite this regulation, pharmacies have recently been able to increase their range of services. 
For example, some provinces now permit pharmacies to renew and prescribe medications. These 
additional services lead to higher revenues for pharmacies and drug stores in Canada. These revenues 
are also more profitable, which is important for this industry because 63% of their expenses come from 
drug purchases. 
4.2 Applying Harm Reduction to the Pharmaceutical Industry 
As we saw with the oil and gas industry, it is important to determine whether harm reduction 
frameworks are applicable to the pharmaceutical industry specifically, even though we have already 
determined that the frameworks apply to corporations overall. After all, there might be some feature of 
pharmaceutical industries that misaligns with the cluster concept of harm reduction that leads us to 
exclude it from harm reduction frameworks. This section will show that harm reduction frameworks 
do apply to the pharmaceutical industry. 
4.2.1 There is at least one identifiable harm associated with the behaviour.  
Here, I highlight three areas of concern within the pharmaceutical industry: influencing prescriptions, 
inaccessibility of drugs, and industry sponsorship of clinical trials. These are areas of concern because 
they all compromise the safety of people who consume these drugs. This harm is important because 
doctors are meant to prescribe medications that improve health outcomes with the least amount of risk. 
When pharmaceutical companies influence physicians to prescribe their drugs more frequently, when 
people cannot access existing drugs, and when pharmaceutical companies influence the outcomes of 
clinical trials, physicians’ ability to prescribe drugs that are maximally effective with minimal risk is 
 
 94 
called into question. The risk to patient (or potential patient) safety is serious and when these risks are 
realized, it constitutes one major harm that the pharmaceutical industry does to consumers.  
4.2.1.1 Influencing Prescriptions Through Gifts 
One of the most heavily-researched harms from the pharmaceutical industry is the relationship between 
pharmaceutical companies and physicians. Pharmaceutical companies are in an uncommon situation 
when it comes to marketing their products because physicians act as gatekeepers to prescription 
medication. Thus, a pharmaceutical company’s sales often depend on how many and how frequently 
doctors prescribe their drugs. The obvious result is that it is in the pharmaceutical company’s best 
interest to convince as many physicians as possible to prescribe their drugs and to convince each 
physician to prescribe their drug often. This relationship leads to many ways that consumers are 
ultimately harmed. Here, I will focus on just one of these issues: gift giving.  
The pharmaceutical industry courts medical students and physicians in the form of gifts. These 
gifts range from low-value, such as pens and notepads, to high-value, such as all-expenses-paid trips to 
conferences and significant amounts of research funding for the physician. According to the literature, 
gifts are powerful tools for pharmaceutical companies because giving a gift activates a reciprocity norm 
in medical students and physicians (Katz et al. 2003; Stokamer 2003). This reciprocity norm compels 
medical students and physicians to return the favour of the gift through their behaviour. Katz et al. 
(2003) point out that this reciprocity norm is so strong that those who accept gifts without providing 
anything in return are stigmatized as “moochers” or “free loaders”. Further, it is important to note that 
the size of the gift does not seem to matter in terms of changing physician behaviour. Cheap gifts are 
just as effective as expensive gifts at changing physician prescribing behaviour (Katz et al. 2003). Katz 
et al. assert that the primary reason for pharmaceutical companies to provide gifts to physicians is to 
interfere with their judgment and encourage them to prescribe brand-name drugs more frequently, often 
without the patient’s best interest in mind. Katz et al. also rightly point out that, even if the patient was 
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wary of the physician receiving gifts and being influenced by these gifts, the patient has little choice 
but to accept their physician’s recommendation. For Katz et al., pharmaceutical companies are not 
simply providing information. If they were, physicians would willingly trade their time for this valuable 
information and would not expect or need material gifts in return. Recall the case of John Kapoor and 
fentanyl described at the beginning of the chapter. Clearly, Insys Therapeutics was trying to influence 
prescriptions, as it cannot be argued that the financial bribe and exotic dancers were merely in the 
interest of providing information. 
There is research that demonstrates that medical students’ and physicians’ prescriptions are 
impacted by pharmaceutical gift-giving (Blackmer 2020; Green 2008; Katz et al. 2003; Komesaroff 
2010; Komesaroff and Kerridge 2002). In her landmark review, Wazana (2000) identified that 
pharmaceutical gift-giving improved residents’ and physicians’ knowledge of treating complex 
illnesses. However, it also led to an inability to identify incorrect claims about a medication, led to a 
positive attitude toward pharmaceutical representatives, led to increased awareness, preference, and 
rapid prescription of new drugs, increased requests for new drugs that had little additional benefit, 
increased prescription rates for the drugs, and led to fewer prescriptions of generics in favour of new 
drugs that showed no increased benefits. Clearly, pharmaceutical gift-giving interferes with medical 
professionals’ ability to prescribe drugs or other courses of treatment in the patient’s best interest. This 
is the major harm that comes from influencing prescriptions. 
Recent research shows that, despite laws making it illegal for pharmaceutical companies to 
give gifts to physicians, the practice continues to persist (Makowska 2017). Thus, while gift-giving by 
pharmaceutical companies may have been reduced by legal changes, it has not been eradicated and 




The second major harm that I will discuss is making medication inaccessible to those who cannot afford 
them. In this dissertation, I use the term “potential patients” to denote those who would use medications 
if they were able to procure them but cannot due to various barriers. These barriers include price, 
distribution, and manufacturing of the needed drugs. 
High prices of drugs for potential patients is common in developed nations. Many drugs, 
especially brand-name drugs, are very expensive and a potential patient is forced to choose between 
dying of a disease or themselves and/or their family becoming financially bankrupt. For example, one 
patient was prescribed a cancer treatment that would cost $45,000 per treatment. Even after their family 
took out a second mortgage, they were unable to afford the treatment. Luckily, this patient was eligible 
for financial assistance from the pharmaceutical company themselves, but others are not so lucky 
(Smith 2016). The fact that these financial assistance programs from the pharmaceutical companies 
themselves even exist (e.g. Genentech USA Inc. 2020) is evidence that many potential patients are 
unable to afford the cost of treatment. 
Further, there are many diseases that require pharmaceuticals for effective treatment, but these 
drugs are not manufactured because they are unprofitable, either because the disease is too rare for the 
drug to be profitable or the disease occurs in a developing nation where potential patients cannot afford 
the drugs. These types of drugs are called “orphan drugs” (Gericke et al. 2005) although they are 
sometimes divided into two categories, where the former diseases are treated using “orphan drugs” and 
the latter are drugs for “tropical diseases” (Villa et al. 2009). For the purposes of this dissertation, I will 
divide these drugs into the two categories of “orphan drugs” and drugs for “tropical diseases”.  
The main tension in the debate over whether orphan drugs should be produced is between the 
principle of non-abandonment and the principle of utility. The principle of non-abandonment states that 
“there are no valid reasons in principle to preclude any patient with a rare disease from having a rightful 
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claim to the resources available” (Pinxten et al. 2012, p. 151). In other words, every individual, 
regardless of the diseases that they have, has a rightful claim over health care resources to treat their 
diseases. This principle clearly applies to the case of orphan drugs. No matter how rare the disease the 
patient has, they have a rightful claim to medical resources to treat their rare disease. On the other hand, 
the principle of utility points out the opportunity cost of treating rare diseases. The large amount of 
resources put into research, development, and marketing of drugs for rare diseases could be put toward 
treating diseases that affect much larger populations, thus increasing social utility more efficiently 
(Pinxten et al. 2012). 
The United States, Japan, Australia, Taiwan, and Europe all have orphan drug legislation. This 
legislation is aimed at incentivizing pharmaceutical companies to develop and market drugs for rare 
diseases. In Europe, this means incentives for treating up to 8000 diseases in over 250,000 patients 
(Pinxten et al. 2012). In the United States, these are incentives for treating over 6500 diseases in 25-30 
million patients (Genetic and Rare Diseases Information Center n.d.). Orphan drug legislation was 
enacted in the United States in 1983 and has since been used to encourage the development and 
marketing of over 600 drugs and biologics (U.S. Food & Drug Administration 2018), which has been 
deemed to have a “modest impact” on the rates of drugs being produced to treat rare diseases (Seoane-
Vazquez et al. 2008). 
As of September 2019, there was no orphan drug legislation in Canada. In 2012, the Canadian 
government announced that they would investigate orphan drug legislation, but it was clear that this 
legislation was not a priority. In October 2017, all traces of an orphan drug legislative framework were 
deleted from government websites (Forrest 2017). As of September 2019, the Government of Canada 
states that they approved 16 drugs that were classified as orphan drugs in Europe or the United States 
in 2017 alone. The page on rare diseases lists incentives for drug production, but these are incentives 
that are available to all pharmaceutical companies regardless of orphan status and may or may not apply 
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to orphan drugs. Generic messaging about using data gathered from trusted foreign regulators and 
decreasing review time is also included on this website (Health Canada 2018). 
McMillan and Campbell (2017) argue that Canada needs an orphan drug regulatory framework 
that is tailored specifically to the existing Canadian policy framework and individual patients’ needs. 
They emphasize that there are up to 8000 rare diseases that, when aggregated, affect 1 in 12 Canadians. 
Most of these diseases are genetic and appear in children. McMillan and Campbell acknowledge that 
there may be little momentum for an orphan drug policy framework in Canada because of the existence 
of Health Canada’s Special Access Programme, which allows Canadians to use unapproved drugs to 
treat clinical conditions. However, McMillan and Campbell point out that while this is useful for low 
cost generic drugs, it is inaccessible to patients with rare diseases that often have steep medication costs, 
since drugs acquired through the Special Access Programme cannot have their costs covered by 
insurance companies. McMillan and Campbell suggest that the government support academic research 
into orphan drugs instead of mirroring the United States and offering tax credits, since most orphan 
drug research in Canada is done through academic networks. 
As for tropical diseases, it is true that pharmaceutical corporations often fail to provide 
medication in developing nations because these potential patients cannot afford the medications. 
Consider the case of eflornithine, which cured even the late stages of African trypanosomiasis, a lethal 
sickness that was common in sub-Saharan Africa. Aventis, after acquiring the rights to the drug, decided 
that the drug was not profitable and stopped producing it altogether. The preventable death of thousands 
followed. The drug only came back into production when it was found that it could temporarily remove 
women’s unwanted facial hair. Only after a strong international campaign by Doctors Without Borders 
and a mass media exposure of Aventis’s production of eflornithine did Aventis start to donate the drug 
to clinics in central Africa (Clare 2017). The case of eflornithine is a clear case of harm that a 
pharmaceutical company did to society. Despite Aventis’s reaction to the international campaign, the 
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livelihood of thousands of people in sub-Saharan Africa continue to rest on the goodwill of a 
pharmaceutical company. 
Eflornithine is not the only drug that has been inaccessible to those in developing nations. Eden 
et al. (2019) surveyed ten pediatricians in nine different countries and found that costs were a major 
factor in low-middle income countries accessing medications on the World Health Organization 
Essential Medicines list. Many families refused medication solely based on cost. Eden et al. call for an 
organized effort between countries, the World Health Organization, pharmaceutical companies, 
physicians, and nurses to ensure access, affordability, and quality of generic drugs. Echoing this 
sentiment, Villa et al. (2009) describes how worldwide orphan drug legislation could be altered to better 
include treatments for tropical diseases under its umbrella. For example, they suggest that orphan status 
could be extended to all treatments for diseases that are endemic in developing nations. Research grants 
could encourage the development of these treatments and international or national organizations could 
sign advance purchase commitments to guarantee revenue for the pharmaceutical company that 
produces these treatments. These suggestions could improve accessibility of drugs throughout Canada, 
where many do not have private health insurance and public health insurance does not cover all costs.  
4.2.1.3 Industry Biasing Clinical Trials 
Pharmaceutical companies are spending billions of dollars on clinical research every year. In the United 
States alone, industry-sponsored clinical research trials jumped from $4 billion in 1994 to $14.2 billion 
in 2003 (Moses III et al. 2005). In 2003, industry-sponsored research represented 57% of biomedical 
research funding in the United States while the National Institutes for Health represented 28% of 
biomedical research funding. The most recent Canadian data shows that brand-name pharmaceutical 
companies spend over $900 million on research and development per year. This spending is expected 
to grow to over $1 billion in 2023 (Ozelkan 2018a).  
 
 100 
These data should give us pause. In the United States, pharmaceutical companies spent more 
on research and development than the National Institutes for Health. In Canada, over 14% of revenues 
are being spent on research and development. Why are companies spending all this money? The answer 
seems to be that spending on clinical research trials brings favourable results to the pharmaceutical 
company, regardless of whether this is the pharmaceutical manufacturer’s intent. These results allow 
pharmaceutical companies’ drugs to gain approval from Health Canada. In fact, three meta-analyses 
surveying over 1100 clinicals trials found that industry-sponsored research leads to more favourable 
results for pharmaceutical companies (Bekelman et al. 2006; Lexchin et al. 2003; Sismondo 2008). 
These data should concern us because regulators rely on the data from pharmaceutical 
manufacturing companies to determine whether those drugs are safe and/or risky to prescribe. Further, 
medical practitioners rely on data from clinical trials to determine whether it is safe, or worth the risk, 
to prescribe drugs to patients in their specific circumstances. Without accurate data from clinical trials, 
medical practitioners could be prescribing drugs inappropriately and unsafely. They may also be over-
prescribing drugs in situations where it is ineffective. In these cases, the drug may be prescribed instead 
of another more appropriate and effective drug, which harms patients directly. Thus, a bias toward 
positive outcomes in clinical trials should be concerning for governments, medical practitioners, and 
patients around the world. 
Angell (2008), former Editor of the New England Journal of Medicine, writes that 
pharmaceutical companies used to fund clinical trials but gave full latitude to the academic researchers 
to design, test, analyze, write, and publish their findings. These days, pharmaceutical companies are 
closely involved in each of these processes, often designing, testing, analyzing, writing, and publishing 
findings themselves. Sometimes, they use academic researchers as a front to demonstrate legitimacy of 
doctored results. In fact, some academic researchers do not even have access to the data from the clinical 
trial that they ran. 
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According to Angell, there are several ways that bias works its way into the clinical research 
process. First, test drugs are compared to low doses of existing drugs so that the test drug looks more 
effective, or the test drug is compared to high doses of existing drugs so that the test drug looks like it 
has fewer adverse effects. Oftentimes, test drugs are compared against placebos, which is a common 
tactic that was also mentioned in Bekelman et al.’s (2006) meta-analysis. Sometimes, pharmaceutical 
companies choose to only publish the favourable data and reduce the emphasis on adverse effects. 
According to Angell, bias “permeates the entire system. Physicians can no longer rely on the medical 
literature for valid and reliable information” (p. 1070-1).  
Angell is not the only scholar to have noticed bias in clinical research. In a Cochrane Systematic 
Review, Lundh et al. (2017) find that industry-sponsored published research papers report higher levels 
of effective drugs and have more favourable conclusions compared to non-industry-sponsored studies. 
Spielmans and Parry (2010) report that pharmaceutical companies often have drastically different 
conclusions on the efficacy of their medications in their internal data compared to their published data. 
Negative results are often suppressed while positive results are published. Pharmaceutical companies 
also often engage the services of ghostwriters, where a journal article is written in a manner that is 
favourable to the pharmaceutical company. An academic or other authority figure that appears detached 
from the pharmaceutical company then allows the pharmaceutical company to use their name as the 
author of the article. The internal company documents that Spielmans and Parry review can be shocking 
to those who are not familiar with the conflict of interest literature in the pharmaceutical company. 
Ultimately, Spielmans and Parry conclude that pharmaceutical companies selectively use their 
scientific data to market their drugs through journal articles and sales representatives. “Until such issues 
are resolved […] any great enthusiasm for so-called evidence-based medicine should be viewed with 
scepticism” (p. 26). 
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Other scholars echo this concern for bias in publications (Amsterdam et al. 2017; Devaiah and 
Merchison 2016; Muckart 2013; Steinbrook and Kassirer 2010) and conflicts of interest (Mecca et al. 
2015; Steinbrook and Lo 2012). To address these concerns, Mansi et al. (2012) list ten 
recommendations on improving credibility in industry-sponsored clinical research. These 
recommendations include publishing all results, both negative and positive, improving understanding 
and disclosure of conflicts of interest, transparently reporting statistical research methods used in each 
study, and ensuring that authors have access to, and know that they have access to, complete study data. 
These recommendations address many of the concerns listed in this section, but there is no guarantee 
that pharmaceutical companies will heed these recommendations. 
One way to operationalize Mansi et al.’s suggestions is to register clinical trials. Currently, 
Health Canada does not require registration of clinical trials. Instead, it hosts a database of clinical trials 
that identifies whether the trial meets regulatory standards. However, it does not require researchers to 
disclose the outcome of the clinical trial. Unfortunately, without this information, medical practitioners 
are unable to judge whether a drug’s clinical trials warrant its prescription in certain populations.  
In contrast, clinical trials performed in America are required by law to be registered on 
ClinicalTrials.gov. The registry is maintained by the National Library of Medicine and the National 
Institutes of Health. When registering a clinical trial, researchers must publish basic results that cover 
the study’s outcomes of the efficacy of the drug and adverse effects on trial participants. Since 
September 2008, this information has been made public for physicians, patients, medical researchers, 
and the general public to access. As a result, medical practitioners and patients can view the outcomes 
of all of the clinical trials associated with a drug and decide whether the risks are appropriate for their 
particular situation before using a drug. While registries do not prevent all of the bias in the research 
and development process, they certainly go a long way to reducing it, since results of all clinical trials 
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must be published. As many of the concerns listed above surround publication bias, mandatory clinical 
trial registration can be an effective tool to help reduce bias. 
4.2.2 The behaviour is tenacious at the population level. 
Pharmaceuticals are a core part of our healthcare system. Both brand name and generic drugs are 
multibillion-dollar industries that are not expected to slow down. These companies are so important 
that governments have repeatedly worked with them to balance the industry’s financial interests with 
the health of the population at large, both within their respective countries and around the world. 
Governments around the world continue to work with pharmaceutical companies to balance their 
financial interests with the global need for pharmaceutical products. 
 As discussed throughout this dissertation, I posit that there are two parts to tenacity of the 
pharmaceutical industry: the industry itself is tenacious and the harms that the industry perpetuates are 
also tenacious. First, the pharmaceutical industry needs to be tenacious. Imagining life without 
pharmaceuticals results in a world that is significantly less healthy, less happy, and less prosperous. 
The global pharmaceutical industry provides an indispensable service to people around the world. We 
all need the pharmaceutical industry to help us prevent health disasters, improve quality of life, and 
save lives. 
Second, the harms that the pharmaceutical companies do to consumers and potential patients 
are also, unfortunately, tenacious. The pharmaceutical industry will continue to be driven by profits 
since they are, at their core, a business. They will make decisions based on price, analyze their ability 
to recuperate costs, and price their pharmaceuticals in profitable ways. As a result, pharmaceutical 
companies will likely continue marketing their drugs to physicians, they will price their drugs 
profitably, which means that there will be some populations in the world that cannot afford to access 
medications, orphan drugs and drugs for tropical diseases will continue to be rare, and the 
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pharmaceutical industry will continue doing their best to ensure that their investment into clinical trials 
work out in their favour.  
The quick answer to these harms is to ask governments to regulate the pharmaceutical industry 
more closely. However, it is important to note that we have known about these issues with the 
pharmaceutical industry for at least two decades and governments have failed to regulate or otherwise 
resolve the harms that the pharmaceutical industry does to patients and potential patients. There are 
likely a myriad of reasons why the government has not stepped in or has not stepped in to a large enough 
extent. I will not go into those possible reasons here. The point is that governments sometimes do not 
regulate away the harms from industries and in the case of the pharmaceutical industry in Canada, the 
government has not regulated away the harms at all. As a result, we must turn to other tools, like my 
harm reduction framework, to encourage corporations to change on their own. Of course, in the spirit 
of harm reduction, multiple solutions to this problem are welcome and it is certainly consistent with 
harm reduction to continue to pressure governments to regulate the pharmaceutical industry more 
closely. However, actions other than regulation are possible and could be effective as well.  
4.2.3 The behaviour is, to some extent, tolerable. 
Despite all the harms that come with pharmaceutical companies, they should be tolerated by almost 
everybody. Pharmaceutical companies have the knowledge and resources to develop important new 
drugs, and improve existing drugs, that treat a variety of ailments, which range from preventative 
measures, such as manufacturing vaccines, to mere inconveniences, such as reducing gas from a bean-
filled meal, to curing or prolonging the prognosis of a person with a life-threatening illness, like AIDS. 
There is a sense that we should be at least somewhat grateful to pharmaceutical companies for providing 
us with such important resources. 
Remember that tolerating an industry is different from condoning or supporting an industry. I 
acknowledge that there are many people around the world that have been wronged by pharmaceutical 
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companies in various ways, including issues accessing medications due to price or distribution, having 
horrible side effects from medications, and taking medications that lead to long-lasting health issues 
and death. These are all harms that the pharmaceutical industry does to individual consumers and saying 
that we should tolerate the industry does not mean that we must simultaneously support all these 
outcomes of the industry’s actions. We can tolerate pharmaceutical companies for all the good that they 
do while acknowledging their harms and demanding that they do better. Indeed, doing just that deeply 
aligns with my harm reduction framework. 
Let us now turn to whether the pharmaceutical industry’s harms are tolerable. One interesting 
piece to note is that the pharmaceutical industry does, in fact, enact several intolerable harms as defined 
by Card. Pharmaceutical companies make treatments that bring death to many and the withholding of 
treatments for various reasons also causes death to many. These are clearly intolerable harms. However, 
other harms that may not be intolerable include giving gifts to physicians to influence their 
prescriptions. In many of these cases, patients may not be provided the fastest or cheapest solution to 
their medical problems, but they are not harmed to a point where they subjectively view their lives as 
not worth living. Staying with the pluralistic view of harm reduction and the theory in my framework, 
we can simultaneously praise pharmaceutical companies for all of the good that they do for people 
around the world while simultaneously condemning their intolerable harms and asking them to reduce 
those harms to tolerable ones, and also going further to reduce other harms. We may think that the 
pharmaceutical industry itself is tolerable while recognizing that some of the harms that they do are 
intolerable. This is consistent with my discussion of tolerability in Chapter 1.  
4.2.4 The primary harms are to the self. 
The primary harms that the pharmaceutical industry does are to others. This is to say that the 
pharmaceutical industry does not do harms against itself in ways that an injection drug user harms 
themselves when they use. However, as we saw in the oil and gas industry, I continue to argue that the 
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harms that the pharmaceutical industry does to others is at such a magnitude that it cannot be ignored. 
Again, the fact that corporations do harm to others instead of harm to themselves gives us an even 
stronger mandate to intervene. Leading physicians to over-prescribe and selectively prescribe more 
expensive medications, withholding pharmaceuticals from those who cannot afford them, and being 
irresponsible in the process of drug testing are all major harms that are worth reducing.  
Recall that my harm reduction framework holds that companies get to choose which harms 
they reduce and how much they reduce those harms. Thus, my harm reduction framework would not 
go as far as the ethics of care might demand. As discussed above, the ethics of care might require or 
strongly prefer that corporations eliminate the harms that they do to consumers and potential patients. 
While I recognize the intuitive draw of this position, using my harm reduction framework requires only 
that pharmaceutical companies reduce whichever harms they choose to whichever extent they choose, 
so long as they are reducing some harm. Again, this is a feature of my harm reduction framework 
because I want to encourage companies to reduce harm in areas where they would otherwise do nothing. 
4.2.5 The harm is worth reducing even if it is not cost-efficient. 
The United Nations Declaration of Human Rights Article 25 states, “Everyone has the right to a 
standard of living adequate for the health and well-being of himself and of his family, including food, 
clothing, housing and medical care and necessary social services, and the right to security in the event 
of unemployment, sickness, disability, widowhood, old age, or other lack of livelihood in circumstances 
beyond his control”. This Article suggests a strong international stance toward the right to health care. 
As a crucial part of health care and security in the event of sickness, pharmaceutical drugs, and the 
companies that make them, are essential. Whether or not it is cost-efficient to provide health care to all, 
it is each person’s individual right to receive it. 
If we want pharmaceutical companies to continue operating, it is without a doubt that it is 
worthwhile to reduce the harms that they do to individuals in the process of providing, or withholding, 
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treatments for a variety of diseases. Appropriate prescriptions, access to treatment regardless of disease 
or ability to pay, and safe and accurate clinical trials are all part of ensuring our right to health care. 
The harm involved in these processes should be reduced to promote our right to health care without 
unnecessarily harming patients or potential patients in other ways. 
4.2.6 Significant harms are due to stigma or criminalization of the behaviour. 
Like other analyses in this dissertation, this criteria of the cluster concept of harm reduction does not 
apply to the pharmaceutical industry. Though many people may not like pharmaceutical companies or 
their executives, there is no significant stigma or criminalization of the pharmaceutical industry in the 
way that there is toward injection drug users and sex workers. However, as argued in Chapters 2 and 3, 
failing this criterion does not preclude the entire harm reduction framework from applying to 
pharmaceutical companies. Like corporations in general and the oil and gas industry, harm reduction 
frameworks apply to pharmaceutical companies despite there being no significant harms due to stigma 
or criminalization of the industry. 
4.3 Case Study: Merck & Co. Inc. 
Now that we know that my harm reduction framework applies well to companies in the pharmaceutical 
industry, it is worthwhile to do a case study on one of them to demonstrate how my framework can lead 
a company to do less harm. All the major brand-name pharmaceutical companies in Canada post 
information about their corporate social responsibility efforts online. Many of them publish annual 
corporate social responsibility reports, either as interactive links on their website or in a document that 
is available for the public to download. Of all the major brand-name pharmaceutical companies in 
Canada, Merck & Co. Inc. (Merck), known as MSD outside of the United States and Canada, seems to 
have the most comprehensive corporate social responsibility report. Thus, it seems prudent to analyze 
their report and identify areas where my harm reduction framework would ask Merck to act differently. 
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 Merck’s 386-paged 2017/2018 Corporate Responsibility Report details four main areas of 
focus: access to health, employees, environmental sustainability, and ethics and transparency. It is 
interesting to note that page 4 justifies Merck’s corporate responsibility approach to investors. “In 
exercising our fiduciary duty to our shareholders, we take a long-term perspective on shareholder value 
that takes into account both our company’s relationship with society as a whole and the interests of our 
many diverse stakeholders.” This statement implies that Merck is cognizant of the fact that many of its 
shareholders may think that corporate social responsibility is an activity that needs justification. This 
statement also reminds us that pharmaceutical companies are indeed companies first and have a duty 
to generate profits. Any framework applied to the pharmaceutical industry must be consistent with that 
duty and my harm reduction framework does just that. 
 Before launching into a discussion about their four areas of focus, Merck’s report discusses 
their contribution to the United Nations Sustainable Development Goals. Progress includes reducing 
the mortality rate of mothers, implementing differential pricing to convert potential patients into 
patients, increasing the number of women who work for Merck, reducing water consumption, 
increasing sustainable energy consumption, reducing pollution, and hiring members of 
underrepresented groups.  This progress is grouped into eight of the Sustainable Development Goals: 
1. Good Health and Well-Being 
2. Gender Equality 
3. Clean Water and Sanitation 
4. Affordable and Clean Energy 
5. Decent Work and Economic Growth 
6. Responsible Consumption and Production 
7. Climate Action 
8. Partnerships for the Goals 
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The report then discusses materiality of corporate responsibility initiatives. The company is 
focused on corporate responsibility initiatives that are both important to stakeholders and important for 
business success. The matrix presented in their report shows that the most important issues are pricing 
and commercialization, research and development, intellectual property, and privacy of patient data. 
The first three relate to the main area of “access to health” while the latter relates to the main area of 
“ethics and transparency”. Clearly, Merck views its key responsibility as providing access to health.  
Merck acknowledges its lobbying in its corporate responsibility report. While industry 
lobbying is often seen as unethical, Merck seems to think that its lobbying efforts are laudable. For 
example, in the United States, they lobbied for “market-based solutions for access to innovative 
pharmaceutical, vaccine and biologic products” and “maintaining a strong business environment for 
U.S. operations in the states”. In Europe, the company lobbied for “fostering a framework for a sound 
pricing and procurement regime in and across diverse EU member state economies” and “science-based 
policies for biologic medicines”.  
The report also discloses contributions to political parties “where permitted by law in the U.S., 
Canada and Australia” (p. 51). In 2017, the company gave $657,250 in political contributions to 
politicians in the United States, $61,255 to politicians in Australia, and $875 to politicians in Canada.  
The remainder of Merck’s corporate responsibility report discusses its four areas of corporate 
responsibility in excruciating detail. I will draw out Merck’s position on the three areas of harm that I 
have identified in section 4.2.1: influencing prescriptions, inaccessibility, and industry sponsorship of 
clinical trials. 
4.3.1 Influencing Prescriptions 
Merck’s corporate responsibility report details a Global Scientific Education Initiative. The company’s 
scientists and medical professionals developed a course that details the clinical trials process, regulatory 
review process, and post-approval monitoring. This course was developed in conjunction with Yale 
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University and is taught in 85 schools across 20 countries. A second course developed by Merck aims 
to “foster new collaborations between academia and industry” (p. 138). Both courses are provided for 
free to medical students. The corporate responsibility report emphasizes that these and other educational 
materials are meant to inform and not promote Merck’s pharmaceuticals. Their position is that they 
simply keep medical professionals up to date about the latest advances in medical science.  
The report includes information about Merck’s relationship with medical professionals. The 
report says that the company wants medical professionals to have “balanced and accurate information” 
(p. 336) about its pharmaceuticals. They point to guidelines that align with the International Federation 
of Pharmaceutical Manufacturers & Associations Code of Practice and the World Health 
Organization’s Ethical Criteria for Medicinal Drug Promotion. Merck employees are expected to follow 
these guidelines, adhere to laws and regulations, and adhere to its internal Code of Conduct.  
Merck employees discuss their products with health care professionals, sponsor promotional 
and/or educational meetings, offer scientific presentations at conferences, and publish in peer-reviewed 
journals. The report cites heavy regulation that surrounds its relationship with medical professionals. It 
mentions a “robust anti-bribery/anticorruption program” and “prohibits the offer, promise, or giving of 
any payment or benefit at any time to an individual or entity for the purpose of improperly influencing 
decisions or actions with respect to our business” (p. 336). Where legal, the company provides product 
samples to physicians. 
4.3.2 Inaccessibility 
For potential patients in the United States, Merck has developed a State AIDS Drug Assistance 
Program. This program provides low-cost HIV medication to about one-third of patients living with the 
disease in the United States. Merck has also developed a U.S. Patient Assistant Program that provides 
free medication for potential patients who need CRIXIVAN or ISENTRESS, both of which are drugs 
used to treat HIV. Much like the Genentech financial assistance program mentioned above, this 
 
 111 
program benefits patients who apply through Merck’s processes and are accepted as eligible patients. 
Some patients may also be eligible for a coupon for ISENTRESS or ISENTRESS HD.  
For access to pharmaceuticals in developing nations, Merck highlights its efforts to provide 
low-cost pharmaceuticals to sub-Saharan Africa and low-income countries as defined by the World 
Bank. To provide these pharmaceuticals, Merck cuts costs in its manufacturing and supply chain and 
licenses their formulas to generic drug manufacturers. Merck offers their lowest prices to governments 
in these developing nations. Further, the company prices differently depending on a country’s ability 
to pay, specifically with drug therapy for HIV. However, the report falls short of taking on responsibility 
for making medications accessible. 
“To truly enhance access to treatment in low- and middle-income countries, the 
international community must collaborate to strengthen health care infrastructure, to 
ensure adequate financing for health, and to help build local health care capacity 
through training and support. Pharmaceutical companies alone cannot solve these 
immense public-health problems. Sustainable solutions will come from comprehensive 
approaches that draw on the expertise of all stakeholders.” (p. 196) 
Merck has also acted with respect to tropical diseases. They have a history of donating 
MECTIZAN, which cures river blindness (onchocerciasis), to affected nations. Collaborations with 
academia, the United States Army, and research institutes around the world allow Merck to continue 
research into pharmaceuticals for tropical diseases. 
4.3.3 Industry Sponsorship of Clinical Trials 
Merck does not disclose how much money they spend on clinical trials in either their annual report or 
corporate responsibility report. However, their corporate responsibility report emphasizes that Merck 
registers clinical trials in accordance with the laws and regulations of where they operate. By registering 
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clinical trials, companies are forced to report the outcomes of the clinical trial regardless of whether 
they are favourable to the pharmaceutical company or not. Note that this does not prevent the 
pharmaceutical company from altering the design of the clinical trial or ending clinical trials early to 
generate favourable results. Further, nations that do not require pharmaceutical companies to register 
their clinical trials miss out on crucial information on drugs that are being tested. As discussed earlier, 
this void of information ultimately harms consumers. 
To mitigate these concerns, Merck requires that all authors of their research papers make 
“substantial contributions” to the study design, analysis, or interpretation, draft the article or “revise it 
critically”, give final approval for publication, and are accountable for the results (p. 129). These criteria 
seem to prevent authors from being merely agents that give credibility to a research study and report 
that was crafted, analyzed, and written by the pharmaceutical company in ways that are favourable to 
its profits. However, this does not prevent Merck from doing all of its research internally, without 
authors from academia, and continuing to design, analyze, and report its findings in a way that is 
favourable to the company. Further, as discussed earlier, even academic researchers can unintentionally 
bias a study’s results. 
The corporate responsibility report then takes great pains to list all the laws, regulations, and 
industry bodies that it adheres to. They discuss the International Conference on Harmonisation Good 
Clinical Practice standards, cite an internal data-monitoring committee, gain the approval of 
Institutional Review Boards or Ethical Review Committees, comply with General Data Protection 
Regulation, and train clinical research associates and contract research organizations according to the 
company’s standards. They are a member of the International Pharmaceutical Privacy Consortium to 
protect patient confidentiality. Note that many of these organizations or processes are required by law. 
Thus, Merck is not always going above and beyond to be an industry leader in corporate responsibility. 
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Instead, they sometimes merely comply with laws and regulations set forth by the governments in the 
countries in which they operate. 
4.4 Harm Reduction for Merck Co. Inc. 
There are several areas where my harm reduction framework would suggest that Merck take additional 
actions. First, I want to clarify that my harm reduction framework would not recommend that Merck 
stop any of their existing corporate responsibility initiatives, as the company sees good reasons to 
pursue them. However, my harm reduction framework would suggest a shift in focus from corporate 
social responsibility to reducing harm. 
4.4.1 Influencing Prescriptions 
My first concern is with the balanced and accurate information that Merck’s sales associates provide to 
physicians and medical students. While the information that they provide may be accurate, the data 
may be drawn from clinical trials that are developed, analyzed, and reported on by Merck employees. 
As discussed in section 4.2.1, clinical trials where pharmaceutical companies are involved are often 
misleading. Thus, Merck would be in a better position to reduce their influence in prescriptions by 
reducing or eliminating their involvement in clinical trials. They could also reform the way that their 
sales representatives and marketers connect with physicians and medical students. Further, they could 
target the root of the problem by publishing all their clinical trial results even in countries, like Canada, 
where doing so is not required by law. 
 Second, Merck openly admits to sponsoring educational events, presenting at conferences, and 
publishing in peer-reviewed journals. The literature shows that these events lead to increases in 
physicians’ tendency to prescribe the company’s brand-name medications despite there being little or 
no additional benefit over generic drugs. Again, over-prescription means that patients are receiving 
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drugs when they should be receiving a different course of treatment that would be more beneficial to 
them. Thus, reducing harm involves reducing or eliminating these behaviours.  
 Here, I want to make a distinction between actions that Merck would be willing to take on 
voluntarily and actions that Merck would take in response to external factors. For reasons of profit, it 
seems unlikely that Merck, or any other brand-name manufacturing company, would voluntary cease 
the promotional activities listed above. If this is indeed the case, reducing harm in these areas would 
require external factors, most likely in the form of additional regulation. Thus, while it is perfectly 
acceptable to pressure Merck, and other brand-name manufacturers, to voluntarily reduce their 
influence on prescriptions through the above means, it is by no means that only way to achieve harm 
reduction. What is important is that Merck considers reducing harms in the above areas. Whether they 
choose to do so is up to them. This outcome is consistent with the two main features of my harm 
reduction framework. 
4.4.2 Inaccessibility 
Merck’s strategy for making drugs more accessible largely centres around its HIV medications in the 
United States and developing countries. While this is an important contribution to worldwide access to 
HIV medication, Merck produces 110 pharmaceutical drugs, the vast majority of which are not 
mentioned in their corporate responsibility report (Merck 2020). Merck could take the next step and 
identify other pharmaceuticals that are difficult for potential patients to access and put plans in place to 
increase accessibility. However, to protect profits, Merck likely cannot do this for all its drugs. 
Decision-makers at Merck would have to prioritize certain pharmaceuticals over others using a variety 
of factors, including profitability, global disease burden, and public relations.  
 
 115 
4.4.3 Industry Biasing Clinical Trials 
Merck postures itself as having taken a great stride in preventing bias in clinical trials by implementing 
stricter requirements for authors’ involvement in research, analysis, and article-writing. However, as 
mentioned above, these requirements do not prevent Merck from doing research with its own 
employees and continuing to bias clinical trial results in the ways described by Angell and other 
scholars above. They can also continue to make use of academic researchers who have financial ties to 
the company and are thus motivated to bias the clinical trial results.  
 Without more information about the processes that Merck uses to engage in clinical trials, it is 
difficult to determine what a harm reduction framework would recommend. Clearly, reducing bias in 
clinical trials is important, but the extent to which Merck can act to do so is unclear. After all, the 
clinical trials registry in America mentioned above was pushed through regulation and not through the 
companies themselves. Thus, experts and decision-makers at Merck would have to look into their 
sponsorship finances and procedures more carefully to come to a decision about how to best reduce 
harm. However, there are a number of suggestions in the literature for reducing sponsorship bias. First, 
financial disclosure or disclosure of conflicts of interest as suggested by Mansi et al. may encourage 
pharmaceutical employees to remain at arms-length from the research and development process. After 
all, a study by Merck’s researchers on Merck’s drugs may be weighed less strongly than a third-party 
study. However, financial disclosure merely suggests that it would be best for companies to hire third-
party researchers and does not guarantee that they will do so. Thus, sponsorship bias will persist. 
Second, public trial registries, like ClinicalTrials.gov mentioned above, reduces the tendency for 
corporations to only publish positive results. The ability to look at all the data collected about a 
particular drug allows patients, physicians, other medical practitioners, and anybody else who is 
interested to evaluate the benefits and risks of a drug. While these suggestions make some strides toward 
eliminating bias in the research and development process, they are not all-encompassing. “[A]s long as 
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the pharmaceutical industry controls the production of knowledge, the interests of the industry will 
influence the knowledge that is produced” (Doucet and Sismondo 2008). 
4.4.4 Two Features of My Harm Reduction Framework 
It is important for me to remind the reader that there are two distinct features of my harm reduction 
framework. First, the company’s motivations for pursuing harm reduction do not matter. Second, the 
company can reduce as much or as little harm as it likes and we will still call their efforts “harm 
reduction”.  
 The first feature is important to point out because many of Merck’s corporate responsibility 
efforts might be seen as insufficient and addressing the trends in public relations without attention to 
larger issues. For example, Merck’s commitment to making HIV medication more affordable for 
potential patients around the world might seem like an attempt to distract the public from the fact that 
its other 108 pharmaceuticals command high prices. This might be the case because HIV is a disease 
that has garnered a lot of attention for decades while other diseases that Merck’s products treat are less 
well-known. Contrary to this view, my harm reduction framework says that it does not matter whether 
Merck is reducing the prices of HIV medication for the purposes of distracting the public, for improved 
public relations, or out of the goodness of their hearts. What matters is that their price reduction 
programs effectively make HIV medications affordable for potential patients. Thus, my harm reduction 
framework asks Merck to produce evidence that their price reduction strategies have been increasing 
access to HIV medications. 
 The second feature is important when we consider the difference between my harm reduction 
framework and corporate social responsibility. Many might read over Merck’s corporate responsibility 
report and be dissatisfied with their response to the three issues that I identified in this chapter. After 
all, Merck does continue to perform activities that influence physicians to prescribe their brand-name, 
more expensive medications over cheaper generic options without there being a significant difference 
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in efficacy. The vast majority of Merck’s drugs are still sold at a large margin given their $6.2 billion 
profit on $42.2 billion in sales in 2018 (Securities and Exchange Commission 2019) so it can be argued 
that Merck has a lot more room to provide cheaper medications around the world. Finally, their lack of 
transparency surrounding their funding of clinical trials is concerning. Merck might simply not be doing 
enough for many to consider them socially responsible. However, their actions still reduce harm.  
 My harm reduction approach applauds the work that Merck has done so far and celebrates the 
progress that they have made. After all, Merck could have chosen to continue selling its HIV 
medications without a discount for anybody. While my harm reduction framework encourages Merck 
to continue its discount programs and seek out new ones, it does not require them to do so for their 
actions to count as harm-reducing. The same reasoning applies to all of Merck’s other corporate 
responsibility efforts. 
 My harm reduction framework might be seen as being too lenient on Merck. They clearly have 
the capacity to do more for society and being socially responsible might require that they do more. 
Here, I want to point out that my harm reduction framework still requires Merck to evaluate its 
programs and decide whether they are reducing enough harm according to their motivations. They must 
then act on the outcome of their analysis. If their corporate responsibility report identifies all the harms 
that they are willing to reduce to the greatest amount that they are willing to reduce said harms, then 
using my framework means that we simply applaud the changes that Merck has made up to this point. 
If there are additional harms that Merck wants to reduce or existing harm reduction programs that 
Merck wants to be more effective, then they should make those changes. 
4.4.5 Corporate Social Responsibility 
As with Chapter 3, the reader may still be wondering why my harm reduction framework is importantly 
different from corporate social responsibility with respect to Merck’s case. After all, Merck’s extensive 
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corporate responsibility report gives the appearance that they have addressed every possible ethical 
failing that they could be criticized for, including the criticisms included in this chapter. 
 Again, Merck’s existing corporate social responsibility efforts should be maintained. However, 
my harm reduction framework shifts the focus of these corporate social responsibility efforts onto the 
initiatives that reduce the most harm. So, we can applaud Merck’s partnership with other 
pharmaceutical companies to share information, but we can ask them to focus on reducing harm by 
analyzing their participation in, for example, funding research and development projects.  
 Whether Merck responds to these calls for action rests with their decision-makers. Using my 
harm reduction framework would mean that Merck asks all its decision-makers about the kinds of 
harms that they think they should reduce. Reducing these harms can be motivated by anything, 
including public relations, protecting reputation, and personal interest. Decision-makers must agree on 
which harms to reduce. Next, these decision-makers must agree on how much harm they want to reduce. 
Which harms do they prioritize and why? How much do they want to reduce those harms? How much 
harm is acceptable? 
 I do not know Merck’s answers to these questions, but my framework would require all 
decision-makers to come to an agreement over which harms they will reduce and how much they will 
reduce those harms. In this way, Merck sets their own standard for harm reduction that is “good enough” 
according to the plan that they came up with in the introspection process. It is possible that Merck’s 
strategy would vary greatly after this process, but it is possible that it remains largely the same. What 
is important is that Merck looks strictly at harm-reducing behaviours and determines which of those 
behaviours they are willing to perform and the extent to which they are willing to perform them. This 
focus will likely lead a company like Merck to alter the balance of their social responsibility efforts 
toward initiatives that reduce more harm that stems from their operations.  
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4.5 Key Takeaways from the Pharmaceutical Industry 
The pharmaceutical industry is interesting to study because it is so complex. A transaction at a 
pharmacy requires much more complicated processes than typical transactions. For example, a 
consumer must first see a doctor, who provides a prescription for a product that the consumer has little 
knowledge of or input in receiving. That prescription is then taken to a pharmacy, who often contacts 
an insurance company to pay for some or all the costs of the drug. Finally, the prescription is given to 
the consumer, who then uses the drug.  
 Throughout this complex process, many parties are involved in reducing harm to consumers. 
Thus, many of the suggestions to reduce harm in this chapter have a trickle-down effect to consumers. 
For example, registering all clinical trials informs doctors, who can prescribe drugs using more accurate 
and balanced information compared to relying on pharmaceutical salespeople and manufacturer-
sponsored educational talks. The better-informed doctor then offers a more appropriate treatment for 
the end consumer.  
 The pharmaceutical industry is also an interesting case study when we take the perspective of 
a business. Companies are often looking for ways to increase their market share and increase the size 
of their market overall. These are standard business practices that companies use to increase sales. 
However, the pharmaceutical industry often ends up harming consumers when it tries to do this. 
Increasing their market share involves convincing physicians to prescribe their medication to more 
patients, which would artificially increase market share, as all else being equal, those patients would 
have been more appropriately treated with another drug or no drug at all. Increasing the size of the 
market is no better, as that would involve injuring or ailing more people so that the manufacturer’s drug 
can be prescribed. Thus, standard business practices are actually detrimental to public health and some 
may think that these actions are wholly unacceptable. Thus, this chapter shows us that going about 
everyday business can be the very thing that is harming people. This tension is important, because we 
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can neither tell pharmaceutical corporations not to go about their everyday business nor can we accept 
that people are being harmed unnecessarily. This tension may lead to complicated and nuanced harm 
reduction initiatives, many of which would require deep industry expertise to devise and execute. 
Alternatively, only very superficial harm reduction may be possible due to the complexity of the 
industry. Regardless, I encourage leaders in the pharmaceutical industry to create and execute harm 
reduction initiatives while balancing the needs of every stakeholder involved in the complicated process 
of selling a drug. 
 The fact that harm reduction in the pharmaceutical industry requires deep industry expertise is 
supported by classic harm reduction as described in Chapter 1. Harm reduction looks to the harm-doer 
for guidance on how to best meet their needs. It allows the harm-doer to be the expert on what will and 
will not work for them and allows them to accept or reject any suggestion for a harm reduction initiative. 
The pharmaceutical industry benefits greatly from this perspective because it gives them the freedom 
to be creative with their harm reduction initiatives while simultaneously rejecting suggestions that do 
not work for them. Again, an entire industry may not respond well to any one harm reduction initiative, 
but my harm reduction framework gives us the flexibility to customize harm reduction initiatives for 
each individual corporation. This flexibility may well be useful for complex industries like the 
pharmaceutical industry. Thus, the core harm reduction principle to “meet people where they are” is 
vividly demonstrated by the pharmaceutical industry. 
4.6 Conclusion 
The pharmaceutical industry in Canada, and especially the brand-name pharmaceutical industry in 
Canada, does serious harm to patients and potential patients around the world. They influence 
physicians to prescribe more of their expensive brand-name medications, produce many drugs that are 
inaccessible to those in need, and bias the published results of clinical trials in their favour. These harms 
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are tenacious and worth reducing even if it is not cost-effective to do so. The case study of Merck Co. 
Inc. shows how my harm reduction framework could be implemented in a brand-name pharmaceutical 
company. However, we should keep in mind that, in the spirit of harm reduction, the actual harms to 
be reduced vary greatly depending on the corporation at hand based on their own motivations and 
amount of harm they want to reduce. I cannot offer blanket recommendations for which harms the 
pharmaceutical industry should reduce, nor can I offer specific recommendations for any one 
pharmaceutical company without being involved directly with its decision-makers. Thus, there is more 
work to be done when it comes to implementing my harm reduction framework in corporations. This 





Changing Toward Harm Reduction 
So far, I have developed a harm reduction framework and showed its applicability to the oil and gas 
industry and the pharmaceutical industry. This chapter will demonstrate how a harm reduction 
framework can be implemented in a company, even if it has already taken corporate social 
responsibility measures. 
Anybody looking to implement harm reduction in their corporation will find themselves in a 
period of change. Company leaders will have to envision, plan, implement, and solidify changes within 
the corporation to orient the company toward harm reduction. Managing effective change in a 
corporation has been the subject of much work in scholarly literature and by practitioners in industry. 
The first part of this chapter reviews the scholarly and practitioner perspectives on managing effective 
change and suggests that they should be combined to form an effective change management plan. Next, 
I apply these insights to harm reduction approaches within corporations. I then suggest two models for 
implementing harm reduction in corporations: internal and external.  
 In the second part of this chapter, I demonstrate the usefulness of my harm reduction framework 
in practice. To do so, I present the case of Walmart. The company has endured harsh criticism for its 
actions but simultaneously boasts a robust sustainability campaign. I analyze its corporate social 
responsibility campaign using my harm reduction framework to provide a new way to understand these 
behaviours. Ultimately, I show that harm reduction is a useful framework from which to view social 
responsibility.  
 In the third part of this chapter, I describe reasons why a corporation might want to adopt a 
harm reduction framework. At the end of this section, I provide a conclusion for this dissertation that 
highlights its main contributions. 
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5.1 Change Management Literature 
As discussed throughout this dissertation, and consistent with harm reduction’s dedication to a plurality 
of solutions, harm reduction may not be effective or appropriate for every single corporation. Thus, the 
first step for company leaders is to decide whether harm reduction is a framework that they want to 
adopt to help the company achieve its goals, whatever those goals may be. If the company leaders think 
that harm reduction would be effective and appropriate, perhaps by reviewing my harm reduction 
framework, then they will need to think about how to effectively implement harm reduction throughout 
their organization. 
 The change management literature is frequently divided into two groups in the literature. The 
first group is the scholarly literature, which can be found in peer-reviewed journals and textbooks. The 
second group is the practitioner literature, which can be found in popular management books, blogs, 
and the occasional brief contribution to a peer-reviewed journal article. In turn, the scholarly change 
management literature is divided into three groups: change characterized by rate of occurrence (e.g. 
discontinuous change), change characterized by how it comes about (e.g. planned change, emergent 
change), and change characterized by scale (e.g. Dunphy and Stace 1993) (By 2005). In section 5.1.1., 
I review each of these scholarly theories of change management. Next, in section 5.1.2., I review two 
change management strategies from practitioners. One strategy comes from Jones (2015) and the other 
comes from Vora (2013). I chose these two perspectives to review because they are direct and 
prescriptive.  
The distinction between scholarly and practitioner literature is clear in Bartunek (2007), where 
she encourages scholars and practitioners to straddle the divide between both the scholarly and 
practitioner arenas so that the two groups can collaborate more effectively. Bartunek also encourages 
opportunities for scholars and practitioners to share their perspectives in formal settings where both 
groups are welcome to participate. These opportunities can also allow scholars and practitioners to 
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share information about common interests, such as success metrics. In line with Bartunek’s suggestions, 
this section will briefly review both literatures so that the reader has a basic understanding of change 
management in business. 
5.1.1 Change Management: The Scholarly Perspective 
By (2005) characterizes change as continuous and necessary for survival. In her critical review, she 
reports on three groups of academic literature on change management that attempt to explain how to 
successfully manage change. The first group is “Change Characterized by Rate of Occurrence” (p. 371). 
This is an early approach to change that argues that effective change is impossible if it is constantly 
occurring. Instead, companies need to set routines for people to be comfortable at work. This early idea 
gave way to discontinuous change, in which change happens quickly and all at once. According to 
Birkinshaw et al. (2016), discontinuous change requires companies to change internal processes and 
pivot their strategy to achieve ongoing success. This change occurs suddenly and without precedent. If 
successful, discontinuous change can leave competitors scrambling to compete with a new product or 
service. For example, the launch of ebooks and ereaders threatened the foundation of the entire book 
publishing industry. 
 Unfortunately, discontinuous change is risky and has uncertain outcomes (Pullen 1993). It has 
been correlated with a high rate of change failures in corporations (Birkinshaw et al. 2016). Two 
suggestions have been put forth to help mitigate these failures. The first is “dynamic capabilities”, 
where companies continuously change to keep up with the market. This addition to discontinuous 
change is supported by Holder (1995), who argues that that discontinuous change must be followed by 
continuous change for the firm to succeed. The second is “ambidexterity”, which is when firms cope 
well with conflicting needs. Birkinshaw et al. (2016) argue that combining dynamic capabilities with 
ambidexterity allows firms to succeed more often using a discontinuous change approach.  
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 Discontinuous change has the power to be market-changing but carries a high risk for failure. 
Even if successful, it must be coupled with continuous change for a firm to maintain its position in the 
market. Much like “dynamic capabilities” and Holder’s argument that discontinuous change must be 
followed by continuous change, scholars have looked into continuous change, also known as 
“incremental change”, in which companies constantly adjust to smaller internal and external influences 
(By 2005). Consistent with today’s thinking on change management, the consensus in the literature is 
that change is a continuous and necessary process for companies to remain competitive. Thus, survival 
depends on a company being able to effectively manage ongoing change. 
 The importance of continuous change has led many scholars to study it and determine how best 
to manage it. Lawrence et al. (2006) present four phases to continuous change. First, there must be 
influence, whereby somebody has an idea and impetus for change and influences people to support that 
idea. In this stage, carefully presenting the idea to stakeholders by framing the idea in ways that they 
would support is important. Persuading stakeholders to accept and support the idea is key in this phase. 
The second phase is authority. In this stage, a person with “formal, legitimate power” (p. 61) makes 
themselves responsible and accountable for implementing the new idea. This process removes the fear 
that many stakeholders have over whether the change will be successful. The authority figure also helps 
to demonstrate exactly how the change should be implemented and can use their power to strike down 
any resistance from stakeholders. The third phase is technology. To solidify the change in the 
organization, technology is usually involved so that stakeholders are not relied on to carry out the 
change on their own. In other words, technology helps the authority figure institutionalize change. In 
the technology stage, the original idea is translated into repeatable processes that are aided by 
technology. The fourth and final phase is culture. According to Lawrence et al., this phase is the most 
important but also the most overlooked stage of change. In the culture phase, stakeholders become 
confident in the change and use that confidence to extend or elaborate on the change. They look for 
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related and novel ways to improve upon or develop the initial idea in ways that are strategic to the 
company.  
 Another theory of continuous change management is put forth by Gould (1996). Gould presents 
a Change Wheel with four phases: fine-tuning, building, crisis, and transformation. These phases 
operate simultaneously, not in sequence. Fine-tuning occurs when a company makes small changes that 
improve a company’s ability to operate successfully. Procedures and standards are maintained while 
deviations from them are minimized. Building solidifies a company’s core competencies and makes 
them routine. This phase creates a formal change program that is delivered and monitored throughout 
the firm. Crisis occurs when all routines and structures are put on pause, usually due to new company 
leadership or a power shift among influential members of the firm. Routines and structures are 
dramatically disturbed or ignored altogether and existing standards are set aside. Finally, 
transformation occurs when leadership tests out new ways of operating and acts as a catalyst to new 
behaviours. Existing structures are set aside in favour of trying out new ways of doing things.  
 Continuous change is a careful balance between flexibility and efficiency. The key is to allow 
the firm to be flexible and adaptive to change while maintaining peak efficiency. Hakonsson et al. 
(2012) find that continuous change leads to better long-term organizational performance and reliability 
compared to discontinuous change, which means that a firm can be both highly efficient and changing 
at the same time. So, as long as a company has a long-term strategic focus, it is possible for it to be 
both efficient and continuously changing. This is key for organizational change theory, as it was 
previously thought that being highly efficient and continuously changing were opposed to one another. 
Hakonsson et al. conclude that stable firms can also be continuously changing ones.  
 From this first group of change theories, we can conclude that discontinuous change is best 
reserved for circumstances where a major innovation or disruption occurs. In these cases, change is 
major and it must happen quickly so that a company adapts to the newness. However, discontinuous 
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change must be coupled with continuous change to be successful. After all, a company experiencing 
constant discontinuous change loses its identity while employees struggle to keep up. Continuous 
change is needed to fine-tune the outcome of the discontinuous change and solidify the change within 
the firm. 
 The second group of change theories is “Change Characterized By How It Comes About” (By 
2005, p. 373). The two main areas in the literature under this category is planned change and emergent 
change. “Planned change” typically refers to Lewin’s Theory of Planned Change, although some 
scholars argue that the famed three-step model that we attribute to Lewin was developed after his death 
(Cummings et al. 2016). Regardless, the typical understanding is that Lewin’s theory progresses in 
three steps (Shirey 2013). The first step is “unfreezing”. This stage occurs when a person with authority 
in the firm recognizes a need for change, perhaps due to the latest consumer survey or in response to 
diminishing sales. The authority creates a sense of urgency for others to support the change. The second 
step is “moving” or “transitioning”. In this stage, employees react to changes and shift from their old 
behaviours to new behaviours. Managers must keep employees focused on the outcome of the change 
and reduce their fear of the unknown. Finally, the third step is “refreezing”. In this stage, change is 
institutionalized in the firm and creates a new normal. Successful refreezing leads to stable firms.  
 Lewin’s Theory of Planned Change is used extensively in the nursing and healthcare field 
because it is versatile, simple, and easy to understand. However, it has been criticized for being too 
simple and artificially linear (Bartunek and Woodman 2015). In today’s dynamic and ever-shifting 
world, a more flexible and iterative approach to change seems necessary, at least for some 
circumstances. Regardless, Lewin’s Theory of Planned Change remains highly influential in the 




The criticisms of Lewin’s Theory of Planned Change gave way to emergent change. Emergent 
change was developed in response to work environments that were chaotic or uncertain (Bamford and 
Forrester 2003). In emergent change, changes occur quickly and are complex, which often means that 
change in an organization starts from the bottom and works its way up the hierarchy of the organization. 
In fact, emergent change theorists hold that change occurs so quickly that upper management cannot 
keep up with it all, which radically changes the way that upper management should behave in response 
to bottom-up change. Instead of dictating using a top-down approach, upper management becomes a 
facilitator for change. As Bamford and Forrester note, scholars working in emergent change have 
different views on what it involves and there is no singular agreed-upon theory of emergent change. 
Nonetheless, they all share the features listed here. 
Emergent change is poorly defined and has little empirical evidence for its efficacy. In fact, 
emergent change is so poorly defined that some even use the terms “emergent change” and “continuous 
change” interchangeably (Maimone and Sinclair 2014). A scan of the literature, however, suggests that 
emergent change is a response to an organization’s environment that can be spontaneous, complex, and 
driven by employees, while continuous change is a more deliberate and structured form of change that 
is championed by upper management. 
 The final group of change theories is “Change Characterized by Scale” (By 2005, p. 377). The 
most prominent theory in this group is Dunphy and Stace’s (1993) model for change, which they simply 
call the Dunphy/Stace model. The model forms a matrix with two axes: one with the scale of the change 
and the other with the type of leadership involved in the change. There are four scales of change: fine 
tuning, incremental adjustment, modular transformation, and corporate transformation. There are also 
four leadership styles: collaborative, consultative, directive, and coercive. Depending on the 
combination of scale of change and leadership style, four types of change are possible: participative 
evolution, charismatic transformation, forced evolution, and dictatorial transformation. Through 
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empirical research, Dunphy and Stace (1993) find that high performance is the result of incremental 
adjustment or modular transformation coupled with a consultative or directive leadership style. The 
worst performers are ones that focus on fine tuning with consultative or directive leadership styles. 
 Despite the variety of change management strategies discussed in the literature, most scholars 
agree that change management is a continuous process that must be flexible enough to respond to crises 
but stable enough to ensure that the changes are maintained over an extended period. It is also clear that 
no one model of change management will fit every company in every situation. Thus, the job of 
company leaders is to identify which change management strategy, or which combination of change 
management strategies, is best suited to the corporation’s situation and to use those strategies to 
effectively lead the company change. 
5.1.2 Change Management: The Practitioner Perspective 
The practitioner research on change management is varied and dispersed across multiple mediums. 
Some practitioners publish books on their own theories of change management, but many others share 
their insights on blogs. After scouring over a dozen change management blogs, it is clear that 
practitioners are focused on the finer details of how to go about change in a company rather than 
theories about how to act. For example, instead of publishing a blog post on why it is important for a 
leader within the company to have a vision, they write on how to communicate that vision effectively 
to a specific stakeholder group. Other change management practitioners promote their own views on 
what makes change successful, such as Céline Schillinger’s “Engagement Leadership” (2019) or Lena 
Ross’s “Agile Change” (2019). 
After looking through key texts in the practitioner change management literature, I have found 
that the most direct resource on the practitioner perspective of change is in Leading Sustainable Change 
(2015). The book itself focuses on change toward environmental sustainability, but the foreword is 
important for anybody interested in changing today’s organizations to be more socially responsible. 
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The foreword is written by David Jones, Founder of One Young World, a platform for youth to engage 
in conversations about the world’s most pressing issues, and CEO of You & Mr Jones, a marketing 
technology company. 
 Jones’s first piece of advice is to let other leaders in the corporation and employees know that 
the shift toward being socially responsible is about driving performance and competing in the market, 
not about doing good or saving the world. For Jones, the motivation is clear: the shift toward social 
responsibility is about increasing profits. Second, Jones asks leaders to get all levels of the organization 
on board with the social responsibility shift. They must be informed of the vision and plan for the 
company to make this shift. Leaders should frequently check to make sure that employees understand 
the vision and the plan. Further, rewards should be given for behaviour that aligns with the company’s 
broader goals. Finally, Jones calls for leaders to focus on today’s young adults, also known as 
millennials. They are one of the big groups of people that are driving the shift to sustainable business. 
Millennials are informed, responsible, and powerful through their ability to use technology to bring 
about change. They will not buy from or work for companies that do not meet their standards for 
sustainability. Millennials understand best that businesses should make money, but in the right way, 
and they know how a business needs to change to meet their individual expectations.  
A framework for implementing sustainable change from a blended perspective is provided by 
Manu K. Vora (2013), Chairman and President of Business Excellence Inc., a global consulting 
company, and Adjunct Faculty at the School of Professional Studies at Northwestern University. 
According to Vora, the first step is for companies to understand their abilities, motivation, and attitude. 
A company’s ability is what they can accomplish, their motivation determines the process by which 
they bring about the change, and their attitude determines how well the change is solidified. The second 
step is for companies to engage the 3 Hs: heart, head, and hands. Engaging people’s hearts allows them 
to be emotionally invested in the project. Their heads activate creativity and logic. Finally, their hands 
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help with the implementation of the change. The third step is for the organization’s leaders to lead. 
They must influence and inspire employees and be a catalyst for the change. The best leaders can bring 
about extraordinary performance in their employees in the direction of the change. The fourth and final 
step is to develop leadership ability. In this step, the leader’s vision and plan is realized and further 
change in the direction of sustainability is envisioned. 
Hughes (2007) offers at least two major critiques of the practitioner perspective of change 
management. First, he criticizes the practitioner perspective for being too broad. Different companies 
and situations require different tools and techniques for successful change, and the practitioner 
perspective often does not capture this nuance. Second, Hughes argues that the practitioner perspective 
lacks objectivity, as the claims about effective change management strategies lack the rigourous testing 
of academic change management theory and evidence. 
5.1.3 Bringing Together the Scholarly and Practitioner Perspectives 
Scholarly theories of change management have had impact amongst scholars but have not made their 
way into practice. Pollack (2015) studies the differences between scholars’ and practitioners’ emphasis 
on topics in change management. He finds that scholars are more focused on theories, models, and 
frameworks while practitioners are more focused on empirical evidence. Scholars also tend to talk about 
whole organizations while practitioners emphasize different strategies of change management for 
individuals and project groups that are in particular situations. Further, scholars emphasize change 
management as it relates to performance, strategy, and responses to the environment while practitioners 
emphasize culture, values, and identity. Overall, scholarship focuses on abstract theories of 
organizational change while practitioners focus on specific change situations and are concerned about 




 While Pollack’s research may suggest a sharp division between scholars and practitioners, his 
description of the differences between them may lead us to think that they are complementary instead 
of oppositional. Bringing together the scholarship and practitioner knowledge, we end up with robust 
theories that can be supported by empirical evidence and models and frameworks that can be flexible 
depending on the change leaders’ needs. Additionally, the areas of performance, strategy, responses to 
the environment, culture, values, and identity are all important to consider when undergoing change 
within a company. Thus, bringing both the scholarship and practitioner expertise together might yield 
superior, more effective, or at least more thorough implementation of change. Below are the key 
takeaways from the academic and practitioner literature that are important for this dissertation. 
5.1.3.1 Change is constantly occurring in corporations. 
Change is not something that happens in distinct blocks of time. We cannot cleanly delineate times of 
change and times of stability for a corporation. Instead, big and small changes happen all the time in 
corporations due to both internal and external forces. Internal forces for change can be top-down or 
bottom-up while external forces through events like regulation or competition force the company to 
adapt. Since change is occurring all the time, executives may find it difficult to keep up and need to use 
all the resources at their disposal to support change efforts in their organization.  
5.1.3.2 Change is necessary for survival and is thus a good thing. 
Change is not something to be feared. Change allows a corporation to remain competitive and flexible 
in a dynamic market. Thus, executives would be much better off embracing change than resisting 
change in the hopes of running a stable company. In today’s dynamic market, companies that do not 
change do not survive. 
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5.1.3.3 Constant change must be balanced by stability. 
Though change is constantly occurring, company leaders must find a way to balance change with 
corporate stability. The final stage of change is often said to be integration with company culture where 
the change becomes the new normal in a corporation. A careful balance between continuous change 
and stable processes is important for any corporation to survive. 
5.1.3.4 Change must be institutionalized. 
The final step in any change management process is to institutionalize the change within the company. 
The change must no longer be new and different. Instead, it becomes ingrained in the company culture 
to the point where it is just natural for processes to be done in that way. Institutionalization is often 
forgotten to the detriment of companies, as it helps to provide stability and consistent behaviour from 
employees. 
5.1.3.5 Good leaders are key to a successful change. 
For change to be successful in a company, the change needs to be headed by a dedicated and effective 
leader. The leader must champion the change and act as the face of the change to inspire employees 
and other executives to buy in. Their vision must be compelling. They must recruit allies within the 
firm to help them manage the change and ultimately see it through to its success. The leader is ultimately 
responsible for whether the change is a success or a failure. 
5.1.3.6 Change is different for each company. 
No change management strategy is going to work for every corporation. Company leaders must pick 
and choose the strategies that they think will work for each particular change effort. Strategies may be 
different from one change to the next even within the same company. Much like the core principle of 
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harm reduction to “meet people where they are” and thus customize solutions for each individual, 
corporate leaders must also customize change plans for each situation. 
5.2 Change Management and Harm Reduction 
Here, I want to go into more detail about what the leader must do to manage a successful change. Both 
the scholarly and practitioner literatures lend support to my below characterization of a change leader, 
who I call a “change champion” or more specifically, a “harm reduction champion”.  
First, as seen in the scholarly and practitioner literatures, the shift to harm reduction needs a 
change champion, or in this case, a harm reduction champion, within the corporation. The champion 
must be individually motivated to bring about change toward harm reduction within the company and 
should understand their own ability for, motivation behind, and attitude toward change. The champion 
must be willing and able to be accountable for the change and get others on board. The champion must 
also be willing to be flexible and act quickly when required but know when to slow down and pay 
careful attention to certain aspects of the change when necessary. It is clear from both scholars and 
practitioners that change without a competent leader will fail.  
Second, the harm reduction champion must be able to engage a variety of stakeholders at all 
levels inside and outside the corporation and convince them all that a shift toward harm reduction is a 
good idea. Different stakeholders have different motivations and the champion must be able to connect 
to them all. As a result, champions must be able to articulate why a change toward harm reduction is 
good for the bottom line and for the environment and society. Importantly, the actual motivation of the 
champion does not have to be either or both options. They simply must be able to make a case for 
pursuing harm reduction from the perspective of both options. 
Finally, the champion must identify the influencers in the company. They must know who is 
on board with their change plan and who is not and actively work to bring more people on board. 
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Perhaps certain generations, like millennials, are more familiar with the change that the organization 
wishes to bring about, and so those groups of people are engaged more frequently. If an organization 
finds that millennials are not the right group to help champion the change and provide advice to the 
leader, then perhaps there is another group that could perform these actions in their place. Regardless, 
the champion must identify groups of individuals who will act as allies throughout the company. 
5.2.1 The Harm Reduction Champion 
As we have seen, scholars and practitioners have both emphasized the importance of a corporate leader, 
or what I am calling a “change champion”, when it comes to change management. Somebody within 
the organization must be willing to champion the shift to harm reduction. There are at least two ways 
that this champion could operate. These two options are no different from the usual options for leaders 
looking for corporate change. They can either use the company’s internal resources and/or hire an 
external consultant for help. For the sake of brevity, I will refer to these options as operating “internally” 
or “externally”. Thus, if operating internally, the harm reduction champion relies on internal company 
resources to plan and execute the change. Alternatively, the harm reduction champion could rely more 
on external support, through a harm reduction consultant, to plan and execute the change. Regardless, 
the harm reduction champion must have influence within the company and the ability to communicate 
with decision-makers who will listen to them. 
5.2.1.1 Champions Working Internally 
This option requires the harm reduction champion to work with other leaders within the company, 
usually executives, who have the power to make decisions that pivot the company in meaningful ways. 
Together, these leaders would be responsible for initiating, leading, and solidifying the change toward 
harm reduction within the company, although the harm reduction champion may be ultimately 
accountable for successful change. The main benefit of this approach is that the company can act on 
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the desires of the decision-makers without outside influence. Most importantly, the corporate decision-
makers can control their research processes to ensure that the harms they are most interested in, for 
whatever reason, are made salient to the rest of the firm. Thus, harms that decision-makers want to 
reduce out of the goodness of their hearts or because they value a certain cause are guaranteed 
consideration. Further, harms that the firm feels strongly about reducing, again for whatever reason, 
will be made salient as well. Since the decision-makers are operating amongst themselves, they will be 
able to have all their voices heard and be able to come to an agreement about which harms to reduce, 
and how much to reduce them by, based on how much the group prioritizes said harms.  
There is a worry with executives working only amongst themselves. Though harm reduction 
does not judge whether high-risk behaviours are ethical or not, ethics is involved insofar as it describes 
the way that people ought to behave. So long as there is behaviour that affects other people, ethics 
usually has something to say about it. Thus, in a broad sense, harm reduction is involved in ethics. That 
being said, research has shown that it is difficult to convince businesspeople to act more ethically, even 
after teaching them how to do so in the workplace. As a result, the internal leaders and other decision-
makers may have no reason to choose to reduce harms to the environment and society because it is 
ethical to do so. Instead, they may all choose to only focus on the bottom line. If this phenomenon 
spreads to multiple corporations or industries, we will be left with entire categories of harms that 
corporations do the environment and society that are left unaddressed. 
Teaching business ethics initially seemed like a promising route to developing more ethically-
minded students (Park 1998). Studies have found that business ethics education can improve students’ 
ability to recognize ethical issues (Gautschi and Jones 1998) and increase the likelihood of students 
making ethical decisions when faced with an ethical dilemma (Wang and Calvano 2015). Additionally, 
May et al. (2014) found that a business ethics course could enhance students’ perceived ability to 
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manage ethical issues, increase the perceived importance of ethical issues, and encourage students to 
raise ethical issues at work.  
 However, the effectiveness of business ethics education has been challenged by several 
scholars. In their meta-analysis, Waples et al. (2009) found that business ethics education had little 
effect on changing students’ ethical judgment, ethical awareness, and perception of themselves and 
others as ethical. They also found the least amount of support for business ethics education actually 
impacting students’ behaviour. Overall, they concluded that business ethics education was minimally 
effective.  
Several other studies confirm that women in business are more likely than men to make ethical 
decisions (Ritter 2006), act ethically (Wang and Calvano 2015), and have attitudes toward business 
ethics that are more ethical (Albaum and Peterson 2006). Since high-ranking employees of large 
companies are overwhelmingly male, these results are troubling. However, there is some evidence that 
business ethics education is more effective in men than women (Luthar and Karri 2005; Wang and 
Calvano 2015), which offers men the opportunity to progress to women’s level of ethical decision 
making and behaviour.  
This research suggests that businesspeople may not be the best at acting in ethical ways. As a 
result, the internal leaders and other decision-makers may focus disproportionately on harms that affect 
the corporation’s bottom line and completely ignore the wide variety of harms that are unethical in their 
own ways. For example, questions of justice, virtue, and utility in the utilitarian sense may not arise. 
Even with formal training in ethics, businesspeople may not change their decision-making in the 
workplace. Thus, entire categories of harms will be ignored. 
This is not to say that focusing on harms that impact the corporation’s bottom line is wrong or 
unethical. Again, according to my harm reduction framework, corporations can reduce any of the harms 
that they want, to whatever extent that they want. However, research suggests that internal leaders may 
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be unlikely to reduce harms that do not impact the bottom line, even if they are aware that these harms 
exist. As a result, entire categories of harms will persist. Thus, if harm reduction becomes 
commonplace, we should be prepared to reduce harms that do not impact the bottom line in ways other 
than asking corporations to internally decide to do so. 
5.2.1.2 Champions Working Externally 
Given the above analysis, there are at least two ways that a change champion could benefit from hiring 
a harm reduction consultant. First, a harm reduction consultant can help the company become aware of 
all the harms that the corporation does to the environment and society, regardless of whether they 
impact the bottom line. Second, the harm reduction consultant can explain the importance of reducing 
harms that do not impact the bottom line and potentially convince decision-makers to reduce those 
harms when they otherwise would not. 
First, harm reduction consultants will have training in the varieties of harms that corporations 
do to the environment and society. Many of them might be ethicists that work with corporations. Thus, 
they will have a deep knowledge of ethics and the variety of ways that a corporation may act unethically 
and do harm to the environment and/or society as a result. Due to this knowledge, harm reduction 
consultants may be able to expose all the harms that a corporation does to the environment and society, 
potentially highlighting some of the harms that the internal leaders were unaware of previously. This 
process might alert decision-makers to harms that they otherwise would have overlooked. 
As a reminder, it is still perfectly consistent for a harm reduction consultant to bring attention 
to all the harms that a corporation does to the environment and society, then have decision-makers 
decide to only reduce the harms that impact the bottom line. However, the point is that decision-makers 
would first consider all the harms that their corporation does, regardless of whether those harms impact 
the bottom line, which might encourage decision-makers to reduce additional harms. If the decision-
makers are not attuned to the all of harms that their corporation does, then they fail this process. As a 
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result, there will be no chance that the company reduces a variety of harms to the environment and 
society. In turn, the maximal amount of harm may not be reduced. After all, a company may have 
decided to reduce additional harms that did not impact the bottom line had they been aware that these 
harms existed. A harm reduction consultant would go a long way to help mitigate this issue.  
Second, if taken seriously, a harm reduction consultant could convince decision-makers to act 
on harms that the decision-makers would have otherwise ignored. The harm reduction consultant could 
do this by explaining the importance of reducing harms that do not impact the bottom line. For example, 
an appeal to autonomy might convince a company leader to provide native-language oral or written 
contracts to contractors who cannot read or write in English. Though this process does not impact the 
bottom line, it has serious implications for the way that people are treated around the world. A harm 
reduction consultant exposing a harm like this and providing reasons for why the harm is important to 
reduce may convince decision-makers to reduce more harms than they otherwise would have. 
Unfortunately, a harm reduction consultant that identifies several harms that the corporation is 
not interested in runs the risk of alienating the decision-makers in exchange for being thorough. As a 
result of this process, corporate decision-makers might view harm reduction as just another obstacle 
that they have to overcome to make profits, just like many corporations today perform corporate social 
responsibility solely for the sake of profits. On a more charitable view, however, decision-makers could 
see harm reduction as the newest challenge that they can exploit to gain a competitive advantage. This 
is merely speculation, however, so suffice it to say that some corporations may not appreciate a third 
party telling them that they do a variety of harms, especially harms that they have never considered, to 
the environment and society and that they should reduce said harms. 
5.2.1.3 Choosing an Option 
In alignment with harm reduction’s core principles, the implementation option that is used depends on 
the individual company’s choice. However, I do know that different corporations need different options 
 
 140 
for implementation. Some corporations may prefer to keep their harm reduction processes internal, 
while others prefer to seek outside expertise to help them in an area where they may not be as strong. 
Other factors, such as cost and time, may affect whether a corporation decides to implement harm 
reduction internally or externally. Staying true to harm reduction frameworks, then, means allowing a 
plurality of options on how to implement my framework. 
Ultimately, the best option is to accept the combination of the implementation options that 
reduces the most amount of harm. Given that the harms being reduced are only and all the harms that 
corporations are willing to reduce, to the extent that they are willing to reduce them, I support the 
combination of implementation options that convinces corporations to reduce the most amount of harm 
to the greatest extent that they are willing. For example, suppose that corporations that hired harm 
reduction consultants were able to reduce a lot of harm in the agricultural sector because of the experts’ 
creative solutions to existing problems. In this case, it may be best for the agricultural sector to follow 
a model of implementation that involves hiring a harm reduction consultant. Suppose, however, that 
the banking sector requires a high level of confidentiality and thus prefers to implement harm reduction 
internally. Since they are unwilling to use a third party, supporting their internal implementation seems 
like the best way to reduce harm. Thus, the implementation method comes down to whatever 
combination of them reduces the most harm for each industry, and often each individual company. 
5.3 Ranking Harms 
Now that a corporation has a grasp on which harms it wants to reduce, it might be useful to identify the 
harms are more urgent than others. It is likely that any single company would do more than one harm 
to the environment and society. However, given limited resources, it becomes important for a company 
to be able to rank their harms to help decide which harms to address and which to leave constant.  
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 This fact generates a theoretical question for the implementation of harm reduction frameworks 
in corporations: how do we prioritize harms such that the most important harm is reduced first, followed 
by the second most important harm, and so on? An intuitive answer to this question is to suggest that 
the worst harms get reduced first and the least harmful behaviours get targeted last. However, ranking 
harms is not as simple as this intuition suggests. First, there are multiple dimensions of harms, including 
the intensity of the harm, how long the harm is going to last, and so on. Corporations may value these 
dimensions of harm differently. Second, there is the question of buy-in within a corporation. Perhaps 
upper management is only concerned with reducing harms that will improve their public relations 
efforts. Alternatively, upper management may only have the resources for harms that are cheaply 
reduced. These considerations make it difficult for us to theoretically identify which harms are most 
important to reduce first. Further, suggesting that all corporations should reduce harm according to a 
theoretically ranked list of priorities goes against the core harm reduction principle to “meet people 
where they are” and customizing solutions to each individual. Thus, the best I can do is to provide some 
ways that we can think about resolving this issue of ranking harms in order from most to least important. 
5.3.1 Multiple Dimensions of Harm 
In An Introduction to the Principles of Morals and Legislation (1970), Bentham famously offers seven 
dimensions of pleasure and pain. These dimensions can help us identify how pressing it is to reduce a 
particular harm. The seven dimensions are as follows: 
1. Intensity: how deeply felt the pleasure or pain will be 
2. Duration: the length of time that the pleasure or pain will be felt 
3. Certainty or Uncertainty: how likely it is that the pleasure or pain will come about 
4. Propinquity or Remoteness: how soon one will feel the pleasure or pain 
5. Fecundity: the likelihood that the pleasure or pain will be followed by similar feelings 
6. Purity: the likelihood that the pleasure or pain will not be followed by opposite feelings 
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7. Extent: how many people will feel the pleasure or pain 
As a utilitarian, Bentham’s focus is on maximizing pleasure and minimizing pain. However, 
harm reduction is more focused on minimizing pain and does not say much about maximizing pleasure. 
This thinking aligns with a view called “negative utilitarianism”. Those who argue for negative 
utilitarianism claim that, all other things equal, reducing suffering or pain is more important than 
increasing happiness or pleasure. Acton and Watkins (1963) provide some reasons for thinking this 
way. First, we tend to think that those who are in pain deserve sympathy in a way that those who are 
experiencing pleasure do not. In fact, Acton argues, offering sympathy already implies that you are 
offering it to somebody in pain. Further, Acton argues, this sympathy comes from the fact that we feel 
compelled to help those who are suffering when we do not feel the same toward those who are happy. 
Other reasons for reducing suffering or pain over producing happiness or pleasure are put forth 
by Walker (1974). He argues that failing to relieve pain is morally worse than failing to produce 
pleasure. In other words, we think that we ought to avoid causing pain and to relieve it as much as 
possible whereas we do not feel the same way about producing pleasure. Further, when resolving moral 
dilemmas, we always consider the amount of pain that a behaviour will cause and there is less emphasis 
on producing pleasure. Where we do talk about producing pleasure, we often mean it in the sense that 
it will relieve pain. 
Thus, it might make sense to interpret Bentham’s dimensions of pleasure and pain differently 
from the traditional utilitarian framework. We could do this by emphasizing the pains of harms rather 
than emphasizing the joy from pleasure. Accordingly, we can evaluate harms according to an altered 
version of Bentham’s seven dimensions as follows: 
1. Intensity: how deeply felt the harm will be 
2. Duration: the length of time that the harm will be felt 
3. Certainty or Uncertainty: how likely it is that the harm will come about 
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4. Propinquity or Remoteness: how soon the harm will be felt 
5. Fecundity: the likelihood that the harm will be followed by more harm 
6. Purity: the likelihood that the harm will not be followed by non-harm 
7. Extent: how many people are affected by the harm 
Given these seven dimensions of harm, we might think that intense, long-lasting, certain, 
nearby harms that are likely followed by more harm that affect a lot of people are the most pressing to 
address. On the other hand, harms that are weak, short-term, uncertain, remote, that are not likely to be 
followed by additional harm and affect very few people are the least pressing. Perhaps this is true in a 
theoretical context, but it would be unrealistic for me to say that ranking harms in these ways reflect 
the way that corporations should actually reduce the harms that they do to the environment and society.  
These multiple dimensions of harms make it very difficult for us to even theoretically determine 
which harms are worse than others. For example, what kind of harm is worse: one that is intense and 
uncertain or one that is long-lasting for a very small group of individuals? We would need some kind 
of measurement for what kinds of harms are worse than others. This process might require a way of 
weighing the multiple dimensions differently or ranking the dimensions of harms from most to least 
important. This task is complex and difficult to accomplish in a way that everybody agrees with.  
I argue that such a task would not even be useful in the context of corporate harm reduction. 
Corporations will value these dimensions of harm differently. For example, an environmentally-
focused corporation may worry more about the duration of their harms, while those who employ child 
labour may worry more about the intensity of their harms. This reasoning suggests that there is a strong 
need for corporate buy-in before any kind of harm reduction initiative takes place. Thus, I argue that 
the best way to rank harms from most to least important is to allow each individual corporation to 
consider these multiple dimensions of harms alongside corporate buy-in.  
 
 144 
5.3.2 Corporate Buy-In 
Recall that one of harm reduction’s core principles is to “meet people where they are” by customizing 
solutions to each individual and respecting their decisions on which harms to address and which to 
leave constant. Abiding by this core principle to corporations means that I, as a harm reduction 
consultant, must consult companies individually to create a customized plan for harm reduction. Thus, 
there is no one way to rank harms for all corporations, or even for all corporations within a particular 
industry. Whether working internally or externally, corporate decision-makers and harm reduction 
consultants must rank harms for companies individually by fully respecting the company’s wishes to 
reduce some harms and to leave other harms alone. 
Further, when implementing a new concept like a harm reduction framework, it is prudent to 
expect at least some resistance from corporations. After all, corporations are responsible for driving 
profits and many have a legal or moral obligation to do so. Since corporations all drive profits in 
different ways, applying harm reduction to corporations will likely take place in different ways. For 
example, a corporation with a socially responsible mission embedded into the core of its operations 
will likely reduce harms differently from a corporation that only reduces harms to improve its 
reputation. In line with the spirit of my harm reduction framework as described earlier in this chapter, 
it is not necessary to judge which one of these motivations are better. The important fact is that 
corporations want to reduce at least some harm and as stated above, their reason for wanting to do so 
does not matter. 
 Since corporations are all unique and will reduce harms for different reasons in different ways, 
it is prudent to allow corporations to identify which harms they are willing to reduce, however much 
they wish to reduce it. Again, any harm reduced is better than no harm reduced, and we ought to 
encourage any amount of harm reduction. So, a corporation may decide that it wants to only reduce 
environmental harms because of its reputation for protecting the planet. Another corporation may only 
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be able to choose harms that are very cheap to reduce. Yet another corporation may only choose to 
reduce harms that impact its bottom line. All of these options are aligned and consistent with my harm 
reduction framework. 
 So, given the uniqueness of each individual corporation, it is meaningless to suggest a ranking 
of harms in order from most to least important for all corporations to reduce. Instead, individual 
corporations should reduce whichever harms to whatever extent that allows them to reach their 
individual harm reduction goals. A general, theoretical ranking of harms from most to least important 
to reduce is imprudent. Instead, we should focus on which harms a corporation thinks is important to 
reduce and help them reduce those harms to the best of their ability within the constraints of their 
resources and willingness to act. This reasoning aligns deeply with the core principles of harm reduction 
frameworks, specifically the core principles of looking at each individual case separately and “meeting 
people where they are”. 
5.4 Harm Reduction in Practice: The Case of Walmart 
So far, we have identified a harm reduction champion who will work either internally or externally to 
generate a list of harms that the corporation does to the environment and society in the course of its 
operations. The champion may have prioritized these harms based on what is most important to the 
corporation. Here, we will see how this process looks like once it has been operationalized in the 
corporation. 
Walmart has done its fair share of harms around the world but works to reduce their harms to 
their environment. Walmart is known internationally and is often discussed as a role model for 
implementing sustainability in its business practices. This section shows that my harm reduction 
framework is an excellent lens through which to view Walmart’s actions.  
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5.4.1 Bad Press 
Walmart is an international conglomerate of subsidiaries that are known for their affordable goods, 
summarized in Walmart’s slogan, “Save money. Live better.”. The company is enjoying its 13th year 
as the largest company in the world with 2018 being its fifth consecutive year at the top (Fortune 2019). 
With over $500 billion in annual revenues and 2.3 million employees, Walmart provides economic 
growth and jobs all over the world.  
 The company has had its fair share of ethical issues. Walmart has been the subject of 
unflattering news articles and events that change the way that consumers think about shopping. For 
example, in November 2012, there was huge fire in a factory that made clothes supplied to Walmart, 
among other fashion retailers. At least 112 people died in the incident and investigations showed that 
the high death toll was due to there being no emergency exits in the building. Walmart had previously 
audited the building in May 2011 and gave it a “high risk” categorization, followed by a “medium risk” 
categorization in August 2011. Walmart continued to do business with this factory (The Associated 
Press 2012). 
5.4.2 Sustainability Efforts 
At the same time, Walmart has been investing in its sustainability efforts. Many of its vehicles 
run on alternative energy and the company is on track to reach zero waste from their operations in 2025. 
To tackle food waste, the company keeps prices low for all food and discounts non-optimal foods for 
quick sale. Walmart donates extra food to local food banks as well. Walmart also aims to reduce plastic 
waste by minimizing the amount of plastic packaging used for its products and removing plastic bags 
from circulation, while making all remaining plastic packaging recyclable. As of 2019, Walmart stores 
are well on their way to reaching the company’s sustainability goals, as they will have reduced 
greenhouse gas emissions by 28,000 tonnes of carbon dioxide due to investments in energy 
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infrastructure. 87% of all waste is being diverted, including 11 million pounds of food being donated 
to local food banks. 
Dauvergne and Lister (2011) applaud several multinational companies, including Walmart, for 
tackling global sustainability issues through their business. They especially applaud Walmart’s high-
reaching, measurable goals. According to Dauvergne and Lister, multinational companies have been 
making sustainability part of their core operations, much like Dowling and Moran’s (2012) suggestion 
for “built in” corporate social responsibility campaigns, as discussed in Chapter 2. With these “built in” 
strategies, multinational corporations are making legitimate efforts at sustainable change and gaining 
recognition for their actions. 
However, Walmart’s sustainability efforts have not gone without comment. Baue (2009) 
describes two groups of people who weigh in on Walmart’s sustainability claims. The first group is 
“the oxymoron camp”, which sees Walmart’s promises of sustainability to be at odds with its long 
supply chains, disposable products, and underpaid contractors. The other group, “the salvation camp”, 
argues that Walmart’s sustainability program should be used as a tool to pressure other large companies 
to take on sustainable missions quickly so that they can compete. Ultimately, Baue argues that 
sustainability at Walmart is complex and difficult to communicate in concise, public-relations-
approved tag lines for the public. 
5.4.3 Walmart and Harm Reduction 
At this point, it is tempting to ask a variety of questions. Should we shop at Walmart and support it as 
a company? Is Walmart a morally good or morally bad company? Is Walmart evil? These are all 
interesting questions and can be taken up by other business ethicists. I am not interested in these 
questions. The question that I am interested in is: does Walmart reduce harm according its own 
standards for doing so? 
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Again, according to my harm reduction framework, the company’s motivations for reducing 
harm do not matter and the amount of harm that is reduced does not matter. Instead, using my 
framework means that executives will perform an analysis of the harms that they do to the environment 
and society, determine the harms that they want to reduce and the extent to which they want to reduce 
those harms, and then hold themselves accountable to those plans. So, whether we should shop at 
Walmart or whether the company is morally good, bad, or evil is not relevant to my harm reduction 
framework. 
From a harm reduction perspective, we know that Walmart is focused on reducing harms to the 
environment. The company wants to reduce harms to the environment by reducing carbon emissions 
and reaching zero waste by 2025. This is the extent to which Walmart wants to reduce environmental 
harm. So, according to my harm reduction framework, Walmart should take their goals seriously and 
be encouraged to reach those goals. It seems as if Walmart has done so. 
What we can learn from the Walmart example is that a company that faces ethical issues can 
simultaneously implement harm reduction to do less harm to the environment and society. Walmart 
does many harms around the world, such as contracting companies that do not ensure the safety of its 
workers, but they reduce harm when it comes to environmental issues. This is a better situation than 
Walmart both failing to ensure the safety of contracted workers while polluting indiscriminately and 
generating excessive amounts of waste. Thus, while Walmart may not be a perfectly responsible 
company, they are at least doing less harm than they otherwise could. Walmart’s harm reduction is very 
much aligned with the spirit of harm reduction and demonstrates the usefulness of my harm reduction 
framework. 
5.4.4 Walmart and Corporate Social Responsibility 
Walmart’s sustainability efforts are currently understood as being part of their corporate social 
responsibility platform. Here, I will elaborate on why a harm reduction lens is importantly different 
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from a corporate social responsibility lens. Simply put, if viewed from the perspective of corporate 
social responsibility, Walmart is arguably not doing enough. Recall that corporate social responsibility 
is thought to have at least four parts: economic, legal, ethical, and discretionary or philanthropic.  The 
trouble here is that Walmart is potentially not fulfilling its ethical duties. While sustainability is 
certainly a worthwhile cause, Walmart’s failure to ensure safety among its contracted workers, among 
several other criticisms of Walmart’s behaviour, should make us question whether the company is truly 
ethical. Further, Walmart’s record of philanthropy can be called into question. While their website 
boasts $250 million in charitable donations from 1994 to 2019, the amount pales in comparison to their 
profits of over $126 billion in 2018 alone. It can be argued that a giant international conglomerate with 
a 24.5% profit margin can afford to give more to charity. 
Using my harm reduction framework, we can push these criticisms aside. Instead of asking if 
Walmart is acting ethically, we instead ask what harms they are reducing and applaud the contributions 
that the company has made to improving the environment and society. After all, harm reduction is 
crucial to companies who want to be socially responsible. Additionally, instead of asking whether 
Walmart is philanthropic enough, we ask if Walmart is donating the amount of money that its decision 
makers deem important to the causes that they choose for whatever reason. Again, we applaud what 
work they choose to do in bettering the environment and society. Further, we can encourage Walmart 
to reach its sustainability and other harm reduction goals. What is important is that Walmart is taking 
actions in the right direction to improve the state of the environment and society. Questions of whether 
they are ethical or philanthropic come second to that. In this way, we focus on what is really important: 
actively removing the harms done to our environment and society. This removal of harm should be 
encouraged and part of being encouraging is validating the work that has already been done and 
supporting the corporation in doing more of the same kind of work. 
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The reader may be worried here that my low threshold approach sets the bar too low. If we are 
to applaud any harm reduction that Walmart does to the environment and society, how can we push 
them to do more when we think that they should be reducing more or different harms? My response is 
to recall again that Walmart’s existing harm reduction programs do not preclude it from pursuing other 
harm reduction programs. Consumers and government agencies can continue to ask Walmart to do 
more and be specific about what they want Walmart to do, which may convince the company to act. In 
fact, this kind of criticism should be welcome so that we avoid the potential situation where corporations 
see themselves as socially responsible and thus find it unnecessary to change their practices. For 
example, some suggest that Walmart is a socially responsible company and can use that to improve 
profits (Patrick 2018). If Walmart is to accept this interpretation of their sustainability campaign, there 
is a risk that executives will think that their social responsibility initiatives are sufficient and need no 
change when in reality, the company continues to perform harmful actions. Simultaneously applauding 
the good but pointing out additional harms shows corporations that, while they may be successful in 
some aspects of being socially responsible, there is still more work to be done.  
5.5 Conclusion 
This dissertation started with a review of the literature on harm reduction, which is a concept from the 
health policy and social services domains. Harm reduction is the concept that we can, and in some cases 
we ought to, reduce the harms associated with a behaviour without requiring cessation of the behaviour 
itself. Harm reduction gained momentum in the wake of drug and HIV challenges in various parts of 
the world. Harm reduction is both compassionate and pragmatic in respecting individuals’ choice about 
how they want to live their lives and focuses on scientific evidence to determine the best ways to reduce 
harm accordingly. Harm reduction frameworks have been applied to injection drug use, tobacco use, 
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and sex work to successfully reduce the harms associated with those behaviours without requiring 
cessation of the behaviour itself. 
 From these examples of harm reduction, I generated a cluster concept to define “harm 
reduction”. My cluster concept has six qualities. The first quality is mandatory while the other five can 
be present or not depending on how closely a harm reduction framework applies to the behaviour at 
hand. The six qualities are as follows: 
1. There is at least one identifiable harm associated with the behaviour. 
2. The behaviour is tenacious at the population level. 
3. The behaviour is, to some extent, tolerable. 
4. The primary harms are to the self. 
5. The harm is worth reducing even if it is not cost-efficient to do so. 
6. Significant harms are due to stigma or criminalization of the behaviour.  
Next, I surveyed the business literature, where I discussed the rise of corporate social 
responsibility. Though the concept is popular and has been taken up by seemingly every corporation, 
there are some gaps in corporate social responsibility. First, there are certain types of corporations that 
may never be considered socially responsible because their core mission is socially irresponsible. 
Second, some corporations have corporate social responsibility campaigns that are far removed from 
their core business and thus seem disingenuous. Finally, some corporations find corporate social 
responsibility impossible because they cannot afford the resources to run such initiatives.  
Harm reduction addresses each of these gaps. For corporations that can never truly be socially 
responsible, harm reduction offers a lower threshold for engagement. For corporations who pursue 
corporate social responsibility activities that are unrelated to their business, harm reduction forces them 
to look at the harms done throughout the course of their normal operations and address those particular 
harms. Finally, since harm reduction has a lower threshold for engagement, corporations who cannot 
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or will not put the resources into corporate social responsibility initiatives can turn to harm reduction 
instead. 
I then demonstrated that harm reduction applies well to corporations by meeting four of the six 
qualities listed above. I then specified two features of my harm reduction framework. First, the 
motivation for pursuing harm reduction does not matter, so long as a corporation is seeking to reduce 
harm. Second, the amount of harm reduced does not matter, so long as the amount of harm reduced is 
at least as much as the amount that the corporation themselves has committed to reducing.  
After that, I applied my harm reduction framework to the oil and gas industry to demonstrate 
its applicability in an industry. The oil and gas industry is responsible for doing severe harm to 
Indigenous communities and damaging the environment. The process of extracting oil from the Earth 
is time- and resource-intensive, thus offering several possibilities for harm reduction in ways that both 
benefit the company financially and reduce harm for the environment. Examples of behaviours to 
reduce environmental harm during exploratory drilling include using water-based fluids instead of 
synthetic fluids while drilling, upgrading to modern equipment, and using water-powered drilling. 
I also applied my harm reduction framework to the pharmaceutical industry to demonstrate its 
applicability in another industry. The pharmaceutical industry, especially the brand name 
pharmaceutical industry, is responsible for several harms including influencing doctors to over-
prescribe their medications, making their drugs inaccessible to many populations that need them, and 
failing to develop orphan drugs and drugs to treat tropical diseases. The case study of Merck Co. Inc. 
showed that even pharmaceutical companies with extensive corporate social responsibility 
commitments can reduce more harm. Depending on the internal decisions made by Merck’s decision-
makers, a greater commitment to harm reduction may be required by the company. 
Finally, my dissertation took a practical perspective to determine how my harm reduction 
framework can be implemented. My research revealed a need for a strong company leader, either 
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working internally or externally. The option, or combination of options, that reduces the most harm is 
the one that I endorse. The case of Walmart then demonstrated that my harm reduction framework can 
capture the complexity of a company that does both harm and good. This interpretation of Walmart 
differs from the interpretation of corporate social responsibility. Where corporate social responsibility 
would arguably ask Walmart to do more, a harm reduction approach encourages the company to 
continue along its path of reducing harm to the environment. 
Here, I will remind the reader that using the term “harm reduction” may seem off-putting to 
some corporations. They may not want to use the word “harm” in their marketing materials. I recognize 
this difficulty. However, what my framework is called in practice is something that requires further 
research. My harm reduction framework may be given a new name, or perhaps it might be subsumed 
under “corporate social responsibility” with a particular lens or focus. Whatever the case may be in 
practice, the harm reduction framework for corporations that I have developed here remains true to the 
harm reduction frameworks that have come before it and so I use the name “harm reduction” in this 
dissertation to indicate that alliance.  
I expect that this dissertation captures an intuition that is expressed when the public is outraged 
by a corporation that claims to be socially responsible by going above and beyond without addressing 
the harms that they do first: corporations should reduce the harms that they do throughout their 
operations before looking to do good by going above and beyond, especially if going beyond means 
taking a “bolted on” approach to corporate social responsibility. This outrage is important for 
corporations to respond to because it is at the core of much discontent from the public over their 
corporate social responsibility strategies. Frustrations have mounted over corporate greenwashing, 
executives making empty statements about change, and distracting the public with promises of going 
above and beyond while continuing to treat their own contractors or employees horribly. For many, this 
is a situation that needs to change, and harm reduction offers a tool to realize that change. 
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It is due to the above sentiment that I hope this dissertation provides a groundwork for 
corporations to enact change among their own operations. Harm done to the environment and society 
is sometimes grave and irreversible, so it is important that action is taken sooner rather than later. I 
strongly encourage those who work in business consulting, especially those who advise on corporate 
social responsibility, to take on harm reduction as another tool to offer to decision-makers who are not 
taking ownership of the harms that their own businesses cause throughout their operations. For 
example, my two features of allowing corporations to choose which harms they want to reduce to 
whatever extent they wish to reduce them makes it easier to get an executive’s approval. My hope is 
that this low threshold approach entices executives to sign on. 
Overall, in this dissertation, I have developed a harm reduction framework based on existing 
harm reduction literature that applies well to corporations. I have demonstrated that my framework is 
both robust and practical. A shift from corporate social responsibility to my harm reduction framework 
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